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ABSTRACT
Sudden cardiac death accounts for 35-45% of all deaths in 
heart failure, presumably from malignant ventricular 
arrhythmias. The aetiology of sudden arrhythmic death has 
not been fully elucidated, although a number of mechanisms 
exist which could potentially be arrhythmogenic. These 
include activation of the renin-angiotensin system, an 
increase in sympathetic nervous activity, electrolyte 
depletion and the use of inotropes and diuretics. It is 
likely however, that these mechanisms are secondary to the 
underlying electrophysiological changes in the myocardium 
resulting from the processes of myocyte damage and 
necrosis, compensatory hypertrophy and fibrosis which 
occur in the failing heart. In order to understand the 
basic mechanisms responsible for sudden death in heart 
failure, there is a need for animal models in which the 
electrophysiological changes produced by myocardial damage 
and the interrelationship between the myocardial 
electrophysiological substrate, neurohormonal activity and 
inducibility of arrhythmias can be studied in detail.
In this study cardiac failure was induced in rabbits by 
injection of the cardiotoxin adriamycin lmg/Kg twice 
weekly for 8 weeks. Electrophysiological recordings were 
made in conscious animals using bipolar pacing electrodes,
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implanted in the right ventricular apex. Recordings were 
made of the effective refractory period and the Stimulus-T 
interval of the paced evoked response. Neurohormonal 
assays and measurement of plasma electrolytes were 
undertaken durimg the study, and pathological analysis 
when the animals died.
Progressive shortening in the stimulus-T interval and 
effective refractory period occurred in the adriamycin 
treated animals. No significant changes were seen in 
controls.
Right ventricular papillary muscles from uninstrumented 
animals were used for in vitro electrophysiological 
studies.
Action potential duration and effective refractory period 
were significantly shorter in the adriamycin group 
compared to controls.
The changes in these electrophysiological parameters were 
independent of changes in plasma electrolytes and 
neurohormones. Captopril did not reverse the 
electrophysiological changes, but did cause a reduction in 
heart and liver weight, and ventricular ectopic activity.
A cohort of animals treated with adriamycin and frusemide 
did not have a progressive shortening in effective 
refractory period and stimulus-T interval, and this 
questions the reproducibility of the electrophysiological 
changes in the study.
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CHAPTER 1 
INTRODUCTION AND HISTORICAL REVIEW
1.1 Prognosis in congestive heart failure.
Management of patients with congestive cardiac failure 
has tended to concentrate on alleviation of symptoms 
associated with this condition. Consequently, research 
undertaken in this area has mainly focussed on the 
pathophysiological mechanisms which are associated with 
the haemodynamic abnormalities found in patients with 
heart failure. Although death from progressive 
ventricular dysfunction is a significant feature of the 
condition, sudden unexpected death, presumably from 
ventricular tachyarrhythmias, accounts for 35% - 45% of 
all deaths in heart failure (Burggraf, G.W. & Parker,
J.0.(1975); Lee, W. & Packer, M.(1984); Cohn, J.N. et 
al(1984)). Although some authorities differ in their 
viewpoint, a useful working definition of sudden death is 
death from circulatory failure within 1 hour of the onset 
of symptoms in a patient with advanced left ventricular 
dysfunction whose heart failure symptoms have remained 
stable or improved over the previous 2 to 4 weeks and in 
whom another cause for circulatory collapse cannot be 
identified clinically (Packer, M. (1985)). Excluded from 
such a diagnosis therfore are the 10% - 15% of patients
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whose deaths follow the typical presentation of acute 
myocardial infarction or pulmonary embolus. As a result 
of research undertaken into haemodynamic abnormalities 
associated with heart failure, clinicians are now able to 
improve cardiac performance by pharmacological means. 
Subsequently, it is likely that sudden unexpected death 
from ventricular tachyarrhythmias will become the most 
frequent cause of death in patients with congestive heart 
failure.
1.2 Relationship of ventricular arrhythmias to prognosis 
in congestive heart failure.
To identify a subset of patients with heart failure who 
are at risk for subsequent sudden unexpected death, we 
must first try to understand the pathophysiological 
mechanisms involved. Sudden unexpected death in heart 
failure is most likely the result of a terminal 
ventricular arrhythmia, either ventricular tachycardia or 
ventricular fibrillation. 24 hour ambulatory monitoring 
studies indicate that 60% - 90% of patients with 
congestive cardiac failure have frequent or complex 
ventricular ectopic beats, and that 40%-60% of patients 
have spontaneous non-sustained ventricular tachycardia 
(Huang, S.K., Masser, J.V. & Denes, P.(1983) ; Meinertz, 
T. et al(1984); Wilson, J.R. et al(1983); Holmes, J. et
23
al(1985); Cleland, J.G.F., Dargie, H.J. & Ford, 1.(1987); 
Von Olshausen, K. et al(1984)). (table 1). Data from 
these studies would suggest that although the occurence of 
ventricular tachycardia would seem to predict total 
mortality (Huang, S.K. et al(1983); Meinertz, T. et 
al(1984); Wilson, J.R. et al(1983) and Holmes, J. et al 
(1985)), the relationship between pre-existing spontaneous 
ventricular tachycardia and sudden death is not so well 
defined. This suggests that the presence of such 
malignant ventricular ectopic activity merely reflects the 
severity of the functional and haemodynamic abnormalities 
which are present, and is not an independent risk factor 
for sudden death. Although Meinertz, T. et al(1984) did 
show a relationship between the frequency of ventricular 
tachycardia and sudden death, the extremely high 
arrhythmia rate, > 20 episodes of Ventricular tachycardia 
in 24 hours, proposed by the authors for the 
identification of high risk patients is extremely rare in 
patients with congestive heart failure. Huang, S.K. et 
al(1983); Wilson, J.R. et al(1983); Holmes, J. et 
al(1985); Cleland, J.G.F. et al(1987) and Von Olshaushen, 
K. et al(1984), found like Meinertz, T. et al(1984) no 
relationship between the occurence of ventricular 
tachycardia and subsequent sudden death, (table 1).
Current evidence therefore suggests that spontaneous 
ventricular tachycardia does not necessarily precede
Table 1.
Relationship of ventricular tachycardia to sudden death in 
heart failure.
Study Number Age FU Aetiology %VT %SD Relation
Huang 35 51112 34117 I DC 60 50 No
Meinertz 74 51110 1113 IDC 49 63 Frequency
Wilson 77 61111 12111 CAD:52% 
IDC:36% 
VHD:12%
51 43 No
Von
Olshausen
60 4519 1215 IDC 42 43 No
Cleland 152 5919 21112 CAD:61% 
IDC:16% 
VHD: 10% 
HBP:6%
61 75 No
Holmes 31 56 14 CAD:52% 
IDC:48%
39 86 No
Unverf. 69 45 12 IDC 25 92 No
IDC=Idiopathic dilated cardiomyopathy.
CAD=Coronary artery disease.
VHD=Valvular heart disease.
HBP=High blood pressure.
VT=Ventricular tachycardia.
FU=Follow-up.
SD=Sudden death. Relation=Relation of VT to sudden death.
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sudden unexpected death, and that its presence on 24 hour 
ECG monitoring does not identify patients who are at high 
risk and require medical intervention. Although the 
current evidence does not permit any association to be 
made between ventricular tachycardia and sudden arrhythmic 
death, this does not necessarily mean that the 
relationship does not exist. One reason for this could be 
inherent problems with the design of the studies which 
have addressed this problem. If we analyse the studies 
cited above it is possible to detect certain areas which 
could lead to problems with interpretation of the data.
Firstly, the number of patients in each study was small. 
The largest study group was only 152 patients (Cleland, 
J.G.F. et al(1987)). None of the other studies included 
more than 77 patients. Small numbers of patients could 
make it difficult to detect any significant relationship 
between spontaneous ventricular tachycardia and sudden 
death. Secondly, the mean duration of follow-up in each 
of the studies was short. The studies by Meinertz, T. et 
al(1984); Wilson, J.R. et al(1983); Von Olshausen, K. et 
al(1984) and Holmes, J. et al(1985) had a mean duration of 
follow-up which was less than 15 months, and only the 
studies by Cleland, J.G.F. et al(1987) and Huang, S.K. et 
al(1983) were of longer duration, 21 and 34 months 
respectively. If the patients in these studies had been 
followed for a greater period of time, a relationship
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between ventricular tachycardia and sudden death might 
have been exposed.
Another important observation is that the incidence of 
sudden death does not increase with increasing severity of 
heart failure, as defined by progressively more limited 
functional class and greater 1 year total mortality 
(Burgraff, G.W. and Parker, J.O.(1975) ; Massie, B. et 
al(1981); Cohn, J.N. et al(1984) and Wilson, J.R. et 
al(1983)). The fact that patients with more severe heart 
failure and greater impairment of left ventricular 
function, who theoretically at least would have a greater 
degree of activation of both the sympathetic and renin- 
angiotensin systems, are not at a higher risk of sudden 
death would tend to exclude these potentially 
arrhythmogenic mechanisms as a cause of sudden death. One 
possible reason why no relationship has been identified 
between sudden death and the severity of heart failure is 
that the clinical picture in patients with severe heart 
failure is so dominated by marked dyspnoea at rest, that 
the onset of a terminal ventricular tachyarrhythmia could 
be difficult to identify clinically.
The failure to identify patients who are at high risk 
of sudden death on the basis of pre-existing spontaneous 
ventricular tachycardia and the degree of left ventricular 
impairment, leads us to examine other potentially 
arrhythmogenic mechanisms.
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1.3 The role of structural factors in arrhythmogenesis in 
congestive heart failure.
Previous reports have validly emphasised the importance of 
structural factors such as myocardial fibrosis in 
predisposing to the re-entry phenomena that are critical 
to the development of ventricular ectopic rhythms (El- 
Sherif, N. et al(1983) and El-Sherif, N. , Sherlag, B.J & 
Lazzara, R.(1975)). Re-entrant phenomena involve a 
disturbance of impulse conduction and require two 
electrophysiologically distinct pathways, with 
unidirectional block in one and slowed conduction in the 
other. Under these conditions, the impulse blocked in the 
first pathway may be conducted sufficiently slowly down 
the second such that it reaches the distal point of the 
first pathway at a time when it is no longer refractory, 
thus permitting reciprocation of the impulse and the 
establishment of a sustained arrhythmia. This mechanism 
is considered to account for the majority of chronic 
recurrent ventricular tachyarrhythmias particularly in 
patients with previous myocardial infarction where the 
necessary electrophysiological substrate can be provided 
by the presence of ischaemically damaged or infarcted 
tissue.
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1.4 The clinical role of ventricular wall stress in 
causing cardiac arrhythmias.
Excessive ventricular wall stress has also been implicated 
as a potential mechanism predisposing to sudden death in 
heart failure. Changes in myocardial fibre stretch 
mediated by changes in ventricular pressures and volumes 
may alter the electrophysiological properties of the left 
ventricle and predispose to the occurence of serious 
ventricular arrhythmias (Bigger, J.T. Jr(1973)). Such 
changes may be greatly exaggerated in areas of ventricular 
asynergy or aneurysm formation, which frequently contain 
the initiating site of re-entry circuits that lead to the 
development of sustained ventricular rhythm disturbances 
(Cohn, M., Packer, M. & Gorlin, R.(1983)). There is 
little evidence however that interventions directed at 
reducing ventricular wall stress can effectively reduce 
the frequency or complexity of ventricular arrhythmias.
One study has shown however that the long term 
administration of oral hydralazine and oral isosorbide 
dinitrate significantly reduced mortality when compared 
with placebo in patients with heart failure,although no 
evidence is available as yet with regard to any reduction 
in ventricular arrhythmias or sudden death (Cohn, J.N., 
Archibald, D.G. & Ziesche, S.(1986)). The Consensus Trial 
Study Group 1987, examined the effect of the angiotensin
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converting enzyme inhibitor enalapril, on mortality in 
patients with severe heart failure. Although overall 
mortality was reduced, there was no reduction in the 
incidence of sudden arrhythmic death.
A more recent study which investigated the effect of 
enalapril on mortality in heart failure reached similar 
conclusions to the Consensus study. The authors found 
that enalapril reduced overall mortality in patients with 
heart failure when compared to placebo, although there was 
no reduction in the incidence of sudden death (The SOLVD 
Investigators(1991)).
In contrast to this study, Cohn, J.N. et al(1991), found 
that enalapril significantly reduced the incidence of 
sudden death in patients with heart failure in a trial 
comparing enalapril with the combination of hydralazine 
and isosorbide dinitrate.
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1.5 Experimental electrophysiological changes in relation 
to myocardial hypertrophy and failure, which may be 
arrhythmogenic.
A number of studies have attempted to assess the 
relationship between ventricular wall stress and the 
potential for cardiac arrhythmias. Gelband, H. & Basset,
A.L.(1973) described the in vitro electrophysiological 
changes in the right ventricular papillary muscles from 
cats with chronic partial pulmonary arterial occlusion who 
developed right ventricular hypertrophy and thence right 
heart failure. The authors found that compared to control 
animals, the average resting potential and the action 
potential overshoot were significantly decreased in the 
animals with heart failure. The rate of rise of the 
action potential was also markedly reduced by 24%. The 
authors also reported that action potential duration at 
100% repolarisation was significantly increased when 
compared to controls. The same authors have also 
described the effects of chronic partial occlusion of the 
pulmonary artery and subsequent right ventricular 
hypertrophy, on cardiac electrophysiology and found no 
significant changes in action potential amplitude, rate of 
rise and duration (Basset, A.L. & Gelband, H.(1973)).
This model has certain limitations. Firstly, no increase 
in heart rate was observed as the cats developed heart
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failure. This differs from the clinical situation where a 
reflex-mediated increase in heart rate is commonly 
observed as a compensatory mechanism to maintain cardiac 
output as the contractile function of the heart begins to 
fail. A second limitation of this particular model is 
that 3 of the cats in the study with apparently overt 
right ventricular failure had relatively normal 
electromechanical properties with respect to the right 
ventricular papillary muscles. Another problem with the 
study was that the definition of heart failure was made 
initially on clinical grounds which were rather arbitrary 
and then only subsequently by a marked elevation in right 
ventricular end diastolic pressure. Large variations were 
also present in the degree of pulmonary banding which was 
used within the group of animals which subsequently 
developed heart failure, and no assessment was made of the 
intrinsic contractile state prior to pulmonary artery 
banding.
More recent studies have examined the effect of acute 
increases in ventricular volume on the
electrophysiological properties of the isolated perfused 
rabbit heart (Reiter, M.J., Synhorst, D.P. & Mann,
D.E.(1988)). The hypothesis proposed in this study was 
that one potential cause of ventricular tachyarrhythmias 
in heart failure in the clinical setting is ventricular 
dilatation. As ventricular volume was increased by
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inflating a balloon in the left ventricle, a progressive 
decrease in left ventricular effective refractory period 
was noted. The change in refractory period was unrelated 
to changes in pacing threshold. No biochemical evidence 
of ischaemia was found which could account for the 
shortening in refractory period. Another important 
feature of this model is that the acute dilatation of the 
balloon was associated with a marked heterogeneity of 
refractoriness, both intra and interventricular. 
Heterogeneity of refractoriness is known to predispose to 
re-entrant ventricular tachyarrhythmias and indeed in this 
model, ventricular tachycardia and fibrillation were both 
frequently induced by the use of the single extra-stimulus 
technique in measuring effective refractory period.
The effects of mechanical stress on the electrophysiology 
of isolated muscle preparations has also been studied by 
Lab, M.J.(1982). The author observed that changes in 
muscle length and tension may result in changes in resting 
membrane potential, action potential duration and 
amplitude. High muscle tension in the form of 
isovolumetric contraction is associated with a shortening 
in action potential duration in both isolated muscle 
preparations and the intact frog heart. This process 
whereby changes in mechanical function may precede and 
alter action potential morphology, and therefore result in
32
cardiac arrhythnias is known as contraction-excitation 
feedback.
Another study in isolated, perfused canine ventricles, in 
dogs with chronic myocardial infarction, investigated the 
effects of volume load on ventricular refractoriness 
(Calkins, H. et al(1989)). It was found that increasing 
volume load resulted in a significant reduction in the 
absolute refractory period, in areas of control 
myocardium. A greater reduction was seen however, in both 
the absolute and relative refractory periods in areas of 
infarcted myocardium. It was also demonstrated in this 
study that the induction of tachyarrhythmias was 
associated with conditions of high volume load and 
reduction in refractoriness.
A number of clinical studies have also demonstrated the 
relationship between changes in myocardial stress and the 
electrical properties of the heart.
Ford, E.L. & Campbell, N.P.(1980) demonstrated that a 
reduction in afterload induced by the vasodilator 
amylnitrate, resulted in prolongation of the surface QT 
interval in normal volunteers.
Taggart, P., Sutton, P.M.I., Treasure, T. et al(1988), 
have shown that action potential duration is reduced in 
patients withdrawn from cardio-pulmonary bypass as 
iAyocardial wall stress is increased.
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Further clinical evidence for contraction-excitation 
feedback is found in a study which demonstrated changes in 
action potential duration in patients undergoing balloon 
valvuloplasty for congenital pulmonary stenosis (Levine,
J.H.(1988)).
Other workers have investigated the electrophysiological 
changes associated with the cardiomyopathies which occur 
in a number of animal species. "Round Heart Disease" in 
turkeys is a naturally occuring cardiomyopathy model 
(Einzig, S. et al(1980)). The aetiology of the 
cardiomyopathy is thought to be viral in origin as C-type 
viral particles have been observed in myocardial cells 
from turkeys by electronmicroscopy (Einzig, S., Jankus,
E.F. & Moller, J.H.(1972)). The natural disease process 
progresses to a cardiomyopathy which is similar in its 
end-stage to endocardial fibroelastosis (Einzig, S. et 
al(1972)). The cardiomyopathy is associated with 
arrhythmias and also it has been noted that sudden death 
occurs frequently. Electrophysiological studies in the 
work by Einzig, S. et al (1981) were performed on 
ventricular endocardial muscle cells from both the right 
and left ventricles, in myopathic and non-myopathic 
animals. The authors found that action potential duration 
was significantly reduced at 50% repolarisation in cells 
from both ventricles and at 90% repolarisation in cells
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When the animals were subdivided on the basis of 
ventricular weight/body weight, the maximum upstroke 
velocity was also reduced in animals with ventricular 
hypertrophy. One possible mechanism for the shortening 
which the authors demonstrated in action potential 
duration was thought to be an increase in intracellular 
calcium concentration. This could result from disruption 
of the sarcolemmal membrane structure during viral 
infection. It has been previously demonstrated that an 
increase in intracellular calcium concentration, 
independent of the aetiology, shortens the action 
potential duration (Carmeliet, E.(1978); McDonald, T.F. & 
McLeod, D.P.(1973); Isenberg, G.(1975); Reuter, H.
(1974)). The mechanism by which an increase in 
intracellular calcium concentration shortens action 
potential duration may be mediated by inhibition of the 
slow inward calcium current or by an increase in potassium 
conductance. Although the principal finding in the study 
by Einzig, S. et al(1981) was of a shortening in action 
potential duration, most experimental evidence would 
suggest that ventricular hypertrophy is associated with 
prolongation of the action potential duration.
Rossner, K.L. & Sachs, H.G.(1978) investigated the 
electrophysiological changes associated with Syrian 
hamster cardiomyopathy. Bajusz, E. et al(1969), first 
described a mutant strain of Syrian hamster which
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spontaneously developed a cardiomyopathy which was similar 
in many respects to human cardiomyopathies. The 
cardiomyopathy is transmitted by an autosomal recessive 
mechanism. The initial myopathic process is manifest as 
small focal lesions which heal with subsequent 
compensatory hypertrophy. The animals eventually die 
from cardiac failure although the clinical picture varies 
with some animals developing gross generalised oedema and 
others apparently unaffected. Electrophysiological 
experiments in the study by Rossner, K.L. & Sachs,
H.G.(1978) were performed on isolated left ventricular 
papillary muscles from the myopathic hamster hearts.
Action potential duration was found to be significantly 
increased in cardiomyopathic hamsters when compared to 
controls at 20%, 50% and 95% repolarisation. Action 
potential overshoot was also found to be significantly 
greater when compared to controls. The
electrophysiological data expressed in this study is not 
consistent with some aspects of the findings of other 
workers who have studied cardiac muscle in either 
spontaneous or induced ventricular hypertrophy. Coltart, 
D.J. & Meldrum, S.J.(1970), have shown that left 
ventricular obstructive cardiomyopathy in man is 
associated with a decrease in upstroke velocity as well as 
a prolongation of action potential duration. Tritthart,
H. et al(1975) also found a decrease in upstroke velocity
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following the induction of right ventricular hypertrophy 
in cats. Basset, A.L. & Gelband, H.(1973) found no such 
change in a similar study in cats. The fact that the 
upstroke velocity was not reduced in the study by Rossner, 
K.L. & Sachs, H.G.(1978) probably reflects an unaltered 
sodium channel. The mechanism by which action potential 
duration is prolonged in cells from the cardiomyopathic 
hamsters may be related to either an enhanced slow inward 
current and/or a decreased late outward current. Previous 
studies have suggested that isotopic calcium uptake by 
left ventricular myocytes from a related strain of 
myopathic hamsters is increased when compared to controls. 
This may suggest that there is an increased trans- 
sarcolemmal calcium ion flux associated with the 
cardiomyopathy (Lossnitzer, K. et al(1975)). This would 
be consistent with an increased slow inward calcium 
current, and would be likely to result in a prolongation 
of the action potential duration (Zipes, D.P., Besch, H.R. 
Jr. & Watanabe, A.M.(1975)).
Uhley, H.N.(1961) measured action potential amplitude in 
transmembrane potentials recorded from myocytes in 
hypertensive rats. No change was observed in this 
parameter in animals who had been hypertensive for 5-8 
months. Studies performed in spontaneously and renal 
hypertensive rats with ventricular hypertrophy, have 
reported increased action potential durations with no
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other abnormalities in action potential morphology (Gulch, 
R.W., Baumann, R. & Jacob, R.(1979); Aronson, R.S.(1980)). 
The apparent heterogeneity in animal models of 
cardiomyopathy may be the result of 2 processes. Firstly, 
a cytopathic effect which could result in shortening of 
action potential duration, and secondly compensatory 
hypertrophy which in most models results in action 
potential prolongation.
1.6 Clinical and experimental effects of potassium 
depletion on cardiac electrophysiology.
Although structural factors are undoubtably important in 
the genesis of ventricular arrythmias and sudden death, 
more recently 3 potentially reversible mechanisms have 
been proposed. These include electrolyte depletion, 
activation of neurohormonal mechanisms and drug therapy in 
heart failure.
Patients with congestive heart failure have marked 
deficits of total body and intracellular potassium, which 
may or may not be reflected by a measurable decrease in 
serum potassium concentration. The administration of 
diuretic drugs may further deplete body stores of 
potassium (as well as magnesium) by promoting the renal 
excretion of these predominantly intracellular cations, an 
effect potentiated by co-existing hyperaldosteronism and
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metabolic alkalosis. Furthermore, the high levels of 
circulating catecholamines in patients with heart failure 
may enhance the movement of potassium into cells by a 
betaa-receptor mediated mechanism, thereby exacerbating 
the hypokalaemic state and potentiating its arrythmogenic 
effects (Brown, M.J., Brown, D.C. & Murphy, M.B.(1983)). 
Recent studies indicate that malignant ventricular ectopic 
rhythms in some patients with congestive heart failure may 
entirely be the result of potassium and magnesium 
depletion. Both short and long term repletion may abolish 
these arrhythmias and reduce the risk of sudden death 
without long-term antiarrhythmic drug therapy (Bertuso, 
J.R. et al(1984); Chadda, K., Balias, M. & Bodenheimer, 
M.M. (1984)).
Potassium and magnesium deficits commonly coexist and 
under such circumstances, repletion of magnesium appears 
to be critical to the success of treatment. Therapy with 
potassium salts alone may fail to restore normal serum 
levels of potassium or normal sinus rhythm, whereas 
magnesium administration corrects not only the 
hypomagnesaemia and hypokalaemia but abolishes the 
accompaning tachyarrhythmias as well (Chadda, K. et al 
(1984)).
Having described hypokalaemia as being important in the 
genesis of ventricular arrhythmias, it is important to 
assess the effects of potassium depletion on isolated
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cardiac tissue and changes in action potential morphology 
which may predispose to cardiac arrhythmias.
Abnormalities of potassium homeostasis can affect the 
electrophysiology of cardiac cells in a number of 
different ways. Effects have been noted previously on 
depolarisation, repolarisation and also on normal 
pacemaker activity in a number of tissues, and these 
effects may potentially be arrhythmogenic. The effect on 
the resting membrane potential of lowering the 
extracellular potassium concentration in isolated muscle 
preparations, is to make the potential more negative 
(Vassalle, M.(1965); Gettes, L.S., Surawicz, B. & Shiue, 
J.C. (1962)). This hyperpolarisation may negate the effect 
of antiarrhythmic drugs which inhibit the inward sodium 
current during depolarisation.
Another mechanism whereby lowering extracellular 
potassium concentration may be arrhythmogenic, is by 
causing prolongation of action potential duration. This 
effect has been previously described (Surawicz, B. et 
al(1959); Roden, D.M. & Hoffman, B.F.(1985); Gettes, L.S. 
et al(1962); Vassalle, M.(1965)). The mechanism whereby 
hypokalaemia-induced prolongation of the action potential 
duration may be arrhythmogenic, is that ventricular 
ectopic beats, arising during the terminal portions of 
prolonged action potentials will have a reduced sodium 
current and will therefore be propagated slowly. This
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slow conduction may predispose to re-entrant 
tachyarrhythmias. These changes may be particularly 
important in arrhythmogenesis when hypokalaemia coexists 
in patients with bradycardias, and also with 
antiarrhythmic drugs that prolong action potential 
duration such as quinidine (Roden, D.M. et al(1986)).
A lowered extracellular potassium concentration also 
increases the slope of phase 4 in the Purkinje network, 
thereby causing or increasing the rate of normal 
automaticity (Gettes, L. & Surawicz, B.(1968); Gettes, 
L.S. et al(1962); Vassalle, M.(1965)). Increased 
automaticity is one of the mechanisms predisposing to 
ventricular tachyarrhythmias.
The major electrocardioghraphic features of hypokalaemia 
are a decrease in T-wave amplitude and an increase in U 
wave amplitude, with the eventual development of marked QT 
prolongation (Surawicz, B.(1967)).
Hypokalaemia may also predispose to arrhythmias by 
interacting with a number of cardioactive drugs. In 
particular effects have been demonstrated with the cardiac 
glycosides and also with class 1 antiarrhythmic agents.
One possible mechanism by which hypokalaemia may 
predispose to digoxin toxicity is by causing an increase 
in cardiac binding of the drug. Cohn, K.E., Kleiger, R.E. 
& Harrison, D.C.(1967) demonstrated that in mice who were
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made hypokalaemic by a low potassium diet, increased 
concentrations of cardiac digoxin were found when compared 
to controls. The effect of the interaction between
hypokalaemia and drugs such as quinidine which not only 
block sodium channels but prolong action potential 
duration has also been well described and may lead to the 
ventricular tachyarrhythmia Torsades de 
pointes in 0.5% to 7% of patients in whom quinidine is 
prescribed (Roden, D.M., Woosley, R.L. & Primm,
R.K.(1986)).
1.7 Clinical and experimental effects of magnesium 
depletion on cardiac electrophsiology.
Electrophysiological effects of changes in extracellular 
magnesium levels on isolated cardiac tissue, have been 
studied by a number of authors. Watanabe, Y. & Dreifus,
L.S.(1972) conducted experiments on isolated, perfused 
rabbit hearts. They found that lowering the extracellular 
magnesium concentration resulted in a reduction in the 
effective refractory period, action potential amplitude, 
membrane resting potential and the maximal rate of 
depolarisation. The effects of increasing the magnesium 
concentration on the other hand produced the opposite 
electrophysiological effects. Data from the above study 
also demonstrated that these effects were maximal in the
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presence of high extracellular potassium concentrations, 
and reduced in the presence of low potassium 
concentrations.
Other workers have found conflicting results however. 
Roden, D.M. & Iansmith, D.H.S.(1987) found no significant 
changes in action potential morphology when magnesium 
alone was removed from the perfusate of canine Purkinje 
fibres. The authors did find that when both 
extracellular calcium and potassium levels were reduced, 
significant changes did occur. These included membrane 
arrest, multiple early afterdepolarisations and delayed 
afterdepolarisations.
Other workers have assessed the direct chronotropic effect 
of changes in magnesium concentration on the cells in the 
canine sinus node. Woods, W.T. et al(1979) described an 
increase in sinus rate on removing magnesium from the 
experimental perfusate, and increasing magnesium resulted 
in a decrease in the sinus rate. The ability of a low 
magnesium concentration to result in a tachycardia is one 
possible explanation for the proarrhythmic effect 
clinically of hypomagnesaemia.
In addition to the in vitro data there is clinical 
evidence that changes in plasma magnesium concentration 
may predispose to cardiac arrhythmias.
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Studies have shown that a reduction in plasma magnesium 
concentration is associated with an increase in 
ventricular ectopic activity. The standard use of 
thiazide diuretics in the treatment of hypertension, and 
the ability of these diuretics to lower magnesium levels 
(Hollifield, J.W.(1986)), has led to a number of studies 
documenting the relationship between hypomagnesaemia and 
ventricular ectopic activity (Hollifield, J.W.(1984); 
Hollifield, J.W.(1986)).
In addition to magnesium depletion resulting in an 
increase in ventricular ectopy, other studies have 
demonstrated that normalisation of hypomagnesaemia may 
terminate ventricular tachyarrhythmias. Ramee, S.T. et 
al(1985) described 2 cases of patients with Torsades de 
pointes associated with hypomagnesaemia, whose arrhythmias 
were abolished by repletion of plasma magnesium. Chadda, 
K. et al(1984) also described the efficacy of magnesium 
replacement in the treatment of ventricular arrhythmias in 
patients with hypomagnesaemia.
Another study which examined the relationship between 
plasma magnesium levels and atrial fibrillation found that 
patients with hypomagnesaemia required significantly 
greater amounts of intravenous digoxin to control the 
ventricular rate when compared to patients with normal 
magnesium levels (De Carli, C., Sprouse G. & LaRosa,
J .C .(1986)).
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Considerable evidence therefore exists both in vivo and in 
vitro that magnesium depletion is associated with cardiac 
arrhythmias, and that magnesium repletion may result in 
the restoration of sinus rhythm.
1.8 The potential arrhythmogenic effect of neurohormonal 
mechanisms in congestive heart failure.
The clinical syndrome of congestive heart failure is 
associated with activation of a number of homeostatic 
mechanisms which modify cardiac output in order to 
maintain blood pressure and perfusion of vital organs.
One of the most important of these mechanisms is the 
renin-angiotensin system. The decrease in cardiac output 
and the resultant increase in sympathetic tone which 
accompany heart failure result in a reduction in renal 
perfusion. This in turn results in an increase in renin 
secretion by the macula densa in the kidney. Circulating 
renin converts angiotensinogen to angiotensin I which in 
turn is converted to angiotensin II by angiotensin 
converting enzyme. Others factors such as the use of 
diuretics may also contribute to activation of the renin- 
angiotensin system by sodium depletion (Brown, J.J. et 
al(1970)). One of the effects of this increase in 
angiotensin II is to stimulate secretion of aldosterone 
which results in an increase in sodium reabsorption in the
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kidney and a concomitant increase in potassium excretion. 
The effect of the increase in sodium reabsorption is to 
expand the vascular volume in an attempt to maintain 
tissue perfusion. Angiotensin II is also a potent 
vasoconstrictor and in this capacity causes an increase in 
systemic vascular resistance and blood pressure. Another 
major effect of angiotensin II is to act directly on the 
efferent renal arteriole to increase glomerular filtration 
pressure and solute clearance (Packer, M., Lee, W.H. & 
Kessler, P.D.(1986)). The argument as to which of these 
functions of angiotensin II is the most important is 
probably unresolved.
In a dissertation on the subject Packer, M.(1987) 
eloquently discusses the problem. The premise which is 
proposed by Packer is that the prime function of 
activation of the renin-angiotensin system is to maintain 
renal function.
It has previously been held that in two different clinical 
situations where cardiac output and blood pressure is 
reduced, namely hypovolaemia and heart failure, the renin- 
angiotensin system is activated in order to maintain blood 
pressure. The author states that the body is able to 
differentiate between the two situations however. In the 
former, atrial natriuretic peptide(ANP) secretion is 
decreased while in heart failure it is increased. The 
effect of ANP is to reduce the release of renin from the
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kidney and negate the effect of angiotensin II on the 
peripheral vasculature (Kleinert, H.D. et al(1984);
DeLean, A. et al(1984)). If the primary function of 
angiotensin II in heart failure was the maintanance of 
blood pressure then it would seem unlikely that the 
actions of ANP and angiotensin II would be antagonistic. 
Another potent argument against its role in the 
preservation of circulatory volume is the site of action 
of angiotensin II in the kidney. If volume preservation 
were its prime function, then it would be more logical 
that the hormone would act on the afferent arteriole and 
thus reduce sodium excretion, rather than cause 
constriction of the efferent arteriole, the sole purpose 
of which is to preserve renal function.
Whether the primary function of the renin-angiotensin 
system is to maintain circulatory homeostasis or preserve 
renal function, there is no doubt that this neuroendocrine 
system is activated in patients with heart failure.
Despite the obvious advantages to the circulation, 
activation of this system may be potentially 
arrhythmogenic.
The systemic vasoconstriction caused by angiotensin II 
limits cardiac function by increasing afterload (Curtiss,
C. et al(1978)). Furthermore the increase in sodium and 
water retention which results from the increase in 
circulating aldosterone levels results in an increase in
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ventricular wall stress and myocardial oxygen consumption 
(Massie, B. et al(1982)). Excessive ventricular wall 
stress has been implicated as a potential mechanism 
predisposing to sudden arrhythmic death in patients with 
heart failure, as discussed in chapter 1.3. This premise 
has been further substantiated by in vitro studies which 
have demonstrated that an increase in afterload may result 
in a decrease in effective refractory period and action 
potential duration (Lermann, B.B. et al(1985); Reiter,
M.J. et al(1988)). This decrease in refractory period may 
lead to the conduction of premature extra-stimuli and the 
initiation of tachyarrhythmias. The decrease in plasma 
potassium and magnesium which accompany the increase in 
aldosterone may also be potentially proarrhythmic as 
discussed in chapters 1.6 and 1.7.
Although the proposal that neurohormonal activation has a 
role to play in the pathogenesis of sudden death in heart 
failure would seem attractive, at least on theoretical 
grounds, the reality of the situation is that there is 
little clinical evidence avalible to confirm this 
hypothesis. The relative incidence of sudden arrhythmic 
death does not increase with increasing severity of heart 
failure (Burgraff, G.W. & Parker, J.O.(1975); Massie, B. 
et al(1981); Cohn, J.N. et al (1984) and Wilson, J.R. et 
al(1983)). The fact that patients with more severe heart
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failure and greater impairment of left ventricular 
function also have the greatest level of activation of the 
renin-angiotensin system, would tend to exclude this as a 
mechanism for sudden death in heart failure.
If the hypothesis that activation of the renin-angiotensin 
system was important in sudden death, then it should 
follow that inhibition of this system should theoretically 
reduce the incidence of those deaths in cardiac failure 
which could be classified as sudden. Perhaps the best 
study so far which has addressed the problem is the 
Cooperative North Scandanavian Enalapril Survival Study 
(Consensus): The Consensus trial study group, (1987).
The Consensus trial was designed as a randomised, double­
blind, placebo controlled, parallel-group trial in 
patients with severe congestive heart failure (New York 
Heart Association functional class IV). The study 
involved two treatment groups, one treated with enalapril 
the angiotensin converting enzyme inhibitor, and the other 
with an identical placebo. At the end of 6 months, the 
crude mortality was 26% in the enalapri1-treated group and 
44% in the placebo group, a reduction of 40%(p= 0.002).
At the end of 12 months, mortality was reduced by 31%. By 
the end of the study there had been 68 deaths in the 
placebo group and only 50 in the enalapril group which 
represents a reduction of 27% (p= 0.003). Perhaps the
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most interesting aspect of the Consensus study however, 
lies in the fact that the entire reduction in mortality 
was found to be among patients with progressive heart 
failure, whereas no difference was observed in the 
incidence of sudden unexpected death. It would seem 
therefore that inhibition of the renin- angiotensis system 
does not have any effect on the incidence of sudden death 
in heart failure, and the proposal on theoretical grounds 
at least, that activation of this system is important in 
the pathogenesis of sudden death, may not be relevant in 
the clinical setting.
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Other studies have confirmed the beneficial effects of 
angiotensin converting enzyme inhibition on overall 
prognosis in heart failure (Furberg, C. & Yusef, S.(1985); 
Creager, M.A., Faxon, D.P. Halperin, J.L.(1982)), but like 
the Consensus study failed to show any change in the 
incidence of sudden death.
As discussed in chapter 1.4, two more recent studies have 
reached conflicting conclusions with regard to the effect 
of angiotensin converting enzyme inhibition on overall 
mortality and sudden death in heart failure. The SOLVD 
Investigators,(1991) found that enalapril reduced overall 
mortality in patients with mild to moderate heart failure 
but had no effect on the incidence of sudden death. The 
study by Cohn, J.N. et al(1991) on the other hand found 
that the reduction in mortality associated with the use of 
enalapril, in comparison with hydrallazine and nitrates, 
was mainly related to a reduction in the incidence of 
sudden death.
The weight of published data would seem at present to 
support the view that inhibition of the renin-angiotensin 
system does not result in a reduction in sudden death in 
heat failure.
The other important neurohormonal mechanism which is 
activated in heart failure is the sympathetic nervous 
system.
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The reduction in cardiac output which occurs in heart 
failure not only results in activation of the renin- 
angiotensin system, but also the sympathetic nervous 
system, in an attempt to maintain circulatory homeostasis 
(Francis, G.S. et al(1984); Francis, G.S.(1985)). This 
increase in circulating catecholamines may be potentially 
arrhythmogenic either directly, or by the depletion of 
potassium and magnesium (Brown, M.J. et al(1983)). It is 
also possible that by increasing afterload secondary to 
systemic vasoconstriction, cardiac action potential 
duration will be decreased as previously discussed. Other 
evidence for the role of increased sympathetic activity in 
predisposing to arrhythmias and sudden death is found in 
the Beta Blocker Heart Attack Trial,(1984). In this 
study, the use of propanolol in post-infarct patients with 
heart failure was associated with a reduction in 
mortality.
1.9 Vasodilator mechanisms of captopril.
Although the principle mode of action of angiotensin 
converting enzyme(ACE) inhibition in producing a 
hypotensive response is the inhibition of the conversion 
of angiotensin I to angiotensin II(a potent 
vasoconstrictor), a number of other vasoactive mechanisms 
have been proposed. This would imply that the effects of
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ACE inhibition in improving prognosis in patients with 
heart failure may be independent of the degree of 
activation of the renin-angiotensin system, and would 
therefore be as pronounced in both mild and severe heart 
failure. In this section therefore the evidence for a non 
angiotensin II mediated hypotensive response of captopril 
is discussed.
The role of prostaglandins in the hypotensive effect of 
captopril was examined in a clinical study by Moore, T.J. 
et al(1981). In this study captopril was given to sodium 
restricted patients with essential hypertension. After a 
single oral dose of captopril, the blood pressure and 
levels of angiotensin II decreased, while the levels of 
the metabolite of PGE^CPGE-M) increased. Prostaglandin 
synthesis was then blocked by the administration of either 
indomethacin or aspirin before repeating the captopril 
dose. The authors found that the PGE-M response was 
effectively blocked and as expected the levels of 
angiotensin II were decreased. The significant finding in 
this study however was that the hypotensive effect of 
captopril was significantly blunted, thus implying a role 
for prostaglandins in the hypotensive effect of captopril. 
Another clinical study reached similar conclusions after 
assessing the effects of indomethacin on the acute 
hypotensive effect of captopril (Silberbauer, K., Stanek,
B. & Tempi, H.(1982)). DeBruyn, J.H.B. et al(1980),
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examined the haemodynamic effects of a single dose of 
lOOmg of captopril in 3 different patient subgroups; 
patients with renovascular hypertension, essential 
hypertension, and anephric patients. The pre-treatment 
concentrations of active renin in plasma were 
significantly higher in the subgroup of patients with 
renovascular hypertension when compared to the 2 other 
groups, while in turn the renin concentration was higher 
in the essential hypertension group when compared to the 
anephric group of patients. The authors found that the 
administration of captopril resulted in a similar 
hypotensive response in all 3 groups. They concluded from 
this that the hypotensive response to captopril would seem 
to be independent of circulating renin levels.
Further evidence for the role of non-angiotensin mediated 
vasoactive mechanisms can be found in animal studies. 
Marks, E.S. et al(1980) found that captopril produced a 
fall in blood pressure in nephrectomised rats despite the 
absence of renin from the peripheral circulation. It was 
also found that in animals made hypertensive by the 
administration of deoxycorticosterone, a potent salt 
retaining steroid, captopril again caused a significant 
fall in blood pressure. The rats in these experiments had 
markedly suppressed plasma renin activity. Another study 
in dogs found that the infusion of angiotensin II into 
sodium depleted animals produced an increase in both blood
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pressure and levels of angiotensin II, and that these 
parameters were related in a dose response curve. 
Following an infusion of captopril, it was found that the 
levels of angiotensin II which were required to produce 
the same blood pressure as a group of animals which were 
not given captopril was significantly higher. This is 
further evidence that the acute hypotensive effect of 
captopril is not entirely dependent on a reduction in 
angiotensin II.
1.10 Possible effects of drug therapy on mortality in 
heart failure.
The role of converting enzyme inhibition in improving 
prognosis in heart failure has been previously discussed 
in chapter 1.8. The increased sympathetic tone which is 
found in patients with heart failure and its 
arrhythmogenic potential would imply that 
pharmacologically blocking the sympathetic adrenergic 
receptors could lead to a reduction in cardiac 
arrhythmias. Limited evidence does exist that direct 
antagonism of the proarrhythmic effects of catecholamines 
may be achieved by the administration of beta adrenergic 
blocking agents. Data from the Beta Blocker Heart Attack 
Trial(1987) indicate that treatment with beta blockers 
substantially reduces the incidence of sudden death in
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patients following an acute myocardial infarction that was 
complicated by congestive heart failure (Furberg, C.D. et 
al(1984)). These observations support the findings of 
uncontrolled studies which indicate that long-term, low- 
dose beta blockade may reduce mortality in patients with 
congestive cardiomyopathy (Swedberg. K. et al(1979)). 
Inherent difficulties exist however with the use of beta- 
blocker therapy in patients with heart failure. The 
negative inotropic effect of these drugs may suppress 
myocardial contractility and precipitate acute pulmonary 
oedema and possibly death in patients whose myocardial 
function is already severely compromised. It is important 
therefore to balance the possible benefits in terms of a 
reduction in the frequency of arrhythmias against the 
probable deterioration in cardiac function.
Most of the drugs which are used to improve cardiac 
performance and relieve the clinical symptoms in patients 
with congestive failure can exacerbate ventricular 
tachyarrhythmias. Of all the available treatment 
modalities, diuretic drugs may prove to be the most 
arrhythmogenic. These agents activate both the 
sympathetic nervous and renin-angiotensin systems and 
promote the renal loss of both potassium and magnesium. 
Although activation of the renin-angiotensin system has 
been proposed as a possible mechanism for sudden
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arrhythmic death in heart failure, a number of previous 
reports have suggested that in patients with mild to 
moderate cardiac failure who are not on concurrent 
treatment, plasma levels of renin may be normal, and may 
only increase following the administration of diuretics 
(Brown, J.J. et al(1970); Bayliss, J. et al(1987)). All 
of these factors acting alone or in concert may 
contribute to the frequency and complexicity of malignant 
veutricular rhythms in patients with congestive heart 
failure. The mechanisms and evidence for the 
arrhythmogenic potential of hypokalaemia and 
hypomagnesaemia have been previously discussed in sections
1.6 and 1.7.
A similar sequence of arrhythmic events has been 
postulated to occur during the administration of diuretics 
in hypertensive patients (Medical Research Council working 
party on mild to moderate hypertension,(1983); Holland, 
O.B., Nixon, J.V. & Kohnert, L.(1981); Papademetriou, V. 
et al(1983)), and may explain the failure of diuretic 
therapy to reduce overall cardiovascular mortality in 
these patients in large-scale trials (Hollifield,
J.W.(1984)).
Another important factor which may contribute to 
ventricular arrhythmogenesis in patients with cardiac 
failure is the use of positive inotropic therapy. The 
most commonly used drug available for oral therapy is
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digoxin, a cardiac glycoside. Although digoxin is 
effective as an agent which increases cardiac 
contractility, it has the disturbing side effect of also 
increasing cardiac irritability. This drug has a narrow 
toxic-therapeutic ratio and in the presence of 
hypokalaemia and hypercalcaemia may provoke serious 
ventricular arrhythmias. Such malignant arrhythmias may 
contribute to the increased cardiovascular mortality noted 
in patients with heart failure and complex ventricular 
ectopy who receive long-term digitalis therapy after an 
acute myocardial infarction (Bigger, J.T. Jr. et 
al (1985)).
Recently developed inotropic agents enhance myocardial 
contractility by increasing intra-myocellular levels of 
cyclic AMP, either by promoting its synthesis 
(catecholamines) or by inhibiting its degradation 
(phosphodiesterase inhibitors): both mechanisms are 
potentially arrhythmogenic. Although intravenously 
administered catacholamines can increase ventricular 
ectopy in patients with congestive heart failure, neither 
dopamine or dobutamine appear to have increased the risk 
for sudden death, since these drugs are not generally 
administered over a long term. Orally active 
phosphodiesterase inhibitors (such as amrinone, milrinone 
and enoximone) are being developed for long-term use and 
appear to have a similar arrhythmogenic potential. This
58
may explain the high incidence of sudden death in patients 
with cardiac failure treated with these agents (Packer,
M., Medina, N. & Yusak, M.(1984)). The Promise Study 
Research Group reported in 1991 on a trial comparing oral 
milrinone with placebo, in patients with grade IV heart 
failure. After a mean follow-up period of 6.1 months, 
mortality was 28% higher in the milrinone group.
1.11 Antiarrhythmic drug therapy in congestive heart 
failure.
In attempting to design a therapeutic approach to the 
prevention of sudden unexpected death in patients with 
congestive heart failure, two central questions need to be 
considered. Firstly which patients with congestive heart 
failure are at a high risk of sudden death and should 
receive prophylactic therapy, and secondly, are 
conventional anti-arrhythmic drugs succesful in preventing 
sudden death in these patients? Although there is general 
agreement that patients with symptomatic ventricular 
tachycardia or ventricular fibrillation should be treated 
to prevent future sudden unexpected death, only a small 
proportion of patients with heart failure who die suddenly 
experience premonitory symptoms. The clinical picture in 
most patients is so dominated by dyspnoea and fatigue that 
the first manifestation of a clinically important
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arrhythmia may be sudden death itself. Some workers have 
suggested that the finding of complex ventricular rhythms, 
in particular non-sustained ventricular tachycardia, 
during ambulatory electrocardiographic monitoring may 
predict future fatal ventricular arrhythmias. However, a 
number of reports indicate that pre-existing spontaneous 
ventricular tachycardia is only a predictor of total 
mortality and not sudden cardiac death (Meinertz, T. et 
al(1984); Huang, S.K. et al(1983); Wilson, J.R. et al 
(1983); Holmes, J. et al(1985)).
Other observers have suggested that the finding of 
sustained ventricular tachycardia during programmed 
ventricular stimulation can identify a high risk 
population (Kaul, U. et al(1987)). However the 
arrhythmias in patients with non-ischaemic cardiac failure 
may be particularly resistant to electrical provocation 
(Naccarelli, G.V. et al(1982); Wellens, H.J.J., Duren,
D.R. & Lie, K.I.(1976)). The lack of success in inducing 
ventricular tachycardia in these studies was in contrast 
to Poll, D.S. et al(1984), who found that in eleven 
patients with idiopathic dilated cardiomyopathy and 
sustained ventricular tachycardia, programmed stimulation 
reproducably induced venticular tachycardia in all 
patients.
The high incidence of ventricular arrhythmias and sudden 
death in patients with heart failure has encouraged many
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clinicians to treat patients with anti-arrhythmic agents 
in the hope of prolonging survival. This has been made on 
the assumption that conventional anti-arrhythmic therapy 
will reduce or abolish ventricular arrhythmias and that 
the suppression of these arrhythmias will reduce the 
likelihood of sudden death.
Whether or not this approach is appropriate depends on two 
important factors. Firstly, does the use of anti- 
arrhythmic drugs prolong survival of patients with heart 
failure? Secondly do the adverse effects of these drugs 
outweigh any potential benifits?
The hypothesis that administration of anti-arrhythmic 
therapy to patients with heart failure reduces the 
incidence of lethal ventricular arrhythmias and thereby 
prolongs survival is an attractive one. Consequently, 
several investigators have attempted to test this proposal 
by assessing the effect of anti-arrhythmic therapy on 
survival in patients with heart failure, although no 
large-scale placebo-controlled trials have been published. 
Two basic types of study have been conducted in patients 
with heart failure. Firstly there are those in which the 
patients are non-randomly assigned to anti-arrhythmic 
therapy, and secondly there are studies in which the anti- 
arrhythmic therapy is directed by electrophysiological 
testing prior to treatment, (table 2).
Table 2.
The effect of anti-arrhythmic treatment on prognosis in 
congestive heart failure.
Study________ EPS_______ Sudden death Overall mortality
Farraley No — Reduced
Cleland No Reduced Reduced
Neri No Reduced No effect
Chakko No No effect No effect
Gomez Yes Increased Increased
Poll Yes - -
Kaul Yes Increased No effect
EPS = Electrophysiological study.
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Parmley, W.W. & Chatterjee, K.(1986), analyzed the 
incidence of sudden death in a sub group of patients with 
heart failure and complex ventricular arrythmias who were 
treated with class one agents (procainamide or quinide) 
n=26, or amiodarone n=13. This subgroup had a cumulative 
survival of 90-95% at 6 months compared to 65% in patients 
not receiving antarrythmic therapy (p<0.05). It was 
therefore proposed that antiarrythic therapy may be of 
benefit in patients with heart failure. Cleland, J.G.F. 
et al(1987) studied clinical variables of prognostic 
significance in 152 patients with heart failure. Within 
this study group 41 patients were treated with amiodarone 
and the rest were not. The authors found that overall 
mortality was reduced in the group of patients treated 
with amiodarone, and in particular the incidence of sudden 
death was reduced. Interestingly, in contrast to the 
Consensus Trial Study Group,(1987), the effect of 
angiotensin converting enzyme inhibition was also to 
reduce the incidence of sudden death, but to have no 
effect on overall mortality. This ambiguity highlights 
the problems in retrospective studies with small numbers 
of patients which are not blinded or randomised, and which 
try to predict clinical features of prognostic 
significance. Another study by Neri, R. et al(1987), 
studied 65 patients with dilated cardiomyopathy. Fifty 
two patients in the study were found to have evidence of
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complex ventricular ectopy as detected by Holter 
ambulatory ECG monitoring. Forty one of these patients 
were treated with amiodarone. The authors found that the 
incidence of sudden death was significantly reduced in the 
group which received anti-arrhythmic therapy. The small 
number of events in this study(only 4 sudden deaths 
occured) would make it unlikely that the statistical 
significance in the reduction in the incidence of sudden 
death was clinically significant.
In contrast to the above studies, Chakko, C.S. & 
Gheorghiade, M.(1985), followed 43 patients with chronic 
heart failure due to dilated cardiomyopathy (28 ischaemic, 
15 idiopathic). On Holter monitoring 88% of the patients 
were noted to have complex venticular arrythmias and non­
sustained ventricular tachycardia was seen in 51 %. 23 of
the patients were placed on long-term therapy with 
procainamide (n=20) or quinidine (n=3). The remaining 20 
patients did not receive antiarrythic therapy. Both 
groups were clinically comparable. At a mean follow-up 
period of 16 months, 16 deaths had occurred, 62% of which 
were caterogized as sudden. No significant difference was 
noted in the survival of patients receiving antiarryhthmic 
therapy compared with those not receiving therapy.
The result of studies using electrophysiological testing 
are also conflicting and methodologically limited. Gomes,
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J.A.C. et al(1984) studied 73 patients with asymptomatic 
complex ventricular arrhythmias. 77% of these patients 
had ischaemic heart disease and had had a myocardial 
infarction at least 6 months previously. 14% had 
cardiomyopathy or valvular heart disease. 
Electrophysiological testing was performed with single or 
double extrastimuli at 2 paced cycle lengths at the right 
ventricular apex and outflow tract. Electrophysiological 
testing identified 20 patients (27%) in whom ventricular 
tachycardia or fibrillation was induced. 17 of the 20 
patients with inducible arrhythmias were placed on 
antiarrhythmic therapy as directed by electrophysiological 
testing, whereas the other patients were randomly 
allocated to antiarrhythmic or no antiarrhythmic therapy. 
The incidence of sustained ventricular tachycardia and/or 
sudden death was 31% in the former group despite directed 
therapy, and only 2% in the latter group. The results 
from this study therefore suggest that 
electrophysiological testing may identify a high risk 
group, however little definitive information is yielded 
about the value of anti-arrhythmic therapy. Poll, D.S. et 
al(1984) have suggested that conventional anti-arrhythmic 
therapy may be relatively ineffective in patients with 
heart failure. They studied 11 consecutive patients with 
idiopathic dilated cardiomyopathy and spontaneous 
sustained ventricular tachycardia. Electrophysiological
64
testing induced the arrhythmias in all 11 patients.
Despite evaluation of 3.7 ^ 2.4 antiarrhythmic drugs per 
patient, including amiodarone in 8, 9 of the 11 patients 
continued to have inducible ventricular tachycardia on all 
drugs. During follow-up 6 patients had sudden death or 
recurrent ventricular tachycardia. Another study assessed 
the effect of anti-arrhythmic therapy in patients with 
complex ventricular ectopy and ventricular tachycardia 
which was induced by programmed electrical stimulation, 
and compared this study group to other patients with 
complex ventricular ectopy but no inducible ventricular 
tachycardia. The latter group were given no anti- 
arrhythmic treatment (Kaul, U. et al(1987)). The authors 
found that the incidence of sudden death was significantly 
higher in the group of patients treated with anti- 
arrhythmic therapy compared to those who were not. One 
significant problem with this study is that the patient 
population was heterogeneous and included 21 patients with 
no structural heart disease. None of these patients had 
inducible ventricular tachycardia and would therefore have 
biased the results as the mortality in these patients 
would presumably be lower than in patients with structural 
heart disease.
In summary therefore, current information is inadequate 
but does not support the administration of conventional 
antiarrhythmic drugs to patients with chronic heart
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failure either directed by electrophysiological studies or 
given empirically.
The most successful approaches to the control of 
arrhythmias in the future for patients with congestive 
heart failure may be endomyocardial resection of the re­
entry pathway(guided by electrophysiological mapping) or 
the use of an automatic implantable defibrillator (Poll, 
D.S. et al(1984)). The use of surgery may be limited 
however as patients often have poor left ventricular 
function. Although the use of such aggressive and 
expensive therapies may be indicated for patients with 
symptomatic ventricular tachyarrhythmias, they are not 
practical solutions to the problem of sudden death in most 
patients with heart failure. With the advent of 
pharmacological agents which can improve pump performance, 
sudden unexpected death from ventricular tachyarrhythmias 
may soon become the most common cause of death in patients 
with congestive cardiac failure. In addition to 
haemodynamic and neurohormonal factors, and the commonly 
used inotropes and diuretics in cardiac failure, there may 
also be an underlying abnormality in cardiac 
electrophysiology which either independently or in 
conjunction with neurohormonal activation may predispose 
to sudden unexpected death. Clinical investigation by 
cardiac electrophysiology has been confined to studies
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which are concerned with the inducibility of ventricular 
tachyarrhythmias in patients with cardiac failure. These 
studies are normally conducted only once in any given 
patient, and are unlikely to involve a control group of 
patients. The measurement of electrophysiological 
parameters such as ventricular repolarisation and 
refractoriness(abnormalities of which may predispose to 
sudden death) in a "one-off" situation would therefore be 
meaningless. Repeated electrophysiological studies in 
patients with cardiac failure or in suitable controls 
would be unethical as cardiac catheterisation is an 
invasive technique not without morbidity and mortality, 
and repeated exposure to such an investigation would 
further compound the risks involved.
There is a need therefore for animal models of chronic 
congestive cardiac failure in which the basic 
electrophysiological mechanisms underlying the 
predisposition to sudden death, and the interrelationship 
between the myocardial electrophysiological substrate, 
neurohormonal activity and inducibility of arrhythmias can 
be studied in detail. Previous publications have 
discussed the electrophysiological changes and 
inducibility of arrhythmias after experimental myocardial 
infarction (Cobbe, S.M. et al(1985); Spear, J.F., 
Michelson, E.L. & Moore, E.N. (1983); Donaldson, R.M. et
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al(1983)), but have not studied animals showing evidence 
of congestive heart failure.
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1.12 Animals models of congestive heart failure(table 3)
A number of methods are available to induce heart failure 
experimentally in animals. Most of these models are 
limited in their usefulness however, as they more readily 
lend themselves to the study of specific problems rather 
than the clinical syndrome of heart failure which is 
dominated by dyspnoea and fatigue. The techniques which 
have been employed to induce heart failure experimentally 
include pressure overload, volume overload and conditions 
in which the myocardium itself is directly damaged,(Smith,
H.J. & Nuttall, A.)
Pressure loading has been used in a number of species to 
induce ventricular hypertrophy and thence failure.
Gelband, H. & Bassett, A.L.(1973) produced right 
ventricular hypertrophy and subsequently failure in cats 
by partial occlusion of the pulmonary artery. The extent 
to which heart failure occured varied considerably between 
animals in the experiments described, and also developed 
over a variable timecourse. Welham, K.C., Silove, E.D. & 
Wyse, R.K.H.(1978) described similar experiments in the 
pig. The authors employed a similar technique to that 
used in cats, and again found that the degree of heart 
failure which occured was variable, with only about two 
thirds of the animals demonstratimg signs of heart 
failure, although all of the animals had evidence of right
Animals models of congestive heart failure.
Author Species
Pressure load Gelband and Basset Cat
Wellham et al Pig
Mercadier et al Rat
Alexander et al Rabbit
Sordahl et al Rabbit
Volume load Flaim et al Rat
Carabello et al Rabbit
Natarajan et al Cat
Forester et al Dog
Myocardial infarction/ 
Cardiomyopathy
Miller et al Dog
Kirk et al Dog
Brooks et al Pig
Pfeffer et al Rat
Bajuze Hamster
Einzig et al Turkey
Laks et al Dog
Arnolda et al Rabbit
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ventricular hypertrophy. An inherent problem with the 
above studies is the degree of technical difficulty which 
is involved. The use of general anaesthesia and surgical 
thoracotomy inevitably lead to a high mortality.
A number of studies have attempted to induce left 
ventricular hypertrophy by constriction of the aorta with 
similar results to those above (Mercadier, J.J. et 
al(1981)1; Alexander, N., Hinshaw, L.B. & Drury, 
D.R.(1957); Sordahl, L.A., Wood, W.G. & Scharwz,
A. (1970)).
The animals models of pressure loading would seem 
therefore more suited to the study of ventricular 
hypertrophy than heart failure.
Volume overload may be induced by the surgical creation of 
aortic to vena-caval fistulae (Flaim, S.F. et al(1979)), 
aortic valve incompetence (Cerabello, B.A. et al(1981)), 
and atrial septal defects (Natarajan, G. et al(1979)). 
Although these techniques may induce heart failure, and be 
of use in the study of the specific models which they 
reproduce, they are not directly relevant to the syndrome 
of heart failure which occurs in the majority of patients.
The model of experimental heart failure which would seem 
to be the most attractive on the basis of clinical
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relevance is that of heart failure occuring after 
myocardial infarction.
Several workers have employed coronary artery occlusion to 
produce myocardial infarction and thence failure 
(Forester, J.S. et al(1972); Miller, R.R., Awan, N.A.& 
Mason, D.T.(1978); Kirk, E.S. et al(1978); Brooks, M., 
Holland, R., AL-Sadir, J.(1977); Pfeffer, J.M., Pfeffer, 
M.A. & Braunwald, E.(1987)). Although this model of 
heart failure is clinically relevant, the heart failure 
which occurs is usually acute and cardiogenic shock often 
supervenes (Lluch, S. et al(1969)).
Another intrinsic problem with such studies is the initial 
mortality rates which may be as high as 50% (Pfeffer, J.M. 
et al(1987)). It would seem therefore that animal models 
of heart failure induced by myocardial infarction are 
unsuitable for the study of chronic heart failure.
The final type of model of experimental heart failure is 
that of the cardiomyopathies. A cardiomyopathy is known 
to occur spontaneously in a specific species of Syrian 
hamster, first described by Bajusz, E.(1969). A naturally 
occuring cardiomyopathy also exists in turkeys (Einzig, S. 
et al(1980)). Other workers have employed acute or 
chronic administration of catecholamines to induce 
myocardial infarction, in particular isoprenaline (Kahn,
D.S., Roden, G. fit Chappel, C.I.(1969)) and noradrenaline
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(Laks, M.M., Morady, B.A. & Swan, M.J.C.(1973)). The use 
of catecholamines in animals has also been found to 
produce myocardial necrosis (Reichenbach, D.D. & Benditt,
E.P.(1970)). The clinical relevance of such models is 
unclear but there have been reports of a clinical 
cardiomyopathy associated with chronic amphetamine useage 
(Smith, H.J. et al(1976)).
1.13 Clinical and experimental aspects of adriamycin 
cardiomyopathy.
Perhaps the myocardial toxin which has been most 
extensively studied in animals is adriamycin. Adriamycin 
is a tetracyclic aglycone to which an amino sugar is 
attached through a glycosidic linkage. This drug is a 
potent broad spectrum chemotherapeutic agent which is 
effective against human malignancy such as leukaemias, 
lymphomas and many solid tumors (Blum, R.H. & Carter, 
S.K.(1984)). The cardiotoxic effects of adriamycin can be 
subdivided into acute and chronic depending on their 
temporal relationship to the administration of the drug. 
The acute cardiovascular effects of the drug develop 
within minutes or hours after its intravenous injection, 
and are characterised by hypotension, tachycardia and 
arrhythmias (Singal, P.K., Deally, C.M.R. & Weinberg,
L.E.(1987)). Acute cardiac decompensation in patients
72
however is not commonly observed during administration of 
the drug (Appelfield, M.M. & Egorin, M.J.(1984)).
Although the acute administration of adriamycin has been 
associated with sudden death in a small number of patients 
(Wortman, J.E. et al(1979)), a number of other studies 
have reported a lack of arrythmias associated with the 
drug. Friers, G.G. et al(1985) investigated a total 
number of 30 patients by continuous ECG monitoring, 24 
hours before, during and 24 hours after adriamycin 
administration. Nine of the 30 patients experienced 
ventricular ectopy prior to adriamycin administration.
Five of the these patients had a decline in the severity 
of their arrhythmias with treatment, 3 patients arrhythmia 
was unchanged and 1 patients arrythmia increased in 
severity. Conversely 6 patients had ventricular ectopy 
observed after treatment where none was seen before 
treatment. No patient experienced cardiac symptoms in 
conjunction with ectopy on the monitor tracing. In the 
remaining 15 patients in this study, no ventricular ectopy 
was seen before or after treatment. There were no 
instances in any patients of ventricular ectopic beats 
occuring in the form of triplets or salvoes, ventricular 
tachycardia or ventricular fibrillation.
Although Wortmann, J.E. et al(1979) described 3 cases of 
sudden death associated with acute adriamycin 
cardiotoxicity as described previously, the 3 cases were
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amoung approximately 550 individual patient treatments 
with adriamycin over a 3 month period and therefore 
represent an uncommon clinical occurence.
Chronic administration of adriamycin to patients is 
associated with the development of a cardiomyopathy which 
often leads to congestive cardiac failure (Buja, L.M. et 
al(1973); Lefrak, E.A. et al(1973); Von Hoff, D.D. et 
al(1979)). Patients treated by repeated injections of the 
drug may eventually show marked hypotension, tachycardia, 
cardiac dilatation and ventricular failure which is 
refractory to positive inotropic drugs and mechanical 
circulatory assistance (Lefrak, E.A. et al(1973)). 
Increases in serum lactate dehydrogenase and creatinine 
phosphokinase have also been reported in patients 
developing heart failure: Lefrak, E.A. et al(1973).
The incidence of adriamycin-induced cardiomyopathy is 
directly related to the cumulative dose of the drug. The 
incidence of the cardiomyopathy increases with increasing 
total dose to 3.5% of patients given 400mg/m2, 7% of those 
given 550mg/m2 and 15% of those given 700mg/m2 (Appelbaum,
F.R. et al(1976); Von Hoff, D.D. et al(1979)). The 
observation of this dose-dependent cardiomyopathy has led 
to the recommendation that the total dose not exceed 
550mg/m2 (Blum, R.H. & Carter, S.K.(1974); Gottlieb, J.A. 
et al(1973)).
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The morphological changes associated with chronic 
adriamycin cardiotoxicity in humans are characterised by 
myofibrillar loss and a marked cytoplasmic vacuolization 
(Billingham, M.E.(1979); Lefrak, E.A. et al(1973)), due to 
swelling of the sarcotubular system. Other changes 
which are known to occur include structural abnormalities 
in mitochondria, increased numbers of lysosomes and a 
accumulation of lipids (Ferrans, V.J.(1978); Singal, P.K. 
et al(1985)). A number of common features of adriamycin- 
induced structural change have been found in the 
myocardium of a variety of species other than man. These 
include rabbits: Jaenke, R.A. (1974); Olson, H.M. et
al(1974), mice: Lambertenghi-Delliers, G., Zanon, P.L. &
Pozzoli, E.F.(1976); Myers, C.E. et al(1977), and rats: 
Callcroft, S.C.W., Gavin, J.B. & Herdon, P.B.(1973); 
Singal, P.K. et al(1985).
Although the morphological changes induced by adriamycin 
can be detected by light microscopy, electron microscopy 
is used for more accurate and specific scoring of the 
degree of cardiotoxicity. A point scoring system for 
assessment of the degree of cardiac damage has been 
described by Bristow, M.R. et al(1978). The cardiac 
biopsies in the above study were scored as follows: 0 was 
allocated to normal biopsies, 1 = scanty cells showing 
early myofibrillar dropout or swelling of the sarcoplasmic 
reticulum, or both, 2 = more widespread changes, with
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groups of cells showing definite myofibrillar dropout or 
definite cytoplasmic vacuolization, or both, and 3 = 
diffuse myocyte damage with more marked cellular changes 
and frank necrosis.
The exact aetiology of adriamycin-induced cardiotoxicity 
is undefined, but two possible mechanisms have beeen 
proposed. Firstly, an increase in intracellular calcium: 
Olson, H.M. et al(1974); Revis, N. & Marusic, N.(1979), 
and secondly damage to cellular and organellar membranes 
by the production of free radicals: Myers, C.E. et 
al(1977); Milei, J. et al(1986); Bachur, N.R., Gordon,
S.L. & Gee, M.V.(1977).
Although the importance of morphological and subcellular 
abnormalities are important in the assessment of animal 
models of heart failure, the syndrome itself is not a 
pathological diagnosis. It is therefore necessary to 
study such models from a haemodynamic aspect and to 
ascertain whether or not there are functional 
abnormalities which would be consistent with a diagnosis 
of chronic heart failure.
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1.14 Experimental haemodynamic aspects of adriamycin 
cardiomyopathy in the rabbit.
Two recent publications have extensively studied 
adriamycin cardiomyopathy in the rabbit and have reached 
similar conclusions with regard to central haemodynamics 
and regional blood flow. Arnolda, L. et al(1985), 
injected New Zealand White rabbits with intravenous 
adriamycin lmg.kg-1 twice weekly for 8 weeks. This was a 
specific dosage regimen designed to limit marrow toxicity: 
Arnolda, L. et al(1985). The authors measured cardiac 
output by the thermodilution technique using a chronically 
inplanted aortic thermister catheter which was inserted 
via the illio-lumbar artery under halothane anaesthesia, 2 
weeks prior to the commencement of adriamycin therapy. 
Blood pressure was measured via a catheter in the ear 
artery and right atrial pressure via an external jugular 
catheter. Both catheters were inserted on the day of 
haemodynamic study under local anaesthetic. Renal blood 
flow in this study was measured by the clearance of125I 
labelled ortho-iodohippurate using a single injection 
method. The haemodynamic studies were performed on 6 
rabbits at weeks 0 and 8 of the study protocol. Plasma 
renin activity, noradrenaline and vasopressin levels were 
also measured at weeks 0,4 and 8. At the end of the study 
protocol the animals were sacrificed and the hearts were
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blotted dry, weighed and samples fixed for histological 
assesment. As well as plasma neurohormonal analysis, 
samples were also taken for Na*, K* and creatinine.
After 8 weeks treatment with adriamycin, the authors found 
that cardiac output had decreased significantly from 
799*61 ml.min-1 to 624:144ml .min-1, representing a fall of 
22%. They also observed a parallel fall in mean blood 
pressure and an increase in total peripheral resistance in 
4 out of 6 animals. Renal blood flow also fell 
significantly over an eight week period and renal vascular 
resistance increased in all animals. No change was 
observed in plasma vasopressin levels over an 8 week 
period but plasma renin activity increased significantly 
by week 4 and plasma noradrenaline levels increased 
significantly by week 8 of the study. No significant 
changes were found in either plasma Na*,K* or creatinine 
over an 8 week period. Marked pathological changes were 
also found at post-mortem, with evidence in all of the 
adriamycin treated animals of serous effusions, left 
ventricular hypertrophy and fibrosis. The heart weights 
of the test group were significantly increased when 
compared to controls and this difference was accentuated 
when the heart weights were expressed as a ratio of the 
body weight which tended to be less in the adriamycin 
group. Microscopic examination also revealed the classic 
morphological changes associated with adriamycin therapy
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which include widespread atrophy and lysis of cardiac 
myocytes, associated interstitial fibrosis, extensive 
myocyte vacuolation and a generalised reduction in 
myofilament numbers.
The second study which has examined the central 
haemodynamics and regional blood flow in adriamycin 
cardiomyopathy in the rabbit is that by (Wanless, R.B. et 
al(1987)). The injections of adriamycin in this study 
were according to the same protocol as Arnolda et al 1985 
ie lmg.kg-1 intravenously twice weekly. The duration of 
the injection protocol was altered between different 
study groups. The different groups were injected for 
periods of 6,8 and 10 weeks, with a further group injected 
for 8 weeks with a 2 week period then allowed before 
making haemodynamic measurements to allow for recovery 
from the unwanted systemic side-effects of the drug. Two 
further groups of animals were also studied, the first on 
arrival in the animal unit and the second after 8 weeks of 
identical conditions to the study groups. The insertion 
of the catheters for haemodynamic study was carried out 
under sodium pentobarbitone anaesthesia at the end of each 
injection protocol. This aspect of the Wanless study was 
different to the Arnolda report in that Arnolda had 
chronically implanted catheters. Right atrial pressure 
was measured with a catheter inserted into this chamber 
via the right external jugular vein. A catheter was also
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inserted into the carotid artery and thence into the left 
ventricle and ascending aorta. A further catheter bearing 
a thermister probe was also inserted into the descending 
aorta via the femoral artery. The haemodynamic 
measurements in this study were performed 48 hours after 
surgery in conscious unrestrained animals.
Another additional aspect of the Wanless study was an 
attempt to assess the response of the heart to increased 
stress. Because it is not possible to induce rabbits to 
exercise, the authors attempted to assess the cardiac 
response to stress by volume expansion with an infusion of 
50ml of isotonic dextrose intravenously. During the 15- 
30 minutes following the intravenous infusion, the cardiac 
output was repeatedly measured as the right atrial 
pressure fell, thus allowing the construction of Frank- 
Starling curves.
When the central haemodynamic measurements were stable, 
cardiac output was measured by thermodilution, regional 
blood flow by the radioactive microsphere technique, and 
right atrial and system blood pressure were also 
continuously monitored. Venous blood samples were also 
taken for measurement of plasma Na^, urea , protein 
content, haemoglobin and white cell count.
Wanless et al 1987 found that after 6 weeks treatment with 
adriamycin, cardiac output fell by 27%, after 8 weeks by 
31% and 2 weeks after 8 weeks treatment by 52%. The
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greater reduction in cardiac output in this study when 
compared to Arnolda et al 1985, could be explained by the 
more accurate measurment of a low cardiac output using a 
left ventricular injection of cold saline. Total 
peripheral resistance increased significantly when 
compared to controls at week 8 although there was no 
change in the mean systolic blood pressure. Right atrial 
blood pressure also increased as treatment progressed, 
becoming significant when compared to controls 2 weeks 
after 8 weeks of treatment. Renal tissue vascular 
resistance increased in parallel with total systemic 
resistance and myocardial and cerebral tissue vascular 
resistance were also found to have increased but again 
only 2 weeks after 8 weeks of treatment. The Frank- 
Starling curves in the cardiomyopathic rabbits were 
clearly distinguishable from the control animals with a 
flattened response seen as a right atrial pressure 
increased. No haemodynamic changes were observed in this 
study between the animals in the control group who were 
studied immediately and those who were studied after 8 
weeks in the animal unit.
Haemoglobin levels decreased significantly after 6 weeks 
of treatment and the white cell count tended to decrease 
although these changes did not reach statistical 
significance. Both of thes parameters returned to control 
values in those animals treated for 8 weeks and then
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allowed to recover for 2 weeks. These results would tend 
to support the premise that 8 weeks of treatment followed 
by a two week recovery period, allows for minimisation of 
the toxic systemic side-effects of the drug.
An interesting difference between the Arnolda and Wanless 
studies is the presence in the former of ascites and 
pleural and pericardial effusions and their absence in the 
study by Wanless et al. It was noted however by Wanless 
et al, that chronic implantation of catheters gave rise to 
endocarditis and severe nephrotic syndrome. Vegetations 
could be seen on the catheter tips and the animals 
developed proteinuria, hypoproteinaemia and serous 
effusions. When the catheters for haemodynamic study were 
implanted only two days prior to the measurments being 
made, such complications were avoided.
From the 2 studies we can see therefore that the model of 
chronic heart failure in the rabbit, induced by the 
cardiotoxin adriamycin has been extensively studied 
haemodynamically and has been shown to produce chronic 
stable, low-output heart failure over a 10 week period.
It would seem therefore that this model has the advantage 
over some of the others which have been previously 
described. Cardiogenic shock does not appear following 
the initial treatment with the drug, (a situation often 
seen following acute coronary ligation) and secondly the 
haemodynamic features of this model and its chronicity
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have many features in common with the broader clinical 
aspects of chronic heart failure.
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1.15 An experimental model for chronic measurement of 
ventricular repolarisation and refractoriness in vivo.
To study in detail the basic electrophysological 
mechanisms underlying the predisposition to sudden death 
in chronic heart failure, a technique is required which 
allows chronic measurement of basic myocardial 
electrophysiological parameters such as repolarisation and 
refractoriness in conscious, unsedated, unrestrained 
animals. Such a technique has been previosly described by 
Manley, B.S. et al(1989). They described a method whereby 
both ventricular repolarisation and refractoriness can be 
measured in vivoby virtue of a chronically implanted 
conventional bipolar pacing electrode. Ventricular 
repolarisation time was measured by recording the 
ventricular paced evoked response by means of an interface 
depolariser (Walton, C., Economides, A.P. & Gergely,
S.(1985)). The paced evoked response is the local 
unipolar electrogram recorded from the right ventricular 
apex while the animals are being paced. The function of 
the interface depolariser is to counteract the capacitive 
charge stored at the electrode endocardial interface as a 
result of the delivery of the pacing stimulus, and it 
allows accurate recordings of the local electrogram to be 
made as early as 5 ms following delivery of the pacing 
stimulus. The stimulus-T interval of the paced evoked
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Figure 1.
Graph illustrating in the upper panel 4 cycles of the 
unpaced surface ECG, and in the lower panel 4 cycles of the 
unpaced right ventricular electrogram.
00 V/DIV ?0. Oms/DIV
CHI.
CHI
CH2
Figure 2.
Simultaneous recording of surface ECG(upper panel) and 
right ventricular paced evoked response (lower panel), during 
right ventricular pacing at cycle length 180ms. The larger 
amplitude and clearer peak of the T wave can be seen in the 
paced evoked response.
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made as early as 5 ms following delivery of the pacing 
stimulus. The stimulus-T interval of the paced evoked 
response is the measurement of ventricular repolarisation 
time. The advantages of this method of measuring 
repolarisation time over the more conventional surface QT 
interval are that the peak of the T wave is well defined 
in comparison to the surface ECG, and that with the 
animals in this study being paced at a constant cycle 
length, no corrective measures are required for changes in 
heart rate, (Fig. 1 and 2). Unpaced QT intervals are 
normally corrected for changes in heart rate by the 
formula described by Bazett HC in 1920. However, recent 
evidence has shown that such corrections are unreliable 
since they do not take into account factors which alter 
repolarisation independently of changes in heart rate 
(Brown, K.F. et al(1982); Butrous, G.S.(1986)). Manley,
B.S. (1989) has also shown that the stimulus-T interval of 
the paced evoked response corresponds closely to the 
cardiac intracellular action potential duration. To prove 
this hypothesis they studied the electrophysiology of the 
isolated perfused rabbit interventricular septum, and by 
recording from both the pacing electrode and a floating 
glass intracellular microelectrode, the paced evoked 
response and cardiac action potential duration could be 
measured simultaneously. To allow assesment of the 
relationship over as wide a range of values of action
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included the addition of d-sotalol to prolong action 
potential duration and exposure to hypoxia to shorten 
action potential duration. The result of these 
experiments was that the stimulus-T interval of the paced 
evoked response and action potential duration were found 
to be strongly correlated (r=0.96).
Effective refractory period was also measured chronically 
by recording the signal from subcutaneous stainless steel 
ECG electrodes and pacing the animals by means of an 
isolated stimulator, driven by a microcomputer based 
programmable pulse genarator. The important conclusion 
from the study by Manley, B.S. et al(1989), is that the 
technique which they have described allows for accurate 
reproducible measurements of both ventricular 
repolarisation time and refractorness for up to 150 days 
following implantation of the pacing electrode, after 
allowing for a 3 week period during which time the 
electrophysiological measurements were allowed to 
stabilise.
The development of a haemodynamically stable model of 
chronic heart failure in the rabbit by virtue of the 
injection of the cardiotoxic adriamycin as described by 
Arnolda, L. et al (1985) and Wanless, R.B. et al(1987), 
and the development of a technique whereby ventricular 
repolarisation and refractoriness can be measured 
chronically in the same species, would seem therfore to
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provide the required means for assessing the myocardial 
electrophysiological substrate which may provide a clue to 
the pathogenisis of sudden death in heart failure. 
Technical difficulties, in particular the problems 
associated with the development of chronic heart failure 
experimentally (as previously outlined), have meant that 
there is little information available from animal studies 
with regard to chronic in vivo electrophysiological 
changes in heart failure. Similar inherent problems exist 
with attempts to define changes in action potential 
morphology in vitro as previously discussed in chapter
1.5.
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CHAPTER 2 
AIMS OF THE STUDY
The principal aim of this study was to investigate the 
electrophysiological changes in adriamycin cardiomyopathy 
in the rabbit, by measuring ventricular repolarisation and 
refractoriness.
The study was designed to investigate the basic 
electrophysiological changes which occur in heart failure 
as a result of myocardial damage, and the 
interrelationship between the myocardial
electrophysiological substrate, neurohormonal activity and 
the inducibility of arrhythmias.
The hypothesis proposed is that changes in ventricular 
repolarisation and refractoriness may occur in heart 
failure and predispose to arrhythmias and sudden death.
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CHAPTER 3 
GENERAL METHODOLOGY
3.1 In vivo electrophysiological studies.
Adult New Zealand white rabbits 2.5-3.5 kg in weight were 
premedicated with fentanyl/fluanisone (Hypnorm,Janssen) 
0.3ml.Kg-1 intramuscularly. Anaesthesia was maintained on 
an oxygen/nitrous oxide/halothane mixture, administered 
via a mask. Using aseptic technique, a conventional, 
tined, bipolar permanent pacing electrode(Pacesetter 818) 
was introduced into the right internal jugular vein via a 
neck incision. The tip of the pacing electrode was 
positioned in the apex of the right ventricle using x-ray 
visualisation. The suitability of the electrode position 
was confirmed by recording the intrinsic ventricular 
electrogram and determining the ventricular pacing 
threshold. 4 stainless steel ECG electrodes (25mm2) were 
implanted subcutaneously and all leads were exteriorised 
via a mid-line dorsal incision. The animals wore jackets 
to protect the external leads from interference by the 
animal, while affording the operator easy access for 
electrophysiological recordings.
89
Following a 3 week period during which all 
electrophysiological measurements were allowed to 
stabilise (Manley, B.S. et al(1989)), animals were 
randomly allocated to either adriamycin-treated or control 
groups. Those animals in the treated group received 
adriamycin (Farmitalia Carlo Erba) lmg.Kg-1 intravenously, 
twice weekly for 8 weeks, and those in the control group 
0.9% saline in equivolumetric doses. After 8 weeks 
therapy, animals were left for a further 2 weeks and 
electively killed. For the duration of the study the 
animals were housed separately 1 per cage. They were fed 
a standard laboratory diet and were allowed to drink water 
ad libitum. The electrical lights in the laboratory were 
switched off at night to observe a normal light/dark 
cycle.
Animals were withdrawn from the study before the end of 
the 10 week protocol if they lost more than 10% of their 
initial body weight. Any other sign of distress or pain 
was also deemed a reason for withdrawal. All of the 
experiments in this study were conducted in observance 
with the Animals(Scientific Procedures) Act 1986.
3.2 Measurements.
Electrophysiological recordings were made in conscious, 
unrestrained, unsedated animals at weekly intervals for
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up to 10 weeks. The right ventricular paced evoked 
response (PER) was recorded from the pacing electrode by 
means of an interface depolariser (Walton, C. et 
al(1985)). This device counteracts the capacitative 
charge stored at the electrode-endocardial interface as a 
result of the delivery of the pacing stimulus. This 
allows accurate recordings of the local endocardial 
electrogram to be made from as early as 5ms after the 
pacing impulse. The amplifier settings on the interface 
depolariser were left unchanged during all of the 
electrophsiological studies. The subcutaneous ECG was 
recorded using a standard amplifier (model 4615-65, ECG 
Biotach,Gould Electronics). All signals were displayed on 
a digital storage oscilloscope(4125/125 Gould Electronics) 
which allowed PER waveforms to be averaged digitally and 
time and voltage measurements to be obtained by means of 
on-screen cursors.
Measurements were made of the Stimulus-R and Stimulus-T 
interval of the paced evoked response, defined as the time 
interval between the leading edge of the stimulus pulse 
and the nadir of the R wave (Stim-R), and the peak of the 
T wave (Stim-T) respectively (Fig.3). All measurements 
were made at paced cycle lengths of 200ms, 180ms and 160ms 
using averages of 8 beats. A minimum of 2 minutes was 
allowed after changing the pacing cycle lengths before 
making recordings to allow for electrical restitution
CH2
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Figure 3.
Graph illustrating 1 cycle of the paced evoked response 
from the right ventricle and demonstrating the Stimulus-R 
and Stimulus-T intervals.
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(Morgan, J.M., Cunningham, A.D. & Rowland, E.(1990)). The 
ECG signal was used for the determination of the effective 
refractory period by means of extra-stimuli delivered by a 
microcomputer-based programmable pulse generator, driving 
an isolated stimulator operating at twice diastolic 
threshold. Extra-stimuli(Sz) were delivered after 8 beats 
of the basic cycle length, initially 80ms after the pacing 
impulse(Si) and subsequently at 2ms increments. The ERP 
was defined as the longest Sx-Sz interval which failed to 
produce a response. The ERP was measured at the same 
cycle lengths as the PER.
Spontaneous sinus cycle length was measured by calculating 
the unpaced R-R interval from the right ventricular 
electrogram. The endocardial QT interval and the surface 
QT intervals were also measured from the beginning of the 
Q wave to the end of the T wave, at the point were the 
tangent to the T wave crosses the isoelectric line. 
Attempts were also made to determine ventricular 
fibrillation threshold by delivering a single pulse of 4ms 
duration after 8 ventricular paced beats at a cycle length 
of 180ms. The onset of each single pulse was adjusted to 
begin 80ms after the onset of the QRS complex and 
subsequently to scan diastole at 5ms increments. The 
strength of the pulse was increased from 1mA to a maximum 
of 50mA in 1mA increments( Inoue, H. et al(1987)).
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Continuous ambulatory ECG monitoring was undertaken using 
the signal from the right ventricular permanent pacing 
electrode. Armoured cable was used to protect the wire 
connecting the pacing electrode to the tape recorder. The 
signals were recorded onto standard C-60 magnetic tapes by 
means of Oxford MR 14 tape recorders. The heart rates was 
too rapid to permit analysis by convential Holter 
recording analysis systems. Tapes were therefore replayed 
and printed onto paper by means of total disclosure mode, 
and the presence of ventricular arrhythmias was noted by 
visual assessment.
Venous blood sampling from the marginal ear vein was 
undertaken at weeks 1, and 8 for plasma Na^, K^, Cl-, 
Mg2'", total protein, albumin and urea. Samples were also 
collected in EDTA and plain test-tubes which were kept in 
ice, for subsequent assay of plasma renin, atrial 
natriuretic peptide(ANP) and noradrenaline respectively. 
The venous blood was centrifuged at 2000 revolutions.min-1 
at a temperature of 4°C. The plasma was removed and 
stored in a freezer at -50° C. The assay methods employed 
for each hormone have been previously described (Millar, 
J.A., Leckie, B.J. & Morton, J.J.(1980); Richards, A.M. et 
al(1987); Prada, M. & Zurcher, G.(1976)).
After each animal died or when they were electively killed 
at the termination of the study, the hearts were excised 
and dissected free from the great vessels. They were then
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blotted dry and weighed. Samples were taken from either 
ventricle for assessment of the wet/dry weight ratio. For 
this purpose the weighed aliquots were placed in an oven 
at 60°C for 5-7 days, the dry weight being taken as the 
weight which was stable on 3 consecutive days. The 
remainder of the heart was placed in formalin for 
histological examination. The liver, kidneys and lungs 
were also removed, blotted dry and weighed, with samples 
taken for histology. Total body weight was recorded at 
the beginning and the end of the study.
3.3 Intracellular electrode studies.
As previously described, New Zealand white rabbits were 
injected with either adriamycin or 0.9% saline for 8 
weeks. Venous blood sampling was undertaken at weeks 1 
and 8 for plasma electrolytes, protein and neurohormonal 
assay. 2 weeks after the end of treatment, the animals 
were killed by an overdose of sodium pentobarbitone 
intravenously. The hearts were excised and the right 
ventricular papillary muscles removed and mounted in a 
tissue bath, volume 0.4ml. The remainder of the heart was 
blotted dry and weighed, with samples taken for histology 
from either ventricle. The liver, kidneys and lungs were
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also removed, blotted dry and weighed with samples stored 
in formalin for histological examination. Total body 
weight was recorded at the beginning and the end of the 
study.
The papillary muscles were superfused at 4ml.min-1 with a 
solution containing( in mmol.I-1) Na^ 142, 4.0, Ca2^
I.8, Mg2  ^ 1.0, Cl" 121, HC03- 28, H2P04" 0.4 and glucose
II.0. The fluid was equilibrated with 95% O2 and 5% CO2 . 
The muscles were field stimulated at 1 Hz using square 
wave stimuli of 1ms duration at twice diastolic threshold. 
The papillary muscles were maintained at 32° C and allowed 
to equilibrate for 3 hours before action potentials and 
ERP1s were recorded. Floating glass microelectrodes 
filled with 4 Molar KC1 were used to record transmembrane 
action potentials and the signals were amplified(model 
M710, WP instruments), displayed on a digital storage 
oscilloscope and recorded onto magnetic tape(storage-7DS, 
Racal) for later analysis. ERP's were determined by 
stimulating the papillary muscles at twice diastolic 
threshold at a cycle length of 1000ms. Extra-stimuli were 
introduced with an increasing S1-S2 interval duration 
until a second action potential was recorded. Action 
potentials were measured to 90% repolarisation APDgo and 
50% repolarisation APD50. The onset of the action 
potential was taken at the beginning of phase 0 
depolarisation. Action potential amplitudes wer%measured
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from the diastolic resting membrane potential to the spike 
of the overshoot. For each muscle, numerous impalements 
of cells were made to sample the population of cells.
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3.4 Statistical methods.
All data in this study is expressed as means(standard 
error of mean). Comparison of data was performed using 
the paired or unpaired Student's t test as appropriate. 
Data which were significantly different at baseline were 
compared by normalising the initial data and expressing 
subsequent data as the percentage change from baseline.
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CHAPTER 4
IN VIVO ELECTROPHYSIOLOGICAL CHANGES IN ADRIAMYCIN-INDUCED 
CHRONIC HEART FAILURE IN THE RABBIT.
This chapter details an investigation into the effects of 
experimental adriamycin cardiomyopathy on ventricular 
repolarisation and refractoriness, neurohormonal 
activation, electrolyte depletion and spontaneous and 
induced ventricular arrhythmias, in order to characterise 
possible mechanisms for the predisposition to sudden death 
in heart failure.
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4.1 Survival data(table 4).
A total of 16 animals entered the study in the adriamycin 
group and 11 animals in the saline control group. Of the 
adriamycin-treated animals, 2 died with evidence of 
subacute bacterial endocarditis(diagnosed by the presence 
of catheter tip vegetations, renal emboli, 
hypoproteinaemia and proteinuria). 1 animal developed 
ventricular fibrillation during rapid ventricular pacing 
at a cycle length of 140ms(no further animals were 
subsequently paced at this cycle length), 3 animals were 
found dead with no apparent cause(the animals were 
previously eating and drinking normally and no gross 
abnormalities were found at post-mortem examination), and 
10 animals survived to the end of the study protocol.
One rabbit died in the saline control group with evidence 
of subacute bacterial endocarditis, 2 animals died during 
radio-isotope scanning(as a result of inadequate isolation 
of recording apparatus) and 8 survived 10 weeks.
Table 4.
Survival data in the adriamycin and saline control groups.
Initial number OM SD SBE Other
Adriamycin 16 6 3 2 1
Saline control 9 3 0 1 2
Initial number = Initial number of animals in study. 
OM = Overall mortality.
SD = Sudden death.
SBE = Subacute bacterial endocarditis.
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4.2 Electrophysiology.
Acute effects of adriamvcinfFigures 4 and 5^
The stimulus-T interval and effective refractory period 
data were collected at cycle lengths ranging from 160ms- 
200ms, but the trends and results were similar at all 
cycle lengths. For simplicity therefore, only the data 
obtained at a cycle length of 180ms are presented. The 
stimulus-T interval and ERP were measured for 5 
consecutive days in 3 adriamycin and 3 saline control 
animals, following the first injection in week 1 of the 
study, to assess any acute effect of the drug on cardiac 
electrophysiology. No change was observed in either of 
these parameters over this period of time.
Chronic effects of adriamycin.
Prior to entering animals into the study protocol for 
weekly electrophysiological testing, the stimulus-T 
interval and the diastolic pacing threshold were measured 
twice weekly. Stable measurements of both these 
parameters were required before the animals entered the 
study. A total of 34 animals had permanent pacing 
electrodes implanted. Of these 27 eventually entered the 
study. The 7 animals which did not enter the study all 
died. The principal cause of death was infection. One of
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Figure 4.
Graph demonstrating the lack of any acute effect of 
adriamycin on the stimulus-T interval. The adriamycin 
treated animals are represented by the broken lines and the 
control animals by the continous lines.
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Figure 5.
Graph demonstrating the lack of any acute effect of 
adriamycin on the right ventricular effective refractory 
period. The adriamycin treated animals are represented by 
the broken lines and the control animals by the continous 
lines.
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the animals had an infection of the neck wound where the 
pacing wire had been inserted. Five of the remaining 
animals were non specifically unwell and were anorexic 
with weight loss of more than 10% of their initial weight. 
The cause of death in these animals was presumed to be 
infection. One other animal died from a broken back after 
struggling to free itself from an animal technician.
Diastolic pacing threshold
The diastolic pacing threshold showed a slight decrease in 
the adriamycin group falling from 4.44 1 0.54V at week 0 
to 4.05 1 0.56V at week 10. A similar pattern was 
observed in the saline control group with the threshold 
falling from 3.85 1 0.61V to 3.06 1 0.23V. These changes 
were not statistically significant and no difference was 
observed between the groups,(table 5).
Analysis of the data for those animals which survived to 
the end of the study, using the paired Student's t-test, 
revealed a similar pattern to above.
The mean diastolic pacing threshold was 4.110.5V at weekO, 
and 4.1:10.6V at week 10 in the adriamycin group, n=9.
In the saline control group the threshold decreased from 
4.210.8V to 3.110.2V, n=7.
Table 5.
Changes in diastolic pacing threshold in adriamycin and 
saline control groups.
Diastolic pacing threshold
Adriamycin
Saline control
WeekO
4.4410.5V(16)
3.8510.6V(11)
Week10 
4.0510.6V(10)
3.0610.2(8)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between groups or 
within the groups between weeks 0 and 10.
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Stimulus-T interval(Ficr.6 and table 6)
The stimulus-T interval progressively shortened over a 10 
week period in those animals treated with adriamycin, this 
change becoming statistically significant by week 4 (p < 
0.05). At week 0 stim-T was 116:11.5ms vs 108:12.0ms at 
week 4, n = 16 and 14 respectively. By week 10 the stim-T 
interval was 102:11.9ms, a decrease of 12% when compared to 
week 0(p< 0.001). There was no significant difference 
between the adriamycin and saline control groups at week 
0, and no change was observed in the saline control group 
over the ten week period. When the adriamycin group was 
compared to the saline control group, the stimulus-T 
interval was significantly reduced by week 4, and by week 
10 stim-T was 102:11.9ms vs 120:13.8ms, a difference of 
15%(p<0.001).
Comparison of paired data in animals which survived to the 
end of the study revealed similar results to those above. 
In the adriamycin group the stimulus-t interval decreased 
from 1161.2ms at weekO to 1021:2ms at week 10, p<0.001 and 
n=10. The values in the saline control group were 122n4ms 
at weekO and 120:14ms at weeklO, n=8.
Table 6
Changes in stim-T and ERP in adriamycin and saline control 
groups.
Week
Adriamycin:n 
ERP(ms) 
STIM-T(ms) 
Control: n 
ERP(ms) 
STIM-T(ms)
0
16
115 1 2.0
116 1 1.5 
11
113 ^ 4.2 
120 1 2.9
5
12
101 1 3.8 
108 1 2.0 
11
114 1 4.0 
118 - 2.9
10
10
98 ^ 2.9 
102 1 1.9 
8
120 ^ 3.2 
120  ^ 3.8
The stim-T interval and ERP significantly decreased in the 
adriamycin group, between weeks 0 and 10(p<0.001).
There were no significant changes in the control group.
ERP = Effective refractory period.
Stim-T = Stimulus-T interval
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Figure 6.
Graph demonstrating the chronic effects of adriamycin on 
the stimulus-T interval. The adriamycin treated animals are 
represented by the broken line and the control animals by 
the continous line. The stimulus-T interval progressively 
shortens in the adriamycin group.
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Effective refractory period(Fiq.7 and table 6)
There was a progressive shortening in ERP over the 10 week
period in the adriamycin-treated group,from 1151:2.0ms at 
week 0 to 1011:3.8ms at week 5(p<0.05). At week 10 the ERP
was 98:12.9ms, a 15% decrease when compared to week 
0(p<0.001). No difference was observed between the 
adriamycin and saline control groups at week 0, and no 
significant change in ERP occured in the saline control 
group over the ten week period. A significant decrease in 
ERP between the adriamycin and saline control groups 
developed by week 5 p<0.05. At week 10 the ERP was 
98:12.9ms in the adriamycin group vs 1201:3.2ms in the 
saline control group p<0.001.
Analysis of paired data in animals surviving to the end of 
the study demonstrated a significant decrease in the 
adriamycin group from 1161:2ms at weekO to 981:3ms at week 
10, p<0.001 and n=9. There was no significant change in 
the saline control group, 1211:4ms at weekO and 1201:4ms at 
week 10, n=7.
Sinus cvcle lenathftable 7)
Sinus cycle length tended to decrease in the adriamycin 
group over a 10 week period from 2381:6.7ms at week 0 to 
221 1:7.9ms at week 10, while the saline control group
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Figure 7.
Graph demonstrating the chronic effects of adriamycin on 
the effective refractory period. The adriamycin treated 
animals are represented by the broken line and the control 
animals by the continuous line. The ERP progressively 
shortens in the adriamycin group.
Table 7.
Changes in sinus cvcle length in adriamycin and saline 
control groups.
Sinus cycle length 
WeekO Week10
Adriamycin 238^7(16)ms 221^8(10)ms
Saline control 230M(ll)ms 238JL3(8)ms
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the groups 
or within the groups between weeks 0 and 10.
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demonstrated a non-significant increase from 2301:3.8ms to 
238:12.8ms. No significant difference was observed between 
the groups at week 0 or week 10.
Analysis of paired data from animals which survived to the 
end of the study revealed a non-significant decrease in 
the adriamycin group from 240:17ms at weekO to 2211:8ms at 
weeklO, n=10, and a non-significant increase in the saline 
control group from 2321:4ms to 2381:3ms, n=8.
Ambulatory ECG recording
A total of 52 ambulatory ECG recordings were attempted, 
although only 12 complete tapes were successfully 
recorded. The low rate of successful recordings was 
caused by animals chewing through the armoured protective 
cable which surrounded the connecting wires. In the 
adriamycin group of animals, 1 episode of ventricular 
bigemini was detected and in the majority of the others 
infrequent ventricular ectopic activity ie less than 10 
beats.Hour-1 was seen. There was no evidence of 
spontaneous ventricular tachycardia or ventricular 
fibrillation. No arrhythmias were recorded in the control 
group.
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Arrhythmia induction
Attempts were made to determine the ventricular 
fibrillation threshold using the protocol described in 
chapter 3.2. Three animals were studied using the 
protocol described by Inoue, H. et al(1985). No 
arrhythmias were induced in any of the animals and further 
attempts were therefore abandoned. It should also be 
noted that no arrhythmias were induced by the single 
extra-stimulus technique when the ERP was measured in each 
animal during the weekly electrophysiological study. 
Attempts to initiate ventricular tachycardia using up to 3 
extra-stimuli were made in 3 adriamycin treated rabbits. 
Because of the unusual electrical restitution properties 
of the rabbit heart, it was observed that addition of a 
second or third extra-stimulus did not result in any 
shortening of the effective refractory period compared 
with the first extra-stimulus. Possibly as a result of 
this, no arrhythmia could be induced. It was considered 
that arrhythmia induction by rapid ventricular pacing(see 
above) was too non-specific and thus systematic attempts 
at arrhythmia induction were not pursued.
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4.3 Biochemistry.
Neurohormonal data(table 8).
The mean levels of plasma noradrenaline, renin and atrial 
natriuretic peptide were measured at week 0 in the 
instrumented and non-instrumented animals prior to 
adriamycin/saline injection. Mean values for 
noradrenaline were 6.04 * 1.05 vs 4.91 Z. 1.14 (nmol. I-1), 
plasma renin concentration 69.6 ^ 8.04 vs 83.7 ^ 6.8 
uU.ml.-1 and ANP 98.0 * 6.5 vs 128.7 * 17.03 (pg.ml"1) in 
the instrumented and non-instrumented groups respectively. 
None of these differences were statistically significant, 
and thus the results for the instrumented and non­
instrumented animals have been pooled.
Plasma noradrenaline levels showed no significant change 
in either the adriamycin or saline control groups when 
samples were compared between week one and eight, nor was 
there any significant change between the groups.
Similarily no change was observed in the levels of ANP in 
either group, over an 8 week period nor between the 
groups. Plasma renin concentration decreased 
significantly in the saline control group between weeks 1 
and 8, but there were no significant differences between 
the groups at weeks 1 or 8. There was no significant
Table 8.
Neurohormonal changes in adriamycin and saline control 
groups.
Week 1 8
Adriamycin:
Renin 74.2 1 6.8(11) 66.6 1 8.5(18)
ANP 137.7 1 24.9(13) 94.3 1 10.7(17)
NA 5.1 1 1.3(19) 5.4 1 0.8(19)
Saline control:
Renin 72.6 1 7.2(12) * 56.1 1 4.2(17)
ANP 118.7 1 12.5(10) 118.8 1 14.4(14)
NA 3.5 1 0.5(18) 5.2 1 1.2(11
Numbers in parenthesis represent numbers of animals.
* = p<0.05
Renin = Plasma renin concentration (uU.ml-1)
ANP = Atrial natriuretic peptide concentration(pg.ml_1) 
NA = Plasma noradrenaline concentration(nmol.I-1)
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change in the level of plasma renin in the adriamycin 
group between weeks 1 and 8.
Analysis of paired data from animals which survived to the 
end of the study demonstrated a non-significant increase 
in plasma noradrenaline levels in both the adriamycin and 
saline control groups between weeks 1 and 8. The mean 
values were 3.8^0.6nmol.I-1 at weekl and 5.8^1.2nmol.I-1 
at week8 in the adriamycin group, n=12, and 3. 3^ .0. 5nmol. I- 
1 vs 5.2^1.4nmol.I-1 in the saline control group.
The mean levels of plasma ANP decreased in the adriamycin 
group and increased in the saline control group although 
these changes were non-significant. The levels in 
survivors were 112 . 6^16pg.ml_:L at weekl vs 84. 2^ .14. 7pg.ml- 
1 in the adriamycin group, n=ll, and 114^14pg.ml-:L vs 
134.2^15pg.ml-:L in the saline control group, n=ll.
Plasma electrolytes
As with the neurohormonal results, the data for the 
instrumented and uninstrumented animals was pooled with 
regards to plasma electrolytes. The mean value of plasma 
fell slightly in the adriamycin group from 4.9^0.12 
mmol.I-1 at week 1 to 4.6^0.08 mmol.I-1 at week 8, and 
showed no change in the saline control group over an 8 
week period 4.8^0.11 mmol.I-1 vs 4.8^0.12 mmol.I-1 There
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were no significant differences between the groups at 
weeks 1 or 8, (table 9).
Comparison of paired data from animals which survived to 
the end of the study revealed similar results to those 
above. There was a non-significant decrease in the 
adriamycin group from 4. 9^0. lmmol. I-1 to 4. 6^ .0. lmmol. I-1, 
n=18 and no change in the saline control group,
4.8-0.lmmol.I-1 vs 4.8^0.lmmol.I-1, n=16.
Plasma Mg2- significantly decreased between weeks 1 and 8 
in the adriamycin group of animals, falling from 0.95 - 
0.05mmol.I-1 to 0.70 - 0.02mmol.I-1. There was a tendency 
for plasma Mg2- levels to fall in the saline control group 
over the 8 week period, although this was less pronounced 
than in the adriamycin group, such that when the groups 
were compared, plasma Mg2- levels were significantly less 
in the adriamycin group when compared to the saline 
control group at weeks 8. There were no differences 
between the groups at week 1 (table 9).
Paired analysis of the data in animals which survived to 
the end of the study again demonstrated a significant 
decrease in the adriamycin group from 0.95^0.05mmol.I-1 to 
0.69-0.03 mmol.I-1, p<0.01 and n=16, and a non-significant 
decrease in the saline control group from 0.95-0.05mmol.I- 
1 to 0.85-0.03mmol.I-1, n=16.
Table 9.
Changes In plasma magnesium and potassium concentrations 
In the adriamycin and saline control groups.
Adriamycin 
K-Weekl 4.87 1 0.12(23)
K "'WeekS 4.59 1 0.08(18)
Mg2-Weekl 0.95 - 0.05(16)
* * *
Saline controls p
4.79 1 0.11(17) NS
4.8 1 0.12(16) NS
0.95 * 0.05(16) NS
Mg2-Week8 0.70 - 0.02(20) *** 0.85 - 0.03(16) 0.001
NS = not significant.
*** = p<0.001.
Numbers in parenthesis represent numbers of animals. 
K- : Plasma potassium (mmol.I-1)
Mg2- : Plasma magnesium (mmol.I-1)
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No significant changes were seen in plasma sodium 
concentration over an 8 week period in the adriamycin 
group of animals. There was a small decrease in the 
saline control group over an 8 week period. Although this 
was statistically significant, there were no differences 
between the groups at weeks 1 or 8, (table 10).
Analysis of paired data revealed no significant change in 
the plasma sodium concentration in either group between 
weeks 1 and 8. The values were 14310.8mmol.I-1 at weekl 
vs 143l0.5mmol.l-1 at week8 in the adriamycin group, n=20, 
and 14310.5mmol.I-1 vs 14210.4mmol.I-1 in the saline 
control group, n=16.
Plasma urea levels showed a non-significant increase in 
the adriamycin group and a non-significant decrease in the 
saline control group over the 8 week period, and there 
were no significant differences when the groups were 
compared (table 11). Analysis of paired data revealed 
similar results to those above. The mean plasma urea 
concentration increased from 6.510.3mmol.I-1 to 
7.010.3mmol.I-1 in the adriamycin group, n=20, and 
decreased from 6.810.3mmol.1-1 to 6.710.3mmol.I-1 in the 
saline control group, n=16.
Table 10.
Changes in plasma sodium concentration in adriamycin and 
saline control groups.
Plasma sodium(mmol.I-1)
Week 1 8 p
Adriamycin 142.810.7(24) 143.010.5(20) NS
Saline control 143.410.5(18) 142.010.4(16) 0.05
There were no differences between the groups at week 1 or 
8.
The numbers in parenthesis represent the nunbers of 
animals.
Table 11.
Changes in plasma urea concentration in adriamycin and 
saline control groups.
Plasma Urea(mmol.I-1)
Week 1 8
Adriamycin 6.610.3(24) 7.010.4(20)
Saline control 7.010.3(18) 6.610.3(16)
There were no significant differences between the groups 
orbetween weeks 1 and 8 in either group.
Numbers in parenthesis represent the numbers of animals.
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4.4 Patholoavftables 12 and 13)
The results in this section represent data from both 
instrumented and uninstrumented animals. At the end of 
the study the mean wet heart weights were significantly 
higher in the adriamycin group when compared to the saline 
control group, a difference of 49%. The liver weights 
were also increased in the adriamycin group by 35% when 
compared to controls. There was no significant difference 
in lung weights between the groups.
Total body weight fell slightly over a 10 week period in 
the adriamycin group and showed a non-significant increase 
in the saline control group, such that at week 10, the 
mean body weight was significantly higher in the saline 
control group.
Analysis of paired data from those animals which survived 
to the end of the study revealed a non-significant 
decrease in body weight in the adriamycin group from 
3.3^0.06Kg to 3.2^0.07Kg, n=18. There was a non­
significant increase in the mean body weight in the saline 
control group from 3.3^,0.08Kg to 3.5^0. lKg, n=16.
When the heart weights were expressed as a percentage of 
total body weight, heart weight was 57% higher in the 
adriamycin-treated animals than controls, p<0.01. The 
liver weight /total body weight ratio was 42% higher in
Table 12
Comparison of heart.liver and lung weights between_tha
adriamycin and
Heart weight(g) 
Liver weight(g) 
Lung weight(g)
ine control groups
Adriamycin
10.810.6(17)
87.816(18)
18.511.4(18)
Saline Control 
7.210.3(16) 0
64.914(15)
1811.1(15)
P
001
.01
NS
Numbers in parenthesis represent numbers of animals. 
NS = Not significant.
Table 13.
Comparison of body weight and heart, liver and lung to 
body weight ratios between the adriamycin and saline 
control groups.
Adriamycin Saline control p
Body weight(Kg):
WeekO 3.310.05(24) 3.2710.08(19) NS
Week10 3.210.07(18) 3.4910.1(16) 0.05
HW/BW % 0.3310.02(18) 0.2110.02(15) 0.01
LW/BW % 2.7710.2(18) 1.9510.2(15) 0.05
LUW/BW% 0.5810.5(18) 0.5210.04(15) NS
Numbers in parenthesis represent numbers of animals.
HW = heart weight 
LW = liver weight 
LUW = lung weight 
BW = body weight.
There were no significant differences in body weights 
between weeks 0 and 10 within either group.
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the adriamycin-treated animals, p<0.05. There was a 
tendency for the lung/total body weight ratio to be higher 
in the adriamycin group when compared to the saline 
control group.
The wet/dry weight ratio of the ventricular samples 
were 5.8 ^ 0.95 in the adriamycin group vs 4.47 ^ 0.29 in 
controls. Although there was a tendency to higher tissue 
water content in the adriamycin-treated hearts, this 
change was not statistically significant and implies that 
the increase in heart weight in the adriamycin group was 
due to an increase in tissue dry matter and not simply due 
to oedema.
Histology
Light microscopy of the adriamycin-treated hearts showed 
widespread atrophy and lysis of cardiac myocytes 
associated with interstitial fibrosis. Extensive 
vacuo1ation and reduction in myocyte size was also seen.
No histological abnormalities were observed in the control 
group.
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4.5 Discussion
The principal finding in this chapter is of a progressive 
decrease in right ventricular effective refractory period 
and repolarisation time measured in vivo in a model of 
chronic cardiac failure. These changes are independent of 
sinus cycle length, since they were made at a constant 
heart rate. There were no significant changes in 
diastolic pacing threshold which might influence ERP. The 
elecrophysiological changes also appear to be unrelated to 
neurohormonal activation as no significant increase in 
plasma noradrenaline or renin concentrations were detected 
in the adriamycin-treated animals. The shortening in 
repolarisation and refractoriness are also independent of 
changes in plasma levels, and the decrease in plasma 
Mg2  ^ could account for no more than 2% shortening in 
action potential duration if we extrapolate from previous 
in vitro studies (Watanabe, Y. & Dreifus, L.S.(1972)).
The most likely explanation therefore is that the effects 
on ventricular repolarisation and refractoriness are 
related to an intrinsic myocardial phenomenon caused by 
the adriamycin cardiomyopathy, and this premise is further 
supported by the in vitro data presented in the next 
chapter.
Although no direct haemodynamic measurements were made in 
this study to support the premise that the animals treated
112
with adriamycin were in heart failure, the significant 
increases in heart and liver weights which were found in 
the animals treated with adriamycin would tend to support 
this hypothesis.
One possible explanation may be that adriamycin 
administration produces a toxic change in myocytes which 
is manifest as a shortening in action potential duration 
analagous to that seen during myocardial hypoxia or 
ischaemia (Janse, M.J. & Kleber, A.G.(1981); McDonald, 
T.F., Hunter, E.G. & MacLeod, D.P.(1971)).
Two principle mechanisms of adriamycin-induced cardiac 
damage have been proposed as discussed previously in 
chapter 1. An increased cytosolic calcium concentration 
has been suggested by some authors (Bers, D.M.,
Philipson, K.D. & Langer, G.A.(1981); Singal, P.K. & 
Pierce, G.N.(1986); Dhalla, N.S. et al(1982); Olson, H.M. 
et al(1974)), while others have proposed damage to cell 
and organellar membranes by the generation of oxygen- 
derived free radicals which produce an increase in the 
rate of endogeneous lipid peroxidation (Bachur, N.R. et 
al(1983); Kalyanaramun, B., Perez-Reyes, E. & Mason,
R.P.(1980); Land, E.J. et al(1983); Doroshow, J.H.(1983); 
Myers, C.E. et al (1977)).
The former mechanism may well be more important in some 
ways to the shortening in ventricular repolarisation and 
refractoriness which has been demonstrated. As discussed
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previously, it has been demonstrated that an increase in 
intracellular calcium concentration may shorten action 
potential duration (Carmeliet, E.(1978); McDonald, T.F. & 
MacLeod, D.P.(1973); Isenberg, G.(1975) and Reuter,
H. (1974)).
The results suggest that the changes in repolarization and 
refractoriness are unrelated to any acute direct 
electrophysiological action of adriamycin however, as no 
changes were demonstrated in either the stimulus-T 
interval or ERP when these parameters were measured for 5 
consecutive days during the first week of the study.
There was also no reversal of the shortening in 
repolarisation and refractoriness after week 8 when the 
adriamycin injections were stopped. Further evidence that 
the electrophysiological changes are unrelated to any 
direct action of the drug is demonstrated in the next 
chapter when in vivo shortening in repolarization and 
refractoriness are seen to occur 2 weeks following the 
last injection of adriamycin.
The histological findings of widespread myocyte damage 
persisting 2 weeks after the last injection of adriamycin, 
suggests that the myopathic process itself may well be 
responsible for the electrophysiological changes.
Another possible mechanism for the in vivo shortening in 
the stimulus-T interval and the ERP may be an increase in 
afterload. It has been previously demonstrated that right
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atrial pressure increases by 100% in animals treated with 
adriamycin according to the protocol used in this study, 
and that there was an increase in systemic arterial 
resistance (Wanless, R.B. et al(1987)). Although 
pulmonary arterial pressure was not measured in this or 
the previous study, it may well be that there was a 
chronic increase in pulmonary pressure and hence right 
ventricular afterload as a result of left ventricular 
dysfunction.
Several authors have investigated the effects of acute 
changes in afterload on ventricular repolarisation and 
refractoriness as discussed in chapter 1. Reiter, M.J. et 
al(1988) have demonstrated that in the isolated perfused 
rabbit heart, as left ventricular volume was increased by 
the dilatation of a balloon in the ventricular cavity, a 
progressive decrease in left ventricular effective 
refractory period was demonstrated. It was also noted 
that ventricular fibrillation and tachycardia were easily 
induced by the single extra-stimulus technique, after, but 
not before, balloon distention. The results in this 
chapter differ from those of Reiter, M.J. et al(1988) in 
that no arrhythmias were induced by the single extra­
stimulus technique in any animal, although we did detect 
evidence of spontaneous ventricular arrhythmias in the 
adriamycin-treated animals, while no spontaneous 
arrhythmias were detected in the Reiter study. This
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difference between the studies could be related to the 
obvious differences between an in vivo preparation and an 
isolated buffer-perfused heart. Reiter, M.J. et al(1988) 
also demonstrated an intra and inter ventricular 
heterogeneity of refractoriness which they related to the 
inducibility of arrhythmias. No comment can be made on 
the heterogeneity of refractoriness in the present study, 
since stimulation was only performed from a single fixed 
site.
Lermann, B.B. et al(1985) have also demonstrated that 
increasing the left ventricular end diastolic volume from 
10ml to 30ml in the cross circulated, servo-controlled 
canine heart was associated with a 7% reduction in left 
ventricular ERP. The effects of mechanical stress on the 
electrophysiology of isolated muscle preparations has also 
been investigated by Lab, M.J.(1982), as previously 
discussed in chapter 1.5. Lab demonstrated that high 
muscle tension, in the form of isovolumetric contraction, 
is associated with a shortening in action potential 
duration in both isolated muscle preparations and the 
intact frog heart.
From a survey of existing literature, this is the first 
time that chronic changes in ventricular repolarisation 
time and refractoriness have been investigated in vivo in 
a model of cardiac failure. Thus comparison of this 
electrophysiological data with other in vivostudies is
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not posssible. The paucity of pre-existing studies of 
chronic electrophysiological changes in heart failure is 
most likely related to the limitations bestowed by the 
available models of heart failure, as previously discussed 
in chapter 1.12.
Although haemodynamic measurements were not undertaken to 
confirm the presence of heart failure, such measurements 
were undertaken in an identical model (Arnolda, L. et al 
(1985) and Wanless, R.B. et al(1987)). Increases in both 
heart and liver weights consistent with cardiac failure 
were found in the present study. The increase in heart 
weight could not be explained by an increase in water 
content alone. One significant difference between the 
results in this study and the study by Arnolda is that I 
observed no activation of the renin-angiotensin system in 
the adriamycin-treated animals, in contrast to their 
observation of an increase in both plasma renin and 
noradrenaline after 4 and 8 weeks treatment with 
adriamycin respectively. Another difference between the 
studies was that the baseline levels of noradrenaline were 
considerably higher in the present study, 5.1+1.3nmol.1-1 
vs 0.7+0.lnmol.1-1. This may imply that the animals were 
stressed possibly by the procedure of blood sampling from 
the marginal ear vein. The method of sampling in the 
study by Arnolda, L. et al(1985) is not specified but may 
have been from an indwelling catheter.
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The absence of stimulation of the renin-angiotensin system 
in the adriamycin-treated animals in this study, does not 
disprove the hypothesis that the animals were in heart 
failure. It has been demonstrated previously that 
patients with untreated heart failure may in fact have 
normal levels of plasma renin, and that only when 
diuretics are introduced into the treatment regime does 
activation of the renin-angiotensin system occur (Brown, 
J.J. et al(1970) and Bayliss, J. et al(1987)). Plasma 
noradrenaline levels in the untreated patients with heart 
failure in the study by Bayliss showed a mean value of 4.2 
nmol. 1-1, compared to 5.4:10.8 nmol. 1-1 by week 8 in the 
adriamycin-treated animals in this study. The similarity 
between these results and those of Bayliss lends further 
support to the argument that this model of experimental 
heart failure is compatible in some respects with the 
clinical syndrome of heart failure. However, the 
possibility of inter-species variability should also be 
borne in mind. This model is limited however by the fact 
that the incidence of sudden death in those animals 
treated with adriamycin was low, only 3 animals in the 
adriamycin group died suddenly and unexpectedly. There 
was also a paucity of complex ventricular arrhythmias as 
detected by continuous ambulatory monitoring. However, as 
with the clinical situation, defining which animals died 
suddenly, presumably from malignant ventricular
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arrhythmias, is difficult. It is possible however that 
the incidence of sudden death may be greater in the 
prescence of intervention with diuretics.
Despite the limitations of the existing experimental 
model, the data suggests that shortening of ventricular 
repolarisation and refractoriness in heart failure may 
represent an intrinsic mechanism predisposing to sudden 
death in heart failure.
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CHAPTER 5
IN VITRO ELECTROPHYSIOLOGICAL CHANGES IN ADRIAMYCIN- 
INDUCED CHRONIC HEART FAILURE IN THE RABBIT.
5.1 Introduction.
The previous chapter has outlined the chronic changes in 
ventricular repolarisation and refractoriness which occur 
in vivo in adriamycin-induced heart failure in the 
rabbit. The shortening in repolarization and 
refractoriness which was demonstrated appears to be 
unrelated to neurohormonal activation or plasma 
electrolyte depletion. The most likely explanation would 
therefore seem to be that either adriamycin produces a 
toxic change in myocytes which is manifest as a shortening 
in action potential duration, or that the 
electrophysiological changes are related to a chronic 
increase in pulmonary arterial pressure secondary to left 
ventricular dysfunction.
Electrophysiological experiments performed in vitro in 
the isolated papillary muscle preparation would provide 
further evidence as to the aetiology of the changes in 
repolarisation and refractoriness. This preparation by 
its very nature would be uninfluenced by the plasma 
concentrations of adrenaline, noradrenaline and
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angiotensin II. The electrophysiological effects of 
changes in plasma electrolyte concentrations in heart 
failure are corrected by superfusion with a standardized 
physiological saline solution. Any electrophysiological 
changes which occur in such a preparation are therefore 
likely to be related to an intrinsic myocardial phenomenon 
or possibly to an adaptive change in the muscle which has 
occurred in response to a chronic increase in afterload.
5.2 Methods.
Two experimental groups of animals were used in this 
study, and the experimental protocol and 
electrophysiological techniques used are described in 
chapter 3. Animals used in this study did not undergo 
intracardiac electrode implantation, since previous 
studies in this laboratory have shown that prolonged 
implantation of a right ventricular electrode results in 
surface fibrosis of right ventricular papillary muscles, 
rendering intracellular microelectrode impalements 
extremely difficult.
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5.3 Results.
5.3.1 Survival data.
A total of 11 animals entered the study in the adriamycin 
group and 9 animals in the control group. No deaths 
occured in either group over the 10 week period of the 
study.
5.3.2 Electrophysiology.(table 14).
The mean action potential duration at 90% repolarisation 
from the right ventricular papillary muscles in the 
adriamycin group of animals was 202^10ms (range:168-236ms) 
vs 264*14ms in controls (range :216-296ms), n = 6 and 5 
respectively and p<0.01. The mean effective refractory 
period was 189^10ms (range :154-220ms) in the adriamycin- 
treated group, vs 290^9ms in controls (range :249-343ms), 
n = 6 and 5 respectively and p<0.001, table 14. These 
results represent a 23% shortening in APD90 and a 35% 
reduction in effective refractory period in the adriamycin 
group.
Table 14.
In vitro changes in action potential duration and 
effective refractory period in the adriamycin and saline 
control groups.
Adriamycin Control p
APD90(ms) 202 1 10(6) 264 1 14(5) 0.01
ERP(ms) 189 1 10(6) 290 1 9(5) 0.001
APD<jo = Action potential duration at 90% repolarisation. 
ERP = Effective refractory period.
Numbers in parenthesis represent the numbers of animals.
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5.3.3 Biochemistry.
Neurohormonal data
The mean levels of plasma noradranaline, renin and atrial 
natriuretic peptide showed no significant differences 
between the instrumented animals discussed in chapter 4 
and the un-instrumented animals in this study, when 
compared at week 0. For this reason, the results have been 
pooled and analysed in chapter 4, table 8.
Plasma electrolytes(tables 9, 10 and 11).
The pooled data for the instrumented and uninstrumented 
animals has been discussed in chapter 4.
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5.3.4 Patholoav(tables 12 and 13K
The pooled data for the instrumented and uninstrumented 
animals have been discussed in chapter 4.
5.4 Discussion.
The principal finding in this chapter is of a significant 
shortening in action potential duration and effective 
refractory period in right ventricular papillary muscles 
from the hearts of rabbits treated with adriamycin for 8 
weeks, and then left for a further 2 week period,
(Wanless, R.B. et al(1987)). These results are similar to 
the shortening in ventricular repolarisation and 
refractoriness which was demonstrated in vivo in the 
previous chapter, although the magnitude of the decrease 
was greater in the experiments in this study. Other 
workers have also described a significant reduction in 
action potential duration in right ventricular papillary 
muscles from rabbits treated with adriamycin, (Shenasa, H. 
et al 1990).
The fact that these changes occured at least 2 weeks after 
the last injection of adriamycin is further evidence that 
the electrophysiological changes are unrelated to any 
direct action of the drug itself. It was also 
demonstrated in the previous chapter that no acute direct
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electrophysiological effect of the drug was seen in vivo. 
The nature of this isolated preparation also lends 
support to the premise that the shortening in action 
potential duration and refractoriness observed in vivo, 
are unrelated to either neurohormonal activation or plasma 
electrolyte depletion. The most likely explanation for the 
in vitro electrophysiological changes remains the toxic 
cytopathic effect of adriamycin(as previously discussed in 
chapter 1). One possible mechanism which has been proposed 
is the accumulation of intracellular calcium. The typical 
sarcolemmal changes which are associated with adriamycin 
toxicity are thought to be a consequence of intracellular 
calcium overload and subsequent loss of structural 
integrity of the cell. Sarcolemmal calcium bound at the 
low affinity sited on the membrane has been associated 
with cellular calcium influx and is correlated with the 
developed force, (Bers, D.M. etal(1981)). Adriamycin has 
been shown in-vitro to stimulate low-affinity calcium 
binding but depress contractile function,(Singal, P.K. & 
Pierce, G.N.(1986)). Other workers have shown that 
adriamycin stimulates calcium ATPase in vitro, and this 
enzyme activity has been associated with low affinity 
calcium binding and contractile force, (Dhalla, N.S. et 
al(1982)). These observations may imply a change in 
sarcolemmal permeability leading to an influx of calcium. 
Previous workers have demonstrated that an increase in
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intracellular calcium concentration, independent of the 
aetiology, shortens the action potential duration,
(Carmeliet, E.(1978); Me Donald, T.F. & MacLeod, 
D.P.(1973); Isenberg, G.(1975) and Reuter, H.(1974)). The 
mechanism by which an increase in intracellular calcium 
concentration shortens action potential duration, may be 
mediated by inhibition of the slow inward calcium current, 
by an increase in potassium conductance, or both. Another 
possible explanation for the electrophysiological changes 
could be an adaptive response to a chronic increase in 
afterload, as discussed in the previous chapters. The 
majority of studies in which a major element of 
hypertrophy is present have demonstrated an increase in 
action potential duration.The shortening in action 
potential duration and refractoriness in this in vitro 
preparation from animals with heart failure, is in 
accordance with the in vivo results presented in the 
previous chapter. The results therefore support the 
hypothesis that the electrophysiological changes are 
unrelated to neurohormonal activation or plasma 
electrolyte depletion.
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CHAPTER 6
THE EFFECT OF CAPTOPRIL ON THE ELECTROPHYSIOLOGICAL 
CHANGES ASSOCIATED WITH ADRIAMYCIN-INDUCED 
CHRONIC HEART FAILURE IN THE RABBIT.
6.1 Introduction.
Activation of the renin-angiotensin system is one of the 
neurohormonal changes which occur in chronic heart failure 
in an attempt to maintain circulatory homeostasis and 
preserve renal function. It has been proposed however 
that the increased activation of this system may 
predispose to sudden unexpected death, by increasing 
ventricular wall stress and myocardial oxygen consumption, 
(Massie, B. et al (1982)), and also by causing depletion 
of both potassium and magnesium. The evidence for the 
proarrhythmic effects of depletion of potassium and 
magnesium is discussed in chapters 1.6 and 1.7.
As discussed in chapter 1.8 however, the subgroup of 
patients with more severe heart failure and greater 
activation of the renin-angiotensin system, are at no 
higher risk of dying suddenly, (Burgraff, G.W. & Packer, 
M.(1975); Massie, B. et al(1981); Cohn, J.N. et al(1984) 
and Wilson, J.R. et al(1983)). As patients with more 
severe heart failure have greater activation of the renin-
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angiotensin system, this would appear to indicate that 
activation of this mechanism was not of paramount
importance in arrhythmogenesis in heart failure.
Studies which have examined the effect of inhibition of 
the renin-angiotensin system in patients with chronic 
heart failure have shown that there is a reduction in the
frequency and complexity of ventricular ectopic rhythms,
(Cleland, J.G.F. et al(1984)), and an increase in exercise 
capacity and overall prognosis, (The Consensus trial 
study group,(1987); Magnani, B. & Magelli, C.(1986); Ader, 
R. et al.(1980); Dzau, V.J. et al(1980); Massie, B. et 
al(1982); The SOLVD Investigators,(1991)). As previously 
mentioned however, only one study has demonstrated a 
reduction in the incidence of sudden death in heart 
failure in patients treated with enalapril, (Cohn, J.N. et 
al (1991)) .
The principal finding of the experiments conducted in 
chapters 4 and 5 is that of a progressive shortening in 
right ventricular repolarisation and refractoriness in 
adriamycin-induced chronic heart failure in the rabbit. 
These electrophysiological changes were unrelated to 
activation of the renin-angiotensin system, as there was 
no significant increase in plasma renin activity over an 8 
week period in those animals treated with adriamycin. As 
previously discussed in chapter 1.9 however, captopril,
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the angiotensin converting-enzyme inhibitor, has an 
alternative vasodepressor effect which is mediated through 
an increase in prostaglandin E2 synthesis. Although there 
is only limited clinical evidence that inhibition of the 
renin-angiotensin system reduces the incidence of sudden 
unexpected death, administration of the drug to patients 
with heart failure has been shown to reduce the frequency 
and complexity of ventricular arrhythmias. The 
experiments described in this chapter were designed to 
assess the effects of captopril on the shortening in 
repolarisation and refractoriness which occurred in the 
animals with heart failure in the previous chapters. An 
attempt was also made to assess the effects of captopril 
on spontaneous and induced ventricular arrhythmias and 
plasma electrolytes.
The possibility existed prior to these experiments that 
captopril could theoretically reduce afterload by virtue 
of its stimulation of the production of prostaglandin E2, 
even in the absence of activation of the renin-angiotensin 
system, and therefore by reducing ventricular wall stress 
and myocardial oxygen consumption, reduce the incidence of 
sudden death: Massie, B. et al(1982).
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6.2 Methods.
Two experimental groups of animals were used in this 
study, and the surgical techniques and 
electrophysiological and other measurements are as 
described in chapter 2.
6.3 Experimental protocol.
Following the implantation of the permanent pacing 
electrodes and the subcutaneous ECG electrodes, a 3 week 
period was allowed during which all electrophysiological 
measurements were allowed to stabilise. The animals were 
then randomly allocated to receive either adriamycin 
injections lmg.Kg-1 twice weekly intravenously for 8 
weeks, or 0.9% saline in equivolumetric doses. Each 
animal was also treated with captopril in a dose of 
2.14mg.Kg-1.day-1, and the total daily dose was dissolved 
in 100ml of the animals drinking water. This dose 
corresponds to an equivalent dose of 150mg.day_1 in man, 
(Overturf, M.L., Sybers, H.D. & Smith, S.A.(1985)). The 
captopril was introduced after 6 completed weeks of 
treatment with either adriamycin or saline. This was to 
allow time for heart failure to develop in the animals, 
(Wanless, R.B. et al(1987)), and also to avoid the 
possibility that captopril might inhibit the cardiotoxic
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effects of adriamycin by its role as an oxygen-derived, 
free radical scavenger, (Westlin, W. & Mullane, K. 
(1988)).
The electrophysiological measurements were made weekly for 
up to 10 weeks. The animals were venesected via the 
marginal ear vein at weeks 1 and 8 of the study for 
subsequent biochemical analysis, and in addition, plasma 
levels of angiotensin II were measured in the animals both 
prior to the introduction of captopril at the end of week 
6, and after 2 weeks of treatment with captopril at the 
end of week 8, using methods previously described,
(Morton, J.J. & Webb, D.J.(1885)). The blood samples 
which were taken for the subsequent analysis of 
angiotensin II were drawn into syringes which were pre­
filled with an angiotensin converting-enzyme inhibitor 
consisting of (per 100ml) 4.64g of EDTA, neomycin 0.2g, 
orthopenanthroline 0.5g in 1ml of absolute ethanol. The 
amount of inhibitor used was 1ml per 20ml of venous blood. 
The samples thus taken were immediately centrifuged and 
the plasma stored at -50°C for subsequent assay.
When the animals died or when they were electively killed 
at the end of the study, the heart, liver, kidneys and 
lungs were removed, blotted dry and weighed. Samples were 
taken from each of these organs for histological 
examination and from the heart and liver for assessment of 
the wet/dry weight ratio.
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6.4 Results.
Results are presented for the adriamycin/captopril and 
saline/captopril groups. In addition, comparison is made 
with the data from the adriamycin and the saline treated 
groups(chapter 4), where appropriate.
6.4.1 Survival data(table 15).
A total of 11 animals entered the study in the 
adriamycin/captopril group, and 9 animals in the saline 
control/captopril group. 2 animals in the adriamycin plus 
captopril group died with evidence of renal failure. One 
of those animals died suddenly and the other developed 
ventricular fibrillation during routine
electrophysiological testing at a paced cycle length of 
160ms. 3 other animals were electively killed as a result
of anorexia and weight loss of over 10% of the total body 
weight. 6 animals survived to the end of the 10 week 
period. Only 1 animal died in the saline 
control/captopri1 group, as a result of a broken back 
during transfer between cages. 8 animals survived 10 
weeks.
If we compare the incidence of sudden death in the 
adriamycin plus captopril group with the group of animals 
treated with adriamycin alone, we find that none of the 5
Table 15.
Survival data in the adriamvcin/captopril and saline 
control/captopril groups.
Initial OM SD SBE Other
11 5 0 0 5
9 1 0  0 1
Initial = Initial number of animals entering study. 
OM = Overall mortality.
SD = Sudden death.
SBE = Subacute bacterial endocarditis.
Adriamycin/Captopri1
Saline control/Captopril
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deaths in the former group were sudden and unexpected.
This is in comparison to the adriamycin treated group 
where 3 of the 6 deaths were classified as sudden.
However, the numbers of sudden deaths are insufficient for 
statistical comparison.
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6.4.2 Electrophysiology.
Diastolic pacing threshold.ftable 16).
The mean diastolic pacing threshold did not change 
significantly in either the adriamycin/captopril or saline 
control/captopril groups over the 10 weeks of the study. 
The levels were 3.2^0.3V at week 0 vs 3.2^0.2V at week 10 
in the adriamycin/captopril group, and 2.8^0.3V vs 
2.9:10.5V in the saline control/captopril group. There 
were no significant differences between the groups.
Stim-T and ERP
The effects of 8 weeks treatment with adriamycin or 
saline, and 4 weeks treatment with captopril, on the 
stimulus-T interval and ERP are tabulated in table 17 and 
illustrated in figures 8 and 9. There was no significant 
difference in stim-T or ERP between the groups at week 0. 
Adriamycin induced a progressive shortening in both stim-T 
and ERP which was significant by weeks 3 and 4 
respectively(p<0.05 and p< 0.01). The shortening 
continued up to week 10, ie after 4 weeks treatment with 
captopril. Adriamycin caused an overall shortening of 14%
Table 16.
Changes in the diastolic pacing threshold in the 
adriamycin/captopril and saline control/captopril groups.
Week 0 10
Adriamycin/Captopril:n 11
Threshold(Volts) 3.2 1 0.3 3.2 H 0.2
Saline control/Captopri1:n
Threshold(Volts) 2.8 .1 0.3 2.9 _1 0.5
There were no significant differences between the groups 
or within the 2 groups between weeks 0 and 10.
Table 17.
Changes in stim-T and ERP in the adriamvcln/captopril and 
saline control/captopril groups.
Stim-T(ms) ERP(ms)
WeekO Week10 WeekO Week10
Adriamycin/ 11811(11) *** 10212(5) 11713(11) ** 10813(5) 
Captopril
* *  * *
Saline control/11911(9) 11912(6) 11810.6(9) 12111(6)
Captopril
*** = p<0.001.
** = p<0.01.
The numbers in parenthesis represent the numbers of 
animals.
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Figure 8.
Graph demonstrating the effect of captopril on ventricular 
repolarisation in heart failure. The adriamycin treated 
animals are represented by the broken line and the control 
animals by the continuous line. Captopril does not prevent 
the progressive shortening in Stim-T interval.
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Figure 9.
Graph illustrating the effect of captopril on the right 
ventricular effective refractory period in heart failure.
The adriamycin treated animals are represented by the broken 
line and the control animals by the continuous line.
Captopril does not prevent the significant shortening in 
ERP.
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in stim-T, and 8% in ERP compared with baseline(p< 0.001 
and p<0.01 respectively). No significant change was 
observed in the stim-T interval in the saline 
control/captopril group over the 10 weeks of the study.
The ERP however was significantly prolonged by week 
10(p<0.05) in the saline control/captopril group.
Analysis of the stimulus-T interval in animals which 
survived to the end of the study revealed a significant 
decrease in the adriamycin/captopril group between weeks 0 
and 10. The stim-T interval decreased from 118.12ms to 
102:12ms, p<0.01 and n=5. There was a non-significant 
increase in the saline control/captopril group from 
11812ms to 1191.2ms, n=6.
The ERP significantly decreased in the animals in the 
adriamycin/captopril group which survived to the end of 
the study, from 11812ms at weekO to 108l3ms at week10, 
p<0.01 and n=5. There was a significant increase in the 
mean ERP in the saline control/captopril group from 
11711ms to 12111ms, p<0.05 and n=6.
When the adriamycin/captopril group was compared with the 
group treated with adriamycin alone, (table 18), no 
significant differences were detected in stim-T at week 0 
or week 10. Neither were there any significant 
differences at baseline or week 10 in the ERP. No 
significant differences were seen at baseline or week 10 
in either stim-T or ERP, when the saline control/captopril
Table 18.
Comparison of stim-T and ERP in the adriamvcin/captopril. 
saline control/captopril. adriamycin and saline control 
grpupg t
Stim-T(ms) ERP(ms)
WeekO Week10 WeekO Week10
Adriamycin/ 11811(11) 10212(5) 11713(11) 10813(5) 
captopril
Adriamycin 11611(16) 10212(10) 11512(16) 9813(10)
Saline control/11911(9) 11912(6) 11810.6(9) 12111(6)
captopril
Saline control 12013(11) 12014(8) 11314(11) 12013(8)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the groups.
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group was compared with the saline control group of 
animals.
Sinus cycle length significantly increased by week 10 
when compared to baseline in the adriamycin/captopril 
group(p<0.01). No significant change was detected in the 
saline control/captopril group over the 10 week period, 
and there was no significant difference between the 2 
groups at weeks 0 or 10, (table 19).
Analysis of paired data also revealed a significant 
increase in sinus cycle length in the adriamycin/captopril 
group from 23916ms to 288118ms, p<0.05 and n=5. There was 
a non-significant increase in the saline control/captopril 
group from 25014ms to 25617ms, n=6.
There were no significant differences at week 0 between 
the adriamycin/captopril and the adriamycin groups of 
animals. At week 10 however, the sinus cycle length was 
significantly greater in the adriamycin/captopril group.
A similar pattern was observed when the saline 
control/captopril and saline control groups were compared, 
(table 19).
Table 19.
Comparison of sinus cvcle length in the
adriamycin/captopril. saline control/captopril. adriamycin 
and saline control groups.
Sinus cycle length(ms) 
WeekO Week10
Adriamycin/captopril
Adriamycin
Saline control/ 
captopri1
Saline control
24217(11)
23817(16)
25013(9)
23014(11)
* 288118(5)
* *
22118(10)
25517(6)
*
23813(11)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05
** = p<0.01
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Ambulatory ECG recording
A total of 30 ambulatory ECG recordings were attempted 
although only 11 were successful, 6 in the adriamycin plus 
captopril group and 5 in the control plus captopril group. 
No evidence of arrhythmias was detected in either of the 2 
groups.
6.4.3 Biochemistry.
Neurohormonal data
Plasma noradrenaline levels significantly increased 
between weeks 1 and 8 in the adriamycin/captopril group. 
There was no change in the saline control/captopril group 
over a similar period. There were no baseline differences 
between the groups of animals, and there were no 
differences between the groups at week 8, (table 20).
Analysis of the mean plasma noradrenaline concentration in 
those animals which survived to the end of the study 
demonstrated a non-significant increase in the 
adriamycin/captopril group from 4.1^0.5nmol.I-1 to 
9.3^2.4nmol.I-1, n=7. There was a non-significant
decrease in the saline control/captopril group from 
10. 4^5. 3nmol. I-1 to 3 . 5^ .0. 6nmol. I-1, n=3.
Table 20.
Comparison of plasma noradrenaline levels in 
adriamycin/captopril. saline control/captopri1, adriamycin 
and saline control groups.
Plasma noradrenaline(n.mol.I-1)
Weekl Week8
Adriamycin/captopril 5.010.76(10) * 11.312.9(8)
Adriamycin
Saline control/ 
captopril
Saline control
5.111.3(19)
6.51(7)
3.510.5(18)
5.410.8(19)
4.110.97(5)
5.211.2(11)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
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Comparison of the mean levels of plasma noradrenaline 
between the adriamycin/ captopril and the group treated 
with adriamycin alone showed that there were no baseline 
differences between the 2 groups. At week 8 however, the 
mean noradrenaline level was significantly higher in the 
former group; 11.3 ^ 2.9 nmol.I-1 vs 5.4 0.8 nmol.l-
1(p<0.05). No significant differences were observed at 
baseline or week 8 when the saline control/captopril group 
was compared with the saline control group, (table 20).
Plasma renin concentration increased significantly 
between weeks 1 and 8 in both the adriamycin/captopril and 
the saline control/captopril groups, as a consequence of 
the treatment with captopril, (table 21). No paired 
analysis was performed because of the magnitude of the 
increase in plasma renin concentration.
When the adriamycin/captopril group was compared to the 
adriamycin group, plasma renin was significantly higher at 
baseline and at week 8 in the group treated with 
captopril. There were no significant differences at 
baseline between the saline control/captopril and the 
saline control groups, although plasma renin was 
significantly higher at week 8 in the saline 
control/captopril group, (table 22). No significant 
differences were detected at baseline or week 8 between
Table 21.
Changes in plasma renin concentration in the
adriamycin/captonri1 and saline control/captopril groups.
Week
Adriamycin/captopril: n 
Renin(uU. ml-1)
Saline control/: n 
captopril
1
11
125.8^,22.7 ***
9
8
8
4558.4*1131.7
6
Renin(uU.ml-1) 99.9*13.7 *** 1807*331.7
***= p< 0.001
There were no significant differences between the groups 
at weeks 1 or 8.
Table 22.
Comparison of plasma renin levels in the
adriamvcin/captopril. saline control/captopril. adriamycin 
and saline control groups.
Plasma renin concentration(uU.ml-1) 
Week 1 Week 8
Adriamycin/captopril
Adriamycin
Saline control/ 
captopril
Saline control
125.8122.7(11) *** 4558.411131.7(8)
* * * *
74.216.8(11) 66.618.5(18)
99.9113.7(9) *** 18071331.7(6)
* * *
72.617.2(12) 56.114 .2(17)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
*** = p<0.001.
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the adriamycin/captopril and the saline control/captopril 
groups.
There were no significant changes in plasma ANP 
concentration between weeks 1 and 8 in the adriamycin/ 
captopril and the saline control/captopril groups. Neither 
were there any significant differences between the 2 
groups in plasma ANP levels at baseline or week 8, (table 
23). Analysis of the mean plasma ANP cocncentration in 
those animals which survived to the end of the study 
revealed a non-significant decrease in the 
adriamycin/captopril group from 176^57pg.ml-1 to 
145^34pg.ml-1, n=7, and a non-significant increase in the 
saline control/captopril group from 126^28pg.ml_:L to 
135^_38pg.ml_1, n=6.
There were no significant differences between the 
adriamycin/captopril and the adriamycin groups of animals 
at either week, and there were no significant differences 
between the saline control/captopril and saline control 
groups, (table 23).
There were no significant differences in angiotensin II 
concentrations pre-captopril between the groups, and post- 
captopril the levels of angiotensin II were undetectable 
in every animal except for 1 in the saline
Table 23.
Comparison of plasma atrial natriuretic peptide(ANP) 
concentration between the adriamycin/captopril. saline 
control/captopril, adriamycin and saline control groups.
Plasma ANP(pg.ml-1)
Week 1 Week 8
Adriamycin/captopril 181.2149.1(10) 144.9:134.3(8)
Adriamycin 137.7124.9(13) 94.3110.7(17)
Saline control 110.7120(9) 135.3138.4(6)
captopril
Saline control 118.7112.5(18) 118.8114.4(14)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the 
adriamycin/captopril and adriamycin groups, nor between 
the saline control/captopril and saline control groups.
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control/captopril group, (table 24). These changes are a 
result of the treatment with captopril
Plasma electrolytes
No significant change was detected in plasma Mg2  ^ levels 
over an 8 week period in the adriamycin/captopril group. 
The mean level of plasma Mg2 + significantly decreased 
however between weeks 1 and 8 in the saline 
control/captopril group, (table 25). Plasma Mg2  ^ levels 
were significantly higher at baseline in the saline 
control/ captopril group when compared to the 
adriamycin/captopril group. When the data were
normalised, there were no significant differences between 
the groups at week 8.
Analysis of the plasma magnesium levels in those animals 
which survived to the end of the study, revealed a non­
significant increase in the adriamycin/captopril group 
between weeks 1 and 8 from 0.72^0.03mmol.I-1 to 
0.75mmol.I-1, n=7. Plasma magnesium levels significantly 
decreased in the saline control/captopril group from 
0 .83^:0.02mmol. I-1 to 0. 72^0. 03mmol. I-1, p<0.05 and n=7.
The mean level of plasma magnesium was significantly 
less at week 1 in the the adriamycin/captopril group when
Table 24.
The effect of captopril on the plasma concentration of 
angiotensin II in the adriamycin/captopril and saline 
control/captopril groups.
Angiotensin II(pg.ml-;L) 
Pre-captopril Post-captopril
Adriamycin/captopril 18^7.59(11) Undetectable(6)
Saline control/ 13.2^3.3(9) Undetectable(6)
captopril
Saline control/ 12(1) 6.3(1)
captopril
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the groups.
One animal in the saline control group had a level of 6.3 
after captopril treatment, and this had fallen from 12 
pre-captopril.
Table 25.
Changes in plasma macmesium and potassium concentrations 
in the adriamvcin/captopril and saline control/captopril 
groups.
Adriamycin/captopril Saline control/captopril 
K- weekl 4.8 1 0.13(8) 5.2 1 0.3(7)
K* week8 5.5 1 0.6(6) 5.0 1 0.16(8)
Mg2- weekl 0.72 1 0.03(7) * 0.83 1 0.02(7)
* *
Mg2- week8 0.75-0.08(8) 0.73-0.02(8)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05
** = p<0.01
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compared to the adriamycin group, (table 26). When the 
data was normalised however, the magnesium levels showed a 
significant decrease in the adriamycin group, (table 27). 
There was no baseline difference in plasma Mg2"- levels 
between the saline control/captopril and the saline 
control groups. The mean level of plasma Mg2-*- was however 
significantly lower in the saline control/captopril at 
week 8, (table 26).
Plasma levels tended to increase over the 8 week period 
in the adriamycin/captopril group, although this increase 
was not statistically significant. There was no
significant change in the saline control/captopril group, 
and there were no significant differences between the 
groups at baseline or week 8, (table 25). Analysis of the 
mean plasma potassium concentration in the animals which 
survived to the end of the study demonstrated a non­
significant increase in the adriamycin/captopril group 
from 4 . 8^0. 2mmol. I-1 to 5 . 5^0. 6mmol. I-1, n=6, and a non­
significant decrease in the saline control/captopril group 
from 5.2^0.3mmol.I-1 to 5.1^0.lmmol.I-1, n=7.
No significant difference in the mean plasma level 
was detected between the adriamycin/captopril and the 
adriamycin groups at baseline. The plasma
concentration was however significantly higher at week 8
Table 26.
Comparison of plasma macmesium concentration in the 
adriamycin/captopri1. saline control/captopril. adriamycin 
and saline control/groups.
Plasma Mg2^(mmol.I-1)
Weekl Week 8
Adriamycin/captopril 0.72^0.03(7) 0.7510.08(8)
*
Adriamycin 0.9510.05(16) 0.7010.02(20)
Saline control/ 0.8310.02(7) 0.7310.02(8)
captopril
* *
Saline control 0.9510.05(16) 0.8510.03(16)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
** = p<0.01.
Table 27.
Comparison of the normalised plasma magnesium 
concentration between the adriamycin/captopril_and 
adriamycin groups.
% change in plasma magnesium
Adriamycin -24.514.5(16)
*
Adriamycin/captopril 6.4113.9(7)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
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in the adriamycin/captopril group. There were no 
significant differences at baseline or week 8 between the 
saline control and the saline control/captopril groups, 
(table 28).
The mean value of plasma Na-" tended to increase in both 
the adriamycin/captopril and the saline control/captopril 
groups over an 8 week period although this increase was 
not statistically significant. There were no
statistically significant differences between these 2 
groups at baseline or week 8, (table 29).
Analysis of the plasma sodium concentration in those 
animals which survived to the end of the study revealed a 
non-significant increase in both the adriamycin/captopril 
and saline control/captopril groups. The mean plasma 
sodium concentration increased from 143^1mmol.l-x to 
146H3mmol.I-1 in the adriamycin/captopril group, n=6. The 
levels in the saline control/captopril group increased 
from 143:12mmol .I-1 to 145Hlmmol. I-1, n=7.
No change was seen at baseline or week 8 between the 
adriamycin/captopril group and the adriamycin group, and 
there were no differences between the saline control and 
the saline control/captopril groups.
Table 28.
Comparison of plasma potassium concentration in the 
adriamvcin/captopril. saline control/captopril. adriamycin 
and saline control groups.
Plasma K*(mmol.I-1)
Weekl Week 8
Adriamycin/captopril 4.810.1(8) 5.5*0.6(6)
Adriamycin
Saline control/ 
Captopril
4.910.1(23) 4.610.1(18)
5.210.3(7) 5.010.2(8)
Saline control 4.810.1(17) 4.810.1(16)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
Table 29.
Changes in plasma urea and sodium in the
adriamycin/captopril and saline control/captopril groups.
Adriamycin/
Captopril
Urea weekl 6.410.3(8)
Saline control/ p
Captopril
7.410.1(7) 0.05
**
Urea week8 35.1120.4(6) 7.010.3(8) 0.05
Sodium weekl 142.110.9(8) 142.611.5(7) NS
Sodium week8 146.313.4(6) 146.712.1(8) NS
Urea = plasma urea concentration in mmol.I-1 
Sodium = plasma sodium concentration in mmol.I-1 
NS = not significant.
** = p<0.01 between weeks 1 and 8 in the 
adriamycin/captopril group.
The numbers in parenthesis represent the numbers of 
animals.
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Plasma urea levels increased significantly over the 8 
week period in the adriamycin/captopril group(p<0.01), 
There was no significant change in the saline 
control/captopril group over a similar period, (table 29). 
When the groups were compared, the mean plasma urea level 
was significantly higher in the saline control/captopril 
group when compared to the adriamycin/captopril group at 
baseline (p<0.05). When the data for plasma urea was 
normalised however, the mean level of plasma urea showed a 
significant increase in the adriamycin/captopril group, 
(table 30).
No baseline differences were seen between the adriamycin/ 
captopril group and the adriamycin group. However at week 
8 the mean level of plasma urea was significantly higher 
in the former group(p<0.05). There were no differences at 
baseline or at week 8 between the saline control/captopril 
group and the saline control group, (table 31).
The significant increase in the plasma urea levels in the 
adriamycin/captopril group probably reflects a combination 
of the nephrotoxicity of adriamycin and the potential for 
captopril to cause a deterioration in renal function by 
reducing glomerular filtration rate.
Table 30.
Comparison of the normalised plasma urea levels between 
the adriamycin/captopril and saline control/captopril 
qrpyipg»
% change in plasma urea
137159(6)
*
-314.9(7)
The numbers in parenthesis represent the numbers of 
animals.
Adriamycin/captopril
Saline control/captopril
* = p<0.05.
Table 31.
Comparison of plasma urea concentration in the 
adriamvcin/captopri1. saline control/captopril. adriamycin 
and saline control groups.
Plasma urea(mmol.I-1)
Weekl Week 8
Adriamycin/captopril 6.410.3(8) 35.1120.4(6)
Adriamycin
Saline control/ 
captopril
Saline control
6.610.3(24) 7.010.3(20)
7.410.1(7) 7.010.3(8)
7.010.3(18) 6.610.3(16)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
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6.4.4 Pathology.(tables 32-35).
The mean wet heart weight in the adriamycin/captopril 
group tended to be higher than in the saline 
control/captopril group, a difference of 10% . There were 
no significant differences in the heart weights when the 
above groups were compared to the adriamycin and saline 
control groups.
There were no differences in the mean liver weights when 
the adriamycin/captopril group was compared with the 
saline control/captopril group, and there were no 
significant differences when comparisons were made with 
the adriamycin and saline control groups.
There were no significant changes in the lung weights 
between the adriamycin/captopril and saline 
control/captopril groups, and neither were there any 
significant differences between these groups and the 
adriamycin and saline control groups.
Total body weight increased significantly in both the 
groups treated with captopril between weeks 0 and 
10(p<0.05). There were no differences between the groups 
at weeks 0 or 10.
In those animals which survived to the end of the study 
the mean body weight showed a non-significant increase in 
the adriamycin/captopril group from 3.06^0.03Kg to 
3.09^0.lKg, n=6. The mean body weight in the saline
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control/captopril group increased from 3.05^0.05Kg to 
3.63^0.lKg, n=8 and p<0.01.
The mean total body weight was significantly less at 
baseline in the adriamycin/captopril group when compared 
to the adriamycin group, although there were no 
significant differences between the saline control and 
saline control/captopril groups. When the data for the 
body weights was normalised however, there were no 
significant differences between the adriamycin/captopril 
and adriamycin groups at week 10.
Both the heart/body weight, liver/body weight and 
lung/body weight ratios were higher in the 
adriamycin/captopril group when compared to the saline 
control/captopril group, although these changes were not 
statistically significant. There was no difference with 
respect to both of these parameters when the groups 
treated with captopril were compared to the saline control 
and adriamycin groups.
The wet/dry weight ratios of the heart and liver tended 
to be higher in the animals in the adriamycin/captopril 
group than in the saline control/captopril group, 
although the difference was not statistically significant. 
There were no significant differences between the wet/dry 
weight ratios of the hearts in the animals treated with 
captopril and those in the adriamycin and saline control 
groups.
Table 32.
Comparison of the heart, liver and lung weights in the 
adriamycin/captopril. saline control/captopril. adriamycin 
and saline control groups.
Heart(g) liver(g) lung(g)
Adriamycin/captopril 9.8*0.8(7) 77.1*3.1(7) 19.612.7(6)
Adriamycin 10.810.6(17) 87.815.8(18) 18.511.4(18)
Saline control/ 8.911.4(7) 73.516.4(7) 19.511.3(5)
captopril
Saline control 7.210.3(16) 64.913.9(15) 1811,1(15)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the 
adriamycin/captopril and adriamycin groups, nor between 
the saline control/captopril and saline control groups.
Table 33.
Comparison of body weights between the
adriamycin/captopril. saline control/captopri1. adriamycin 
and saline control groups.
Body weight(Kg) 
WeekO
Adriamycin/captopril 3.0410.03(12)
Body weight(Kg) 
Week10 
3.310.15(7)
Adriamycin
Saline control/ 
captopril
3.310.05(24)
3.0610.04(8)
3.210.07(18)
3.6810.17(7)
Saline control 3.2710.08(19) 3.4910.1(16)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.01
Table 34.
Comparison of the heart, liver and lung to body weight
ratios in the adriamycin/captopril. saline
control/captopri1. adriamycin and saline control groups,
H/BW L/BW LU/BW
Adriamycin/captopril 0.310.03(7) 2.3610.14(7) 0.5910.09(6)
Adriamycin 0.3310.02(18) 2.7710.2(18) 0.5810.05(18)
Saline control/ 0.2310.02(7) 1.9810.1(7) 0.5110.05(5)
Captopril
Saline control. 0.2110.02(15) 1.9510.2(15) 0.5210.04(15)
H/BW=Heart to body weight ratio.
L/BW=Liver to body weight ratio.
Lu/BW=Lung to body weight ratio.
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the 
adriamycin/captopril and adriamycin groups, nor between 
the saline control/captopril and saline control groups.
Table 35.
Comparison of the wet/drv weight ratio of the heart in the 
adriamycin/captopril. saline control/captopril..adriamycin 
and saline control groups, and the liver wet/dry weight 
ratio between the adriamycin/captopril and saline 
control/captopri1 groups.
Heart Liver
Wet/dry Wet/dry
Adriamycin/captopril 5.610.9(4) 3.610.2(3)
Adriamycin 5.510.7(4)
Saline control/ 4.610.1(7) 3.510.1(4)
captopril
Saline control 4.510.3(4)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the 
adriamycin/captopril and adriamycin groups, nor between 
the saline control/captopril and saline control groups.
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6.5 Discussion.
The principal finding in the experiments described in this 
chapter is that the introduction of captopril following 6 
weeks of treatment with adriamycin did not reverse the 
shortening in stim-T and ERP which had developed by this 
time. Neither was there any statistically significant 
difference in stim-T or ERP at the end of the study 
between the animals in the adriamycin/captopril group and 
those in the adriamycin group described in chapter 4. The 
possible aetiological mechanisms proposed for the 
shortening in stim-T and ERP in the experiments described 
in chapter 4 were either the direct cytoxic effects of 
adriamycin, or an increase in pulmonary arterial pressure 
and consequently right ventricular afterload. The results 
from the experiments in this chapter and from those 
described in chapter 4, would suggest that the former 
explanation is the more likely. The angiotensin 
converting enzyme inhibitor captopril was introduced 
specifically after 6 weeks treatment with adriamycin, as 
at this time it had been demonstrated that in the animals 
treated with adriamycin in the experiments described in 
chapter 4, the stim-T interval and ERP were significantly 
shortened. Another reason for specifically introducing 
captopril at this time was to avoid the drug preventing
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the development of heart failure in this model. One of 
the possible mechanisms proposed for the myopathic effect 
of adriamycin is by an increased production of oxygen- 
derived free radicals, (Bachur, N.R. et al(1977); 
Doroshow, J.H. (1983); Kalyanaraman, B. et al(1980)). 
Captopril is a potent free radical scavenger, (Westlin,
W. & Mullane, K.(1988)), and because of this particular 
property, the introduction of the drug was delayed until 
week 7 of the study.
A progressive and parallel reduction in repolarisation and 
refractoriness was observed in the adriamycin group which 
was treated with captopril. The reduction of 14% and 8% 
respectively was similar in magnitude to the 12% and 14% 
reduction which occured in these parameters in the 
adriamycin group. The lack of effect of captopril on 
repolarisation and refractoriness does not support the 
hypothesis that the shortening in stim-T and ERP in 
adriamycin cardiomyopathy is caused by an increase in 
right ventricular afterload.
Although haemodynamic measurements were not made in 
these experiments it would be expected that captopril 
would reduce pulmonary arterial pressure, (Sharpe, 
D.N.(1980); Ader, R. et al(1980); Topic, N.(1980);
Levine, T.B. & Cohn, J.N.(1982)).
There is some indirect evidence from the data in these 
experiments that captopril had a beneficial effect on
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afterload and also improved cardiac failure. The mean wet 
heart weight of the animals in the adriamycin/captopril 
group was only 10% higher than in the corresponding saline 
control/adriamycin group, a non significant difference.
The mean wet heart weight of the animals in the initial 
group treated with adriamycin was however 58% greater than 
the saline control group. A reduction in heart weight 
would be consistent with a reduction in ventricular 
afterload and an improvement in the heart failure state. 
Similarly, the mean wet liver weight was only increased by 
5% in the adriamycin/captopril group when compared to the 
saline control/captopril group, whereas in the initial 
group treated with adriamycin, the liver weight was 
increased by 35%. Again the reduction in hepatic 
congestion would be consistent with an improvement in 
heart failure. Sinus cycle length also progressively 
lengthened over the 10 weeks of the study in the 
adriamycin/captopril group, and was significantly longer 
when compared to the adriamycin group. This reduction in 
heart rate may also imply an improvement in cardiac 
performance. Angiotensin converting-enzyme inhibition has 
been shown clinically to lower heart rates significantly 
in patients with congestive heart failure, (The consensus 
trial study group,(1987)).
The failure of captopril to reverse the shortening in 
stim-T and ERP which had been proposed as a possible
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mechanism for sudden arrhythmic death in heart failure, 
would suggest that the addition of the drug would have no 
effect on the incidence of sudden death in the study. 
Examination of the mortality data however reveals that 
there were no sudden unexplained deaths in the adriamycin 
group of animals treated with captopril (although 1 animal 
did die suddenly with coexisting renal failure). However, 
the small size of the study groups and the low incidence 
of sudden death in the adriamycin treated animals makes 
meaningful comparisons difficult. It is only possible to 
say that there was a tendency for captopril to reduce the 
incidence of sudden death. If this were so, this would be 
in disagreement with the majority of existing clinical 
evidence which so far has failed to demonstrate any effect 
of inhibition of the renin-angiotensin system on the 
incidence of sudden arrhythmic death, (The concensus 
trial study group,(1987); Furberg, C. & Yusuf, S.(1985); 
Creager, M.A. et al(1982); Magnani, B. & Magelli,
C.(1986); The SOLVD Investigators,(1991)).
It is interesting to note however that the incidence of 
ventricular arrhythmias as detected by 24 hour continuous 
ambulatory monitoring was qualitatively reduced in the 
animals treated with adriamycin and captopril. Indeed 
there was no evidence of ventricular ectopic activity in 
any animals in this group. This is in contrast to the 
animals in the adriamycin group with every animal in the
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group demonstrating evidence of ventricular ectopy. The 
experimental finding of a reduction in ventricular ectopic 
activity is in accord with the majority of clinical 
studies using angiotensin converting-enzyme inhibitors 
which have addressed the same problem, (Cleland, J.G.F. 
et al(1984); Dargie, H.J. et al(1987)). One possible 
explanation for this reduction may be that by preventing 
the decrease in plasma Mg2  ^which was observed in the 
adriamycin group over an 8 week period, captopril 
eliminated one axis of a multifactorial system, and thus 
reduced the arrhythmogenic tendency. It is also 
interesting to note from the experimental data presented 
here that captopril did not prevent the decrease in plasma 
M2  ^ over an 8 week period in the saline control animals. 
The adriamycin group of animals treated with captopril 
also tended to an increase in plasma K- at week 8 when 
compared to baseline, while those animals in the 
adriamycin group demonstrated a tendency for the mean 
plasma to fall over the 8 week period. This effect 
could also be potentially anti-arrhythmic. Data from 
clinical studies have also demonstrated that in patients 
with heart failure, captopril causes an increase in plasma 
and a reduction in the frequency of ventricular ectopic 
activity, (Dargie, H.J. et al(1987); Cleland, J.G.F. et 
al(1984)).
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The effect of captopril on the renin-angiotensin system in 
this experimental model was as expected on theoretical 
grounds. After 2 weeks of therapy with captopril, ie at 
week 8 of the study, the mean plasma renin activity was 
significantly higher in both the groups of animals which 
were treated with captopril. At week 8 the levels of 
renin were also higher in the adriamycin/captopril group 
when compared to the saline control/captopril group, 
although the difference was not statistically significant. 
These results would suggest that captopril has a greater 
effect on inhibition of the renin-angiotensin system in 
heart failure than in controls. The data from the animals 
treated with adriamycin in the experiments described in 
chapter 4 demonstrated no activation of the renin- 
angiotensin system by week 8 however. In parallel with 
the increase in plasma renin was as expected a decrease in 
the levels of angiotensin II. There were no significant 
baseline differences in angiotensin II between the 2 
groups of animals treated with captopril and after 
commencement of the drug the levels of angiotensin II were 
undetectable in every animal except for one in the control 
group whose levels of aangiotensin II were halved.
The other limb of the neurohormonal axis, the sympathetic 
nervous system showed some surprising changes in this part 
of the study. The mean level of plasma noradrenaline in 
the adriamycin group of animals treated with captopril was
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significantly increased at week 8 of the study when 
compared to baseline. It was also higher when compared to 
the animals treated with adriamycin alone. This result 
would appear unusual as the heart rates in the adriamycin 
group of animals treated with captopril were significantly 
reduced by the end of the study when compared to baseline. 
It would be expected that the increase in sympathetic 
stimulation would have caused an increase in heart rates. 
This result is also unusual in another respect. The 
probable improvement in heart failure which was caused by 
captopril and manifest by a lessening in the ventricular 
hypertrophy and hepatic congestion, would if anything 
again be associated with a decrease in noradrenaline 
levels. The clinical study by Cleland, J.G.F. et al(1984) 
demonstrated that in patients with heart failure treated 
with captopril the plasma noradrenaline levels were 
significantly decreased.
One possible explanation for the increase in plasma 
noradrenaline levels in the adriamycin/captopril group is 
that the animals could have had a high sympathetic drive 
as renal function deteriorated. The nephrotoxic effect of 
captopril was manifest as a significant increase in plasma 
urea levels. Another possible explanation is that the 
dose of captopril used in the study was too high and 
resulted in a hypotensive response in the 
adriamycin/captopril group. The fact that there was no
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biochemical deterioration in renal function in the animals 
in the saline control/captopril group would tend to 
indicate that the dose of captopril used was not enough to 
be directly nephrotoxic.
The fact that renal function did deteriorate in the group 
of animals with heart failure which were treated with 
adriamycin is not entirely unexpected. Previous clinical 
studies have reported similar findings, (Cleland, J.G.F. 
et al(1984)). On theoretical grounds, some authorities 
believe that in low-output states the primary purpose of 
activation of the renin-angiotensin system is the 
preservation of renal function. Interference with the 
formation of angiotensin II would predictably result in a 
reduction in glomerular filtration rate. This expectation 
has been confirmed experimentally in the dog, (Kastner, 
P.G., Hall, J.E., & Guyton, A.C.(1982); Hall, J.E. et 
al(1977); Lohmeier, T.E. et al(1977)).
In conclusion therefore, the addition of captopril to the 
adriamycin treated animals with heart failure did not 
reverse the changes in repolarisation and refractoriness 
which had developed prior to the administration of the 
drug. This would tend to support the theory that the 
electrophysiological changes which occured in this study 
were secondary to the toxic myopathic effect of adriamycin 
and unrelated to activation of the renin-angiotensin 
system. The changes in heart and liver weight in the
153
study were consistent with the known effect of captopril 
in improving cardiac output in heart failure. The 
improvement in ventricular ectopic activity in the animals 
treated with adriamycin is also similar to that detected 
clinically and may be related to the repletion of plasma 
electrolytes, in particular and Mg2 .^ Although there 
was a tendency for captopril to reduce the incidence of 
sudden unexplained death in the adriamycin treated 
animals, the failure of the drug to reverse the changes 
in repolarisation and refractoriness may be one possible 
explanation for the failure of inhibition of the renin- 
angiotensin system clinically to reduce the incidence of 
sudden death in congestive cardiac failure.
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CHAPTER 7
THE EFFECT OF FRUSEMIDE ON THE ELECTROPHYSIOLOGICAL 
CHANGES IN ADRIAMYCIN-INDUCED CHRONIC HEART FAILURE 
IN THE RABBIT.
7.1 Introduction.
Diuretic therapy has historically been the mainstay of 
first-line management in patients with congestive heart 
failure. The most widely used agent has been the loop 
diuretic frusemide which acts by inhibiting the 
specific enzymes concerned with the pumping of 
chloride across the lining cell of the ascending limb of 
the loop of Henle. The result is that chloride, sodium, 
potassium and hydrogen ions all remain within the renal 
tubule with the diuresis of sodium. Frusemide has also 
been shown to inhibit 15-hydroxyprostaglandin 
dehydrogenase, the first-step enzyme involved in the 
degradation of prostaglandins, (Stone, K.J. & Hart, 
M.(1976)). The consequence of this is that 
prostaglandins, especially prostaglandin E2, accumulate in 
the renal medulla and directly suppress anti-diuretic 
hormone dependent water permeability of the collecting 
tubules, (Grantham, J.J. & Orloff,J .(1968)).
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Prostaglandins may further prevent the reabsorption of 
sodium chloride from the thick ascending loop of Henle, 
(Stokes,J.B.(1979)). Among the most important side- 
effects of treatment with frusemide are hypokalaemia and 
hypomagnesaemia. Current evidence would suggest however 
that the use of standard doses of frusemide such as 40mg 
or 80mg daily in the management of chronic heart failure, 
causes less hypokalaemia than thiazide diuretics,
(Davidov, M.E., M^Knight, J.E. & Osborne, J.L.(1979); 
Morgan, D.B. & Davidson, C.(1980)). The theoretical risk 
exists however that electrolyte depletion may occur in 
patients treated with frusemide, who have congestive 
cardiac failure. As previously mentioned in chapter 1.6 
and 1.7, a number of reports have demonstrated that 
depletion of and Mg2-" may be associated with 
arrhythmias, and that repletion of these electrolytes may 
improve the arrhythmias without the use of convential 
anti-arrhythmic therapy, (Bertuso, J.R. et al (1984); 
Chadda, K. et al(1984)). The presence of hypokalaemia has 
also been shown to be associated with the severity of 
ventricular ectopic activity in patients with heart 
failure, (Dargie, H.J. et al(1987)), and the presence of 
arrhythmias in patients with hypertension, (Medical 
Research Council working party on mild to moderate 
hypertension,(1983); Holland, O.B. et al(1981); 
Papademetriou, V. et al(1983)).
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In addition to the possible arrhythmogenic effect of 
frusemide in causing electrolyte depletion, the drug has 
important interactions with the renin-angiotensin and 
sympathetic nervous systems. Acute administration of the 
drug is associated with an increase in the release of 
renin, an effect which is thought to be prostaglandin 
dependent, (Johnston, G.D. et al(1983)). The diuresis 
and fall in circulating volume produced by frusemide, also 
result in stimulation of the renin-angiotensin and 
sympathetic nervous systems, (MacKay, I.G., Muir, A.L. & 
Watson, M.L.(1984); Cannella, G. et al(1983)). The 
increased activity of the renin-angiotensin system and the 
stimulation of the sympathetic nervous system are 
potentially arrhythmogenic in patients with heart failure. 
The purpose of the experiments described in this chapter 
was to assess the experimental effect of frusemide on the 
renin-angiotensin system in animals with heart failure, 
and also the interaction between this system and the 
changes in repolarisation and refractoriness which have 
been described previously. The results from the 
experiments in the previous chapters would suggest that 
the shortening in repolarisation and refractoriness in 
heart failure was unrelated to to an increase in plasma 
renin activity. There are theoretical grounds at least 
which would indicate however that stimulation of the 
renin-angiotensin system by virtue of the increase in
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afterload, may cause a reduction in action potential 
duration: Lab, M.J.(1982); Reiter, M.J. et al (1988).
This effect may be potentially arrhythmogenic and cause an 
increase in the incidence of sudden death.
7.2 Methods.
Two experimental groups of animals were used in this 
study. The surgical techniques and the 
electrophysiological and other measurements are as 
described in chapter 2.
7. 3 Experimental protocol.
As in the other experiments, a 3 week period was allowed 
following implantation of the permanent pacing electrodes 
during which time the electrophysiological measurements 
were allowed to stabilise. The animals were then 
randomized to receive either adriamycin or saline 
according to the protocol described in chapter 2.
In addition to the injections with adriamycin or saline, 
each animal was treated with frusemide in a dose of 
5mg.Kg_1 intravenously twice daily. The dose of frusemide 
was chosen on the basis of information obtained in the 
veterinary formularly and also from a small pilot study
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which assessed the effect of differing doses of the drug 
on body weight, urine output, fluid intake and plasma 
electrolytes.
A total number of 7 animals were assessed in the pilot 
study which was conducted over a 7 day period. One animal 
was treated with 0.5 mg.Kg-1 twice daily of intravenous 
frusemide. Another animal with 1 mg.Kg-1 twice daily, 2 
animals with 2.5 mg.Kg-1 and 2 animals with 5 mg.Kg-1. A 
further animal was given 1ml of 0.9% saline intravenously 
twice daily as a control. One of the animals treated with 
5mg.Kg_1 of frusemide observed a fall in body weight of 3% 
over a week and the other had no change. Fluid intake 
increased by 240% and 150% respectively in the 2 animals. 
The average urine output was 60mls and 65mls in 24 hours. 
Plasma decreased and plasma urea increased in both the 
animals at the end of the 7 days. With respect to the 2 
animals treated with 2.5mg.Kg_:L, both had a fall in body 
weight, a substantial increase in fluid intake and average 
urine outputs of 42ml and 27ml. Plasma decreased in 
only one of the animals and plasma urea decreased slightly 
in both animals. The animal treated with lmg.Kg-1 had no 
change in body weight, a 20% increase in fluid intake and 
an average urine output of 2,5ml. Plasma decreased and 
urea increased after 7 days. The animal treated with 
0.5mg.Kg_1 had a 4% increase in body weight, a 27%
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increase in fluid intake and an average urine output of
56ml. Both plasma K- and urea decreased over the 7 days.
The dose of frusemide eventually chosen as mentioned above 
was 5mg.Kg-:L. From the information obtained in the pilot 
study this was the dose which produced the greatest 
response in terms of urine output, and also resulted in a
decrease in plasma potassium concentration.
7.4 Results
7.4.1 Survival data.(table 36).
A total number of 8 animals entered the study in the 
adriamycin group and 7 animals in the control group. 2 
animals died in the adriamycin group, both during week 8 
of the study. Both of the animals had been unwell during 
the 24 hours prior to death and no cause was found at 
post-mortem examination. 6 animals survived to the end of 
the study and were then electively killed. There were no 
deaths in the saline control/frusemide group during the 10 
weeks of the study.
Table 36.
Survival data in the adriamycin/frusemide and saline 
control/frusemide groups.
Initial Overall SD SBE Others
Number Mortality
Adriamycin/frusemide 8 2 0 0 2
Saline control/ 7 0 0 0 0
frusemide
SD = Sudden death.
SBE = Subacute bacterial endocarditis.
Initial number = Initial number of animals in the study.
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7.4.2 Electrophysiology.
Diastolic pacing threshold
The diastolic pacing threshold tended to increase between 
weeks 0 and 10 in both the adriamycin/frusemide and saline 
control/frusemide groups, although these changes were not 
statistically significant. There were no differences 
between the groups at either week(table 37).
Analysis of the pacing threshold in those animals which 
survived to the end of the study demonstrated a non­
significant increase in the adriamycin/frusemide group 
from 2.2:10.3 V to 3.0^0.3V, n=6. The diastolic pacing 
threshold was significantly higher in the adriamycin group 
from chapter 4, when compared to the adriamycin/frusemide 
group at week 0, (table 38). The data were thus 
normalised and there was no significant difference between 
the normalised means at week 10.
There were no differences in the pacing threshold between 
the saline control and saline control/frusemide groups at 
weeks 0 or 10.
Table 37
Changes in the diastolic pacing threshold in the 
adriamycin/frusemide and saline control/frusemide groups.
Week 0 5 10
Adriamycin/frusemidein 8 8 6
Threshold(volts) 2.310.4 2.710.4 3.010.3
Saline control/:n 7 7 7
frusemide
Threshold(volts) 2.910.6 3.110.6 3.510.5
There were no significant differences between groups or 
within the groups between weeks 0 and 10.
Table 38.
Comparison of the diastolic pacing threshold in the 
adriamvcin/frusemide. saline control/frusemide, adriamycin 
an saline control groups.
Diastolic pacing threshold(volts) 
WkO WklO
Adriamycin/frusemide 2.310.4(8) 310.3(6)
*
Adriamycin 4.410.5(16) 410.6(10)
Saline control/ 2.910.6(7) 3.510.5(7)
frusemide
Saline control 3.8+0.6(11) 3.1+0.2(8)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.01.
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Stimulus-T interval
The stimulus-T interval in the group of animals treated 
with adriamycin and frusemide decreased significantly by 
7% over the 10 weeks of the study (p<0.05). There was no 
significant diference however when the 
adriamycin/frusemide group of animals was compared to 
saline control/frusemide group at weeks 0 or 10, (table 39 
and Fig 10). There was no significant change in stim-T in 
the saline control/frusemide group of animals over the 10 
weeks of the study.
The stim-T interval in those animals which survived to the 
end of the study in the adriamycin/frusemide group also 
demonstrated a significant decrease between weeks 0 and 
10. The mean value of stim-T was 106^1ms at week 0, and 
99_l3ms at week 10, n=6 and p<0.05.
The baseline stimulus-T interval was significantly shorter 
in the adriamycin/frusemide group when compared to the 
animals treated with adriamycin alone, (table 40). The 
baseline values were therefore normalised. Although the 
stim-T interval tended to decrease more in the adriamycin 
group, the difference between the groups was not 
statistically significant, (table 41). The stimulus-T 
interval was also significantly greater at week 0 in the 
saline control group when compared to the saline 
control/frusemide group, (table 40). This data was also
Table 39,
Changes in stim-T and ERP in the adriamvcin/frusemide and 
saline control/frusemide groups.
Week 0 5 10
Adriamycin:n 8 8 6
Stim-T(ms) 105.811.3 106.112.6 98.812.8
ERP(ms) 102.512.5 95.512.7 8612.5
Control:n 7 7 7
Stim-T(ms) 104.712.3 106.H2.1 105.813.3
ERP(ms) 102.611.9 106.311.2 10411.1
Stim-T significantly decreased between weeks 0 and 10 in 
the adriamycin/frusemide group, p<0.05. No change occured 
in the saline control/frusemide group between weeks 0 and 
10. There were no significant differences between the 
groups.
The ERP significantly decreased by week 6 in the 
adriamycin/frusemide group, p<0.01, and this difference 
continued to week 10, p<0.001. No change occured in the 
control group. The ERP was significantly shorter in the 
adriamycin/frusemide group at week 10, p<0.001, when 
compared to the saline control/frusemide group.
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Figure 10.
Graph illustra ting  the effect of frusemide on ventricu lar 
repolarisation in heart fa ilu re . The adriamycin treated  
animals are represented by the broken line and the control 
animals by the continuous line. Although there was no 
progressive shortening, stim -T was significantly less at 
week 10 in the adriamycin group.
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Table 40.
Comparison of stim-T and ERP in the adriamvcin/frusemide.
saline control/frusemide. adriamycin and saline_controI
groups.
Stim-T(ms) ERP(ms)
WkO WklO WkO WklO
Adriamycin/ 10611(8) * 99.13(6) 10212(8) *** 86l2(6)
frusemide
* *  * *
Adriamycin 116l2( 16)***102l2( 10) 11512 (16)***9813(10)
Saline control/10512(7) 10613(7) 10312(7) 10411(7)
frusemide
* *  * *
Saline/ 12013(11) 12014(8) 11314(11) 12013(8)
control
The numbers in parenthesis represent the numbers of
animals.
* = p<0.05
** = p<0.01.
*** = pcO.001
Table 41.
Comparison of the normalised stim-T and ERP data— between 
the adriamycin/frusemide and adriamycin groups, and 
between the saline control/frusemide and saline control 
groups.
% change in stim-T. % change in ERP.
Adriamycin/frusemide -712.2(6) -14.712.2(6)
Adriamycin -1111.7(8) -13.511.3(9)
Saline control/frusemide 1.311.8(7)
Saline control -211.6(8)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the 
adriamycin/frusemide and adriamycin groups, nor between 
the saline control/frusemide and saline control groups.
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normalised and there was no significant difference between 
the means at week 10, (table 41).
Effective refractory period
The ERP shortened by 16% in the adriamycin/frusemide group 
of animals by week 10, (p<0.001). The ERP was 
significantly shortened within this group by week 6, 
(p<0.01). When the adriamycin/frusemide group was 
compared to the saline control/frusemide group of animals, 
the ERP was significantly shorter in the former at week 
3(p< 0.05), (table 39) and Fig.11. Analysis of the ERP 
in those animals which survived to the end of the study in 
the adriamycin/frusemide group also demonstrated a 
significant decrease from 101^3ms to 86^2ms at week 10, 
n=6 and p<0.01.
As with the stim-T results, the baseline ERP was 
significantly shorter in the adriamycin/frusemide group 
when compared to the group of animals treated with 
adriamycin alone, (table 40), thus the ERP data was 
normalised. There were no significant differences between 
the normalised means at week 10, (table 41).
Although there was no difference at week 0, the ERP was 
significantly greater at week 10 in the saline control 
group when compared to the saline control/frusemide group, 
(table 40).
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Figure 11.
Graph illu stra tin g  the effect of frusemide on the rig h t 
ventricu lar effective refractory period in  heart fa ilu re .
The adriamycin treated animals are represented by the broken  
line and the controls by the continuous line . ERP 
progressively shortens in the adriamycin group.
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Sinus cvcle length
Sinus cycle length showed a non-significant decrease in 
both the adriamycin/frusemide and saline control/frusemide 
groups between weeks 0 and 10. There were no differences 
between the groups at week 0 or week 10, (table 42).
There was also a non-significant decrease in the sinus 
cycle length in the animals which survived to the end of 
the study in the adriamycin/f rusemide group, from 266.19ms 
to 260114ms, n=6.
The baseline sinus cycle length was significantly 
greater in the adriamycin/frusemide group when compared to 
the group treated with adriamycin alone, (table 43), the 
data were thus normalised for comparison. At week 10 the 
normalised means were not significantly different. There 
were no significant differences between the saline control 
group and the saline control/frusemide group, (table 43).
Ambulatory ECG recording
One complete ambulatory 24 hour ECG recording was made in 
each of the animals in the study both prior to the 
introduction of frudemide and afterwards. There was no 
evidence of ventricular ectopic activity at any time in 
either the adriamycin or control groups.
Table 42.
Changes in sinus cvcle length in the adriamycin/frusemide 
and saline control/frusemide groups.
Week 0 5 10
Adriamycin/frusemide:n 8 8 6
Sinus cycle length(ms) 26217.7 26718.5 260113.7
Saline control/:n 7 7 7
frusemide
Sinus cycle length(ms) 281121.4 269113.1 25716.2
There were no significant differences between the groups, 
or within the groups between weeks 0 and 10.
Table 43
Comparison of sinus cvcle length in the
adriamycin/frusemide. saline control/frusemide. adriamycin 
and saline control groups.
Sinus cycle length(ms)
Adriamycin/frusemide
WkO
262^7.7(8)
WklO
260113.7(6)
Adriamycin
Saline control/ 
frusemide
23816.7(16)
281121.4(7)
221+7.9(10)
25716.2(7)
Saline control 23013.8(11) 23812.8(8)
The numbers in parenthesis represent the numbers of
animals.
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7.4.3 Biochemistry.
Neurohormonal data
Plasma noradrenaline increased significantly in the 
adriamycin group of animals treated with frusemide from 
3.9 _1 0.2 nmol.I-1 at week 1 to 7.9 1.7 nmol.I-1 at week
8, p<0.05. There was no significant difference when this 
group was compared to the corresponding saline control 
group treated with frusemide at weeks 1 or 8, (table 44). 
There was no significant difference between weeks 1 and 8 
in the saline control/frusemide group. The mean plasma 
noradrenaline level demonstrated a non-significant 
increase in the animals in the adriamycin/frusemide group 
which survived to the end of the study. The mean 
concentration at weekl was 3.8^.0.2nmol.l_x and at week8 
8.2^2.2nmol.I-1, n=6. There were no significant 
differences between the adriamycin/frusemide group and the 
adriamycin group at weeks 1 or 8, neither were there any 
significant differences between the saline 
control/frusemide group and the saline control group,
(table 44).
There was no significant difference in plasma ANP either 
between the adriamycin/frusemide and saline 
control/frusemide groups or within the groups over an 8 
week period, (table 45).
Table 44.
Comparison of plasma noradrenaline concentrationJbetween 
the adriamycin/frusemide and adriamycin groups, and 
between the saline control/frusemide and saline control 
groups.
Plasma noradrenaline concentration(nmol.I-1)
Wkl Wk8 p
Adriamycin/f rusemide 3.910.2(8) 7.91,1.7(8) 0.05
Adriamycin 5.111.3(19) 5.410.8(19) NS
Saline control/ 5.811.9(6) 4.811.1(6) NS
frusemide
Saline control 3.510.5(18) 5.211.2(11) NS
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the groups 
other than indicated.
Table 45.
Changes in plasma atrial natriuretic peptide concentration
in the adriamycin/frusemide and saline control frusemide
groups.
Weekl Week8 p
Adriamycin/frusemide:n 7 8
ANP(pg.ml-1) 110.4129.5 152.9127.3 NS
Saline control/:n 6 7
frusemide
ANPCpg.ml-1) 77.2110.3 96.6115.4 NS
ANP = atrial natriuretic peptide.
NS = not significant.
There was no significant difference between the groups at
week 1 or week 8.
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The mean plasma ANP concentration did however increase 
significantly from 86^24pg.ml-1 to 138^25pg.ml_:L in the 
animals which survived to the end of the study in the 
adriamycin/frusemide group, n=5 and p<0.05.
Although there was no significant difference between the 
adriamycin and the adriamycin/frusemide groups at week 1, 
the ANP level was significantly higher in the 
adriamycin/frusemide group at week 8, (table 46). There 
were no significant differences between the saline 
control/frusemide group and the saline control group, 
(table 46).
The mean plasma renin concentration did not change 
significantly between the adriamycin/frusemide and saline 
control/frusemide groups, nor between weeks 1 and 8 within 
the groups, (table 47). There was however a significant 
decrease in plasma renin from 139:l24uU.I-1 to 86^21uU.I-1 
in those animals which survived to the end of the study in 
the adriamycin/frusemide group, n=6 and p<0.05. The mean 
plasma renin level was significantly higher at week 1 in 
the adriamycin/frusemide group when compared to the 
adriamycin group, (table 48), but there was no significant 
difference between the means at week 8 when the data was 
normalised, (table 49). Similar results were found when 
the saline control/frusemide and the saline control groups 
were compared, (tables 48 and 49).
Table 46.
Comparison of plasma atrial natriuretic peptide 
concentration between the adriamycin/frusemide and 
adriamycin groups, and between the saline 
control/frusemide. and saline control groups.
Plasma ANP concentration(pg.ml~1) 
Wkl Wk8
Adriamycin/frusemide 110.4129.5(7) 152.9127.3(8)
*
Adriamycin 137.7124.9(13) 94.3110.7(17)
Saline control 77.2110.3(6) 96.6115.4(7)
frusemide
Saline control 118.7112.5(18) 118.8114.4(14)
The numbers in parenthesis represent the numbers of
animals.
* = p<0.05.
Table 47.
Changes in plasma renin concentration in the 
adriamvcin/frusemide and saline control/frusemide groups.
Weekl Week8 p
Adriamycin/frusemide:n 8 7
Renin(uU.I-1) 1 2 8 . 2 * 2 0 . 2 79.3118.9 NS
Saline control/:n 7 6
frusemide
Renin(uU.I-1) 144.3124.4 79.3119 NS
NS = not significant
There were no significant differences between the groups 
at week 1 or 8, nor between the groups.
Table 48.
Comparison of plasma renin concentration between the
adriamvcin/frusemide and adriamvcin groups, and between
the saline control/frusemide and saline control groups.
Plasma renin concentration(uU.ml-1) 
Wkl Wk8
Adriamycin/frusemide 128.2120.2(8) 79.3118.9(7)
*
Adriamycin 74.2l6.8(11) 66.618.5(18)
Saline control/ 144.3124.4(7) 79.3119(6)
frusemide
**
Saline control 72.617.2(12) 56.114.2(17)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
** = p<0.01.
Table 49
Normalised renin data for comparison between the
adriamvcin/frusemide and adriamvcin groups, and between
the saline control/frusemide and saline control groups.
% change in plasma renin concentration
Adriamycin/frusemide -36112.4(7)
Adriamycin 21.719.9(11)
Saline control -39.2111.4(6)
frusemide
Saline control -8.9113.1(12)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the groups.
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Plasma electrolytes
The mean plasma K- levels were significantly higher at 
week 1 in the saline control/frusemide group when compared 
to the adriamycin/frusemide group, (table 50). There was 
no difference when the normalised data was compared at 
week 8 however. There was no significant difference 
between weeks 1 and 8 in either group. The mean plasma 
potassium concentration demonstrated a non-significant 
increase in those animals which survived to the end of the 
study in the adriamycin/f rusemide group, from 
4.3^0.05mmol.l_1 to 4.4.10.07 mmol. 1 ~1, n=6.
Comparison of the week 1 data revealed that plasma K^ 
was significantly higher in the adriamycin group when 
compared to the adriamycin/frusemide group, (table 51). 
When the data were normalised however, the potassium 
levels demonstrated a significant decrease in the 
adriamycin group p<0.05, (table 52). There were no 
significant differences between the saline
control/frusemide and the saline control groups at weeks 1 
or 8.
Plasma magnesium levels showed a non-significant decrease 
between weeks 1 and 8 in both of the groups which were 
treated with frusemide and there were no significant 
differences between the 2 groups, (table 50).
Table 50.
Changes in plasma potassium and magnesium concentration in
the adriamvcin/frusemide and saline control/frusemide
groups.
Adriamycin/frusemide Saline control/frusemide p
K^Weekl 4.210.04(8) 4.710.13(7) 0.01
K^Week8 4.610.25(7) 4.610.09(6) NS
Mg2-Week1 0.7710.02(8) 0.8310.04(7) NS
Mg2-Week8 0.7210.05(7) 0.7610.02(6) NS
K- = plasma potassium in mmol.I-1 
Mg2  ^ = plasma magnesium in mmol.I-1 
NS = not significant.
There was no difference in the adriamycin/frusemide or 
saline control/frusemide groups between weeks 1 and 8.
The numbers in parenthesis represent the numbers of
animals.
Table 51.
Comparison of plasma potassium concentration between the
adriamvcin/frusemide and adriamycin groups, and between
the saline control/frusemide. and saline control groups.
Plasma potassium concentration(mmol.I-1) 
Wkl Wk8
Adriamycin/frusemide 4.210.04(8) 4.610.25(7)
* *
Adriamycin 4.910.12(23) 4.610.08(18)
Saline control/ 4.710.13(7) 4.610.09(6)
frusemide
Saline control 4.810.11(17) 4.810.12(16)
The numbers in parenthesis represent the numbers of
animals.
** = p<0.01.
Table 52.
Comparison of the normalised plasma potassium 
concentration between the adriamvcin/frusemide and 
adriamycin groups.
% change in plasma potassium concentration
Adriamycin/frusemide 9.715(7)
*
Adriamycin -613.6(16)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
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The mean plasma Mg2- concentration also showed a non­
significant decrease from 0.78-0.03mmol.I-1 to 
0.73M).04mmol.I-1 in those animals in the 
adriamycin/frusemide group which survived to the end of 
the study, n=6.
The mean plasma magnesium level was significantly higher 
at week 1 in the adriamycin group when compared to the 
adriamycin/frusemide group, (table 53). When the data 
were normalised however, there was a significant decrease 
in the adriamycin group when compared to the 
adriamycin/frusemide group, (table 54). There was no 
significant difference between the saline 
control/frusemide group and the saline control group, 
(table 53).
There were no significant differences in plasma sodium 
levels between the adriamycin/frusemide and the saline 
control/frusemide groups. Neither were there any 
differences within the groups between weeks 1 and 8,
(table 55).
There was a non-significant increase in the mean plasma 
sodium concentration from 140^0.6mmol.I-1 to 
141^0.4mmol.I-1 in those animals which survived to the end 
of the study in the adriamycin/frusemide group, n=6.
The mean plasma sodium concentration was significantly 
higher at week 1 in the adriamycin group when compared to 
the adriamycin/frusemide group, (table 56). There was no
Table 53.
Comparison of plasma magnesium comcentration between the
adriamvcin/frusemide and adriamycin groups, and between
the saline control/frusemide. and saline control groups.
Plasma magnesium concentration(mmol.I-1)
Wkl Wk8
Adriamycin/frusemide 0.77^0.02(8) 0.72^0.05(7)
Adriamycin 0.95^0.05(16) 0.7^,0.02(20)
Saline control/ 0.83^0.04(7) 0.76,10.02(6)
frusemide
Saline control 0.9510.05(16) 0.8510.03(16)
The numbers in parenthesis represent the numbers of
animals.
* = p<0.05.
Table 54.
Comparison of the normalised plasma magnesium 
concentration between the adriamvcin/frusemide and 
adriamycin groups.
% change in plasma magnesium comcentration
Adriamycin/frusemide -6.814.8(7)
*
Adriamycin -24.514.5(16)
The numbers in parenthesis represent the numbers of
animals.
* = p<0.05.
Table 55.
Changes In plasma urea and sodium concentration in the 
adriamvcin/frusemide and saline control/frusemide groups.
Adriamycin/frusemide Saline control/frusemide p 
Urea weekl 7.310.3(8) 7.310.4(8) NS
*
Urea week8 9.110.6(7) 8.210.4(6) NS
Na+ weekl 140.110.64(8) 141.110.88(7) NS
Na^ week8 140.810.46(7) 141.010.52(6) NS
Urea = plasma urea concentration in mmol.I-1.
Na- = plasma sodium concentration im mmol.I-1 
NS = not significant.
There was no significant difference between weeks 1 and 8 
in the saline control/frusemide group.
* = p<0.05.
The numbers in parenthesis represent the numbers of
animals.
Table 56.
Comparison of plasma sodium concentration between the
adriamvcin/frusemide and adriamycin groups, and between
the saline control/frusemide and saline control groups.
Plasma sodium concentration(mmol.I-1)
Wkl Wk8
Adriamycin/frusemide 14010.6(8) 14110.5(7)
*
Adriamycin 14310.7(24) 14310.5(20)
Saline control/ 14110.9(7) 14110.5(6)
Frusemide
*
Saline control 14310.5(18) 14210.4(16)
The numbers in parenthesis represent the numbers of
animals.
* = p<0.05.
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significant difference at week 8 when the data were 
normalised, (table 57). Similar results were found when 
the saline control/frusemide group was compared to the 
saline control group, (tables 56 and 57).
Plasma urea increased significantly in the 
adriamycin/frusemide group from 7.3^0.3 mmol.I-1 at week 1 
to 9.1:10.6 at week 8, p<0.05. There were no significant 
differences between this group and the saline 
control/frusemide group, (table 55). There was no 
significant change in plasma urea between weeks 1 and 8 in 
the saline control/frusemide group. The mean plasma urea 
concentration also increased significantly in the animals 
which survived to the end of the study in the 
adriamycin/f rusemide group from 7.0.10. 3mmol. I-1 to 
8.6^0.4mmol.1~1, n=6 and p<0.01.
No significant differences were observed at week 1 
between the adriamycin/frusemide and the adriamycin group. 
Plasma urea was however significantly higher at week 8 in 
the adriamycin/frusemide group. Similar results were 
found when the saline control/frusemide group was compared 
to the saline control group, (table 58).
Table 57.
Normalised plasma sodium concentration for comparison 
between the adriamvcin/frusemide and adriamycin groups, 
and between the saline control/frusemide and saline 
control groups.
% change in plasma sodium concentration
Adriamycin/frusemide 0.34^0.58(7)
Adriamycin 0.41^0.57(19)
Saline control/ 0.45^0.38(6)
frusemide
Saline control -0.8^0.38(16)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the groups.
Table 58.
Comparison of plasma urea concentration between the 
adriamvcin/frusemide and adriamycin groups, and between 
the saline control/frusemide and saline control groups.
P1asma urea concent rat i on(mmo1.1-1) 
Wkl Wk8
Adriamycin/f rusemide 7.3:10.3(8) 9.110. 6(7)
* *
Adriamycin 6.610.3(24) 7.010.4(20)
Saline control/f rusemide 7.310.4(8) 8.2,10.4(6)
frusemide
Saline control 7.010.3(18) 6.610.3(16)
The numbers in parenthesis represent the numbers of
animals.
* = p<0.05.
** = p<0.01)
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7.4.4 Pathology.(tables 59-63).
The mean wet heart weight was 12% higher in the 
adriamycin/frusemide group when compared to the saline 
control/frusemide group,although this difference was not 
statistically significant. There was no significant 
difference when the mean wet heart weights were compared 
between the adriamycin/frusemide and the adriamycin 
groups, although the mean was greater in the adriamycin 
group. The heart weights were significantly higher in the 
saline control/frusemide group when compared to the saline 
cont ro1 group.
The mean wet liver weight was 10% higher in the 
adriamycin/frusemide group when compared to the saline 
control/frusemide group, a non-significant difference. 
There was no significant difference when the liver weights 
were compared between the adriamycin and 
adriamycin/frusemide groups, and the saline 
control/frusemide and saline control groups.
There was a tendency for the mean wet lung weights to be 
higher in the adriamycin/frusemide group when compared to 
the saline control/frusemide group, a non-significant 
increase. There were no significant differences between 
the adriamycin/frusemide and adriamycin groups, and no
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difference between the saline control/frusemide and saline
control groups.
When the heart and liver weights were expressed as a 
percentage of the total body weight, they were 8% and 7% 
respectively higher in the adriamycin/frusemide group when 
compared to the saline control/frusemide group, a non­
significant increase. The heart/body weight ratio was 
significantly higher in the adriamycin group when compared 
to the adriamycin/f rusemide group, but there was no 
significant difference between the saline 
control/frusemide and the saline control groups. There 
was no significant difference in the liver/body weight 
ratios between the adriamycin/frusemide and adriamycin 
groups, nor between the saline control/frusemide and the 
saline control groups. There were no significant 
differences in the lung/body weight ratios between the 4 
groups, although the mean value was greatest in the 
adriamycin group.
Total body weight increased by 8% in the 
adriamycin/frusemide group and 9% in the saline control/ 
frusemide group over the 10 weeks of the study, although 
the increases were not statistically significant. There 
were no significant difference between the 2 groups.
In those animals which survived to the end of the study in 
the adriamycin/frusemide group, the mean total body weight 
increased significantly from 3.56^0.lKg to 3.75:10.1, n=6
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and p<0.05. Paired analysis of the animals in the saline 
control/captopril group also revealed a significant 
increase between weeks 0 and 10, p<0.05.
There were no baseline differences between the 
adriamycin/frusemide and the adriamycin groups, but the 
mean body weights were significantly higher at week 10 in 
the adriamycin/frusemide group p<0.05. There was no 
significant difference between the saline 
control/frusemide and the saline control groups.
The wet/dry weight ratio of the hearts was similar in the 
adriamycin/frusemide and the saline control/frusemide 
groups, 4.8^0.3 in the adriamycin/frusemide animals and 
4.8 H0.1 in the saline controls/frusemide group. There 
were no significant differences when these groups were 
compared to the adriamycin and saline control groups which 
did not receive frusemide, although the greatest value was 
seen in the adriamycin group.
There were no significant differences in the liver wet/dry 
weight ratios between the adriamycin/frusemide and saline 
control/f rusemide groups, 4 . 2.10 • 3 in the 
adriamycin/f rusemide group vs 3.9.10.4 in the saline 
control/frusemide group.
Table 59.
Comparison of heart, liver and lung weight between the
adriamvcin/frusemide and adriamycin groups, and between
the saline control/frusemide and saline control groups.
Heart(g) Liver(g) Lung(g)
Adriamycin/f rusemide 9.41:0.4(8) 79.11:6(8) 20.31:3.3(6)
Adriamycin 10.810.6(17) 87.815.8(18) 18.511.4(18)
Saline control/ 8.410.3(7) 71.714.1(7) 17.611.8(7)
frusemide
*
Saline control 7.210.3(16) 64.913.9(15) 1811.1(15)
The numbers in parenthesis represent the numbers of
animals.
* = p<0.05.
Table 60.
Comparison of body weight and heart, liver and lung to
body weight ratios between the adriamvcin/frusemide and
saline control/frusemide groups.
Adriamycin/ Saline control/ p
frusemide frusemide
Body weight (Kg):
Week 0 3.4610.1(8) 3.210.08(7) NS
Week 10 3.7510.1(6) 3.510.1(7) NS
HW/BW 0.2610.01(8) 0.2410.02(7) NS
LW/BW 2.1710.12(8) 2.0210.05(7) NS
LU/BW 0.5410.09(6) 0.510.05(7) NS
The numbers in parenthesis represent the numbers of
animals.
HW = heart weight.
LW = liver weight.
BW = body weight.
LU = lung weight.
NS = not significant.
Table 61.
Comparison of the heart, liver and lung to body weight 
ratios between the adriamvcin/frusemide and adriamycin 
groups, and between the saline control/frusemide and 
saline control groups.
H/BW L/BW LU/BW
Adriamycin/ 0.2610.01(8) 2.1710.12(8) 0.5410.09(6)
frusemide
*
Adriamycin 0.3310.02(18) 2.7710.2(18) 0.5810.05(18)
Saline control/ 0.2410.02(7) 2.0210.05(7) 0.510.05(7)
frusemide
Saline control 0.2110.02(15) 1.9510.2(15) 0.5210.04(15)
The numbers in parenthesis represent the numbers of 
animals.
* = p<0.05.
H/BW = Heart to body weight ratio.
L/BW = Liver to body weight ratio.
LU/BW = Lung to body weight ratio.
Table 62.
Comparison of body weights between the
adriamvcxn/frusemide and adriamycin groups, and between 
the saline control/frusemide and saline control groups.
Body weight(Kg)
WkO WklO
Adriamycin/frusemide 3.4610.1(8) 3.7510.1(6)
* *
Adriamycin 3.310.05(24) 3.210.07(18)
Saline control/ 3.210.08(7) 3.510.1(7)
frusemide
Saline control 3.2710.08(19) 3.4910.1(16)
The numbers in parenthesis represent the numbers of
animals.
** = p<0.01.
Table 63.
Comparison of the wet/drv weight ratio of the heart and
liver between the adriamvcin/frusemide and adriamycin 
groups, and between the saline control/frusemide and 
saline control, groups.
wet/dry
Heart wet/dry Liver
Adr i amyc i n/f rusemi de
Adriamycin
Saline control/ 
frusemide
4.810.3(8) 
5.510.72(4) 
4.810.1(7)
4.210.3(8)
3.910.4(7)
Saline control 4.510.29(4)
The numbers in parenthesis represent the numbers of 
animals.
There were no significant differences between the groups.
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7.5 Discussion.
The electrophysiological results from the experiments in 
this chapter are somewhat surprising. Firstly, the 
stimulus-T interval only decreased by 7% over the 10 weeks 
of the study in the animals treated with adriamycin and 
frusemide. This is in comparison to the 12% shortening in 
stim-T which was observed in the initial group of animals 
treated with adriamycin. The shortening in repolarisation 
was only significant at week 10 and did not show the 
progressive decrease which occured in the adriamycin group 
of animals. Neither was there any significant difference 
between the 2 groups treated with frusemide at any week.
In contrast to the stim-T interval, the ERP did decrease 
progressively and significantly by week 10. This result 
is also surprising as repolarisation and refractoriness 
normally change in concert. Although an explanation for 
the discrepancy between the changes in refractoriness and 
the lack of significant changes in repolarisation is not 
readily available, there is some evidence which may 
explain the latter observation. If the basis of the 
electrophysiological changes which were seen in the 
animals treated with adriamycin in the initial series of 
experiments was, as presumed, related to the development 
of heart failure and the myopathic effect of adriamycin, 
then if the animals in the group treated with adriamycin
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and frusemide did not have the same degree of heart 
failure or a similar degree of histological evidence of 
cardiac damage then the electrophysiological changes might 
not occur. Although there were no haemodynamic 
measurements made in this study or in the previous studies 
there is some indirect evidence that the animals in the 
adriamycin plus frusemide group did not have the same 
degree of heart failure. The mean wet heart weight in the 
adriamycin plus frusemide group was only 12% higher than 
the corresponding control group, and the liver weights 
were only 10% higher. This is in comparison to increases 
of 49% and 35% in heart and liver weights in the 
adriamycin group. Likewise, the heart and liver to body 
weight ratios were only 8% and 7% higher when compared to 
the saline control/frusemide group. This is in comparison 
to increases of 57% and 42% in these parameters in the 
initial adriamycin group of animals. The absence of 
significant increases in heart and liver weights would be 
consistent with the absence of a significant degree of 
heart failure. The cardiac ventricular muscle samples 
which were prepared for histological examination were 
unfortunately not assessed at the time of publication and 
no comment can therefore be made about the presence or 
absence of histological changes in the animals treated 
with adriamycin and frusemide.
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Another measurement which is important in assessing the 
toxic effects of adriamycin is the body weights of the 
animals. Although the cytopathic effect of the drug on 
the heart muscle was not examined histologically, one 
method of looking at the systemic effects of adriamycin is 
by measuring the change in body weight, which by virtue of 
adriamycin's inhibition of protein synthesis, (Arena, B. 
et al(1974)), and its anorectic effect could result in a 
decrease in body weight or at least a lack of increase 
over a 10 week period. This hypothesis is confirmed in so 
much as the body weights in the adriamycin/frusemide group 
demonstrated a non-significant increase over 10 weeks, and 
in the adriamycin group a non-significant decrease over 
the same period of time such that at week 10, they were 
significantly different with no difference at baseline. 
This is despite the fact that frusemide would be expected 
to reduce body weight. Another general observation which 
was made was that the animals in the adriamycin plus 
frusemide group appeared well throughout the duration of 
the study in comparison to the animals in the adriamycin 
group which in general were at times unwell and anorectic. 
One possible explanation for the supposed lack of toxic 
effect of adriamycin in the animals discussed in this 
chapter may be a biological variation in response to any 
given dose of the drug. Previous studies have 
demonstrated considerable variation both clinically and
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experimentally in the extent of myocardial damage, as 
assessed by endomyocardial biopsy, in response to a 
standard dose of adriamycin, (Bristow, M.R. et al(1978); 
Bristow, M.R. et al(1981)). The rabbits were all obtained 
from the same supplier throughout the study, but an 
unrecognised variation in susceptibility to adriamycin 
cannot be excluded.
Another important factor which may explain the probable 
decrease in cardiotoxicity induced by adriamycin in the 
animals treated with frusemide may be variations in the 
dietary content of elements which reduce the activity of 
free radicals. Previous reports have emphasised the 
importance of selenium and alpha-tocopherol in determining 
the extent of cardiac damage induced by adriamycin. One 
such study demonstrated that the regular administration of 
an alpha-tocopherol-selenium mixture to rabbits lessened 
the degree of adriamycin induced cardiomyopathy, (Vein 
Fleet, J.F., Greenwood, L. & Ferrans, V.J.(1978)).
Although the dietary source remained constant throughout 
this study, it is possible that the raw materials 
incorporated into the diet may have come from different 
suppliers with undetected variations in the concentrations 
of antioxidants.
The role of selenium in preventing the cardiotoxic 
effects of adriamycin is attractive on theoretical 
grounds. As mentioned previously the increased production
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of oxygen derived free radicals has been proposed as one 
possible mechanism for the cytopathic action of 
adriamycin. This mechanism of action of adriamycin could 
potentially be reversed by selenium which increases the 
tissue concentration of of the free radical protection 
enzyme, glutathione peroxidase, (Chow, C.K. & Tappel, 
A.L.(1974)). A higher concentration of selenium in the 
diet of the animals treated with adriamycin and frusemide 
could be associated with a decrease in the level of heart 
failure which occurred. Previous work has in fact shown 
that the selenium content of commercial animal feed may 
vary from deficient to toxic, (Diplock, A.T.(1976)).
Other studies have also demonstrated that the 
cardiotoxicity induced by adriamycin may be attenuated by 
alpha-tocopherol, (Myers, C.E., Me Guire, W. & Young,
R. (1976); Milei, J. et al(1986)).
Clinical studies have demonstrated that the treatment of 
patients with heart failure with diuretics may result in 
activation of the renin-angiotensin system, (Bayliss, J. 
et al(1987); Brown, J.J. et al(1970)). It was expected 
therefore that the animals in this study which were 
treated with adriamycin and frusemide would have an 
increase in plasma renin concentration. Surprisingly 
however there was no significant increase in plasma renin 
between weeks 1 and 8 of the study in the adriamycin group
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treated with frusemide nor between the 2 frusemide treated 
groups. The reason for the lack of activation of the 
renin-angiotensin system in the animals may have been that 
the dose of frusemide was inadequate to cause salt and 
water depletion or that the animals were not in heart 
failure(as indicated by the absence of significant 
increases in heart and liver weights). Another 
possibility is that the blood samples could have been 
taken too early after the onset of frusemide treatment.
Another interesting observation in this study is that 
the mean plasma noradrenaline concentration significantly 
increased between weeks 1 and 8 in the adriamycin plus 
frusemide group. There was no significant difference 
however between the 2 groups or between the 
adriamycin/frusemide and the group treated with adriamycin 
alone. One possible explanation for an increase in 
sympathetic nervous activity could be that the animals 
treated with frusemide were volume depleted and thus had a 
reflex increase in noradrenaline. This would seem 
unlikely however as there was no concomitant activation of 
the renin-angiotensin system. Previous workers have 
suggested however that the neuroendocrine response to 
heart failure is sequential with the sympathetic nervous 
system being activated before the renin-angiotensin 
system, (Bayliss, J. et al(1987)).
178
Other biochemical changes which are commonly associated 
with diuretics are a decrease in plasma and Na^ 
concentrations. There were no significant changes in 
either of these parameters between weeks 1 and 8 or 
between groups. It has also been postulated that the 
decrease in plasma magnesium concentration which occurs in 
heart failure and is potentiated during teatment with 
diuretics may be potentially arrhythmogenic. Although 
there was a significant decrease in plasma magnesium 
concentration between weeks 1 and 8 in the initial group 
of animals treated with adriamycin, and this decrease was 
associated with ventricular ectopic activity as detected 
by ambulatory ECG monitoring, there was surprisingly no 
significant change in plasma magnesium in the adriamycin 
group of animals treated with frusemide. It would seem 
however that the diuretic therapy did have some effect as 
the mean plasma urea concentration was significantly 
increased between weeks 1 and 8 in the adriamycin plus 
frusemide group. This could imply that the animals were 
becoming dehydrated by an overvigorous diuresis.
In conclusion therefore, the reproducibility of the 
electrophysiological results from the first 2 experimental 
series have been called into question by the results in 
this chapter. For some reason it seems that the 
cardiomyopathic effect of adriamycin was significantly 
less or even absent in the animals treated with adriamycin
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and then subsequently with frusemide. This is supported 
by the lack of a significant increase in heart and liver 
weights in the animals, and also by the increase in body 
weight which would suggest that the drug had less systemic 
toxic effects. The possible reasons for the variability 
in the effects of adriamycin have been outlined above, but 
these results do indicate that the conclusions and 
possible extrapolations which were drawn from the results 
in chapters 4 and 6 should be treated with caution.
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CHAPTER 8
ASSESSMENT OF THE RELATIONSHIP BETWEEN CERTAIN INDICES OF 
ADRIAMYCIN TOXICITY AND CHANGES IN VENTRICULAR 
REPOLARISATION AND REFRACTORINESS.
8.1 Introduction.
As discussed in the previous chapter, the absence of a 
progressive decrease in right ventricular repolarisation 
and refractoriness in the animals in the
adriamycin/frusemide group could have been related to the 
absence of the cardiotoxic effects of adriamycin in this 
group.
If this theory were true, the possibility exists that 
there may be a relationship between certain indices of the 
toxic effects of adriamycin, both cardiac and systemic, 
and the changes in repolarisation and refractoriness which 
were seen in the animals in the adriamycin group. It 
might follow therefore that the animals with the greater 
degree of adriamycin toxicity, as manifest by a greater 
heart weight and lower body weight, would have the greater 
change in repolarisation and refractoriness.
This chapter therefore examines the relationship between 
these parameters as assessed by simple regression 
analysis.
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8.2 Statistical analysis.
The data in this chapter have been compared using simple 
regression analysis to generate the correlation 
coefficient and its significance level.
8.3 Results.
Comparison was made between the electrophysiological 
variables; ERP, change in ERP, Stim-T# change in stim-T 
and the parameters which may have reflected evidence of 
adriamycin toxicity; body weight, change in body weight, 
heart weight, liver weight and the heart and liver weights 
as expressed as a ratio of body weight.
The analysis of the data was disappointing. There was no 
significant correlation between any of the 
electrophysiological variables and the indices of 
adriamycin toxicity, when the data from all of the animals 
treated with adriamycin in chapters 4, 6 and 7 were 
analysed. Although the animals in the 
adriamycin/frusemide group did not have significant 
increases in heart and liver weights, and the mean body 
weights were significantly lower in the adriamycin group 
when compared to the adriamycin/frusemide group, there is
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no statistical relationship between the 
electrophysiological changes and these variables which 
would support the proposal that the animals in the 
adriamycin/frusemide group did not develop a 
cardiomyopathy.
As previously discussed however, there is evidence that 
the systemic toxicity of adriamycin can be assessed by 
changes in body weight(Arena, B. et al(1974)). There is 
also evidence that there is considerable variation in the 
cytopathic effect of a given dose of adriamycin(Bristow, 
M.R. et al(1978)).
The results in this chapter do not therefore explain why 
the electrophysiological data in the adriamycin/frusemide 
group was not reproducible.
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CHAPTER 9
GENERAL DISCUSSION ON THE OVERALL FINDINGS IN THE 
EXPERIMENTS DESCRIBED IN THIS THESIS, AND ASSESSMENT OF 
THE STRENGTHS AND WEAKNESSES OF THE STUDY.
The initial series of experiments described in chapter 4 
of this thesis produced some interesting results. The 
most important observation which was made was the 
progressive and significant shortening in ventricular 
repolarisation and refractoriness which occured in the 
animals treated with adriamycin. These 
electrophysiological changes were unrelated to 
neurohormonal activation and were not associated with 
changes in the diastolic pacing threshold. The animals in 
the adriamycin group also had significant increases in 
heart and liver weights when compared to the saline 
control group. Although no haemodynamic measurements were 
made in this study, the increases in these parameters were 
proposed as indirect evidence that the animals in the 
adriamycin group were in heart failure.
A significant decrease was also observed in plasma 
magnesium concentration in the adriamycin group, although 
the magnitude of the decrease in magnesium could not 
explain the the 12% shortening in repolarisation if we
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extrapolate from previous in vitro studies, (Watanabe, Y.
& Dreifus, L.S.(1972)).
Although there was no evidence of arrhythmias in the 
saline control group, each of the animals in the 
adriamycin group had evidence of infrequent ventricular 
ectopic activity, which may have reflected electrolyte 
depletion.
One of the most important issues which this study was 
designed to investigate was the relationship between the 
electrophysiological changes and sudden death. Three 
animals died suddenly and unexpectedly in the adriamycin 
group, and no animal died suddenly in the saline control 
group.
The principal finding in the in vitro experiments which 
were described in chapter 5, was a significant decrease in 
action potential duration and effective refractory period 
in animals treated with adriamycin when compared to 
controls.
These findings were similar but of a greater magnitude to 
the in vivo shortening in repolarisation and 
refractoriness which were described in chapter 4. The 
nature of the in vitro preparation also meant that these 
changes were unrelated to neurohormonal mechanisms and 
electrolyte depletion.
The combination of the electrophysiological changes fron 
chapters 4 and 5 seemed to indicate that these changes
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were most likely the result of the direct cytopathic 
effect of adriamycin. In chapter 6, the effect of 
captopril was assessed on the electrophysiological changes 
associated with adriamycin cardiomyopathy.
The introduction of captopril did not result in the 
reversal of the shortening in repolarisation and 
refractoriness which had resulted from the treatment with 
adriamycin. By the end of the study, the stim-T interval 
and ERP were reduced by 14% and 8% respectively in the 
adriamycin/captopril group. These results are similar in 
magnitude to the changes seen in the adriamycin group.
If the direct cytopathic effect of adriamycin and not an 
increase in afterload is the cause of the 
electrophysiological changes in this thesis, then 
captopril would not have been expected to reverse these 
changes.
Captopril was associated with an improvement in certain 
indices which would indicate, at least indirectly, an 
improvement in cardiac function. The heart weight in the 
adriamycin/captopril group was only 10% greater than in 
the saline control/captopril group. This compares with a 
49% increase in the adriamycin group when compared to the 
saline control group. Neither was there a significant 
increase in liver weight in the adriamycin/captopril 
group.
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Captopril treatment also prevented the significant 
decrease in plasma magnesium which had occured in the 
initial adriamycin group, and caused a non-significant 
increase in plasma potassium at week 8 of the study, which 
resulted in the mean level of plasma potassium being 
significantly greater in the adriamycin/captopril group 
when compared to the adriamycin group 
No evidence of arrhythmias was observed in any of the 
animals in the adriamycin/captopril group, which is in 
contrast to the adriamycin group, and may have been 
related to the absence of electrolyte depletion.
The mean level of plasma renin significantly increased in 
both the groups treated with captopril, as expected. One 
surprising finding in the animals in the
adriamycin/captopril group was the significant increase in 
plasma noradrenaline by week 8 of the study. If captopril 
was associated with an improvement in heart failure then 
it would have been expected that sympathetic nervous 
activity would have decreased.
Although captopril did not reverse the shortening in stim- 
T and ERP,, no animals died suddenly in the 
adriamycin/captopril group.
The results from the final series of experiments described 
in chapter 7 were disappointing. Unlike the results in 
chapters 4 and 6, there was no progressive and parallel 
shortening in stim-T and ERP over the 10 weeks of the
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study. Although the ERP significantly decreased by 16% in 
the adriamycin/frusemide group, there was no significant 
decrease in stim-T when compared to the saline 
control/frusemide group. Both of these parameters should 
change in concert, and the results from these experiments 
therefore cast some doubt on the electrophysiological 
changes previously described in chapters 4 and 6. It was 
suggested that an explanation for this anomaly could be a 
variation in the response of the animals to adriamycin, 
such that the animals in the adriamycin/frusemide group 
were not in heart failure.
This explanation is supported by the lack of a significant 
increase in heart and liver weights in the
adriamycin/frusemide group, and a non-significant increase 
in body weight implying the absence of significant 
systemic toxicity of adriamycin.
No significant increase was observed in plasma renin in 
either of the groups treated with frusemide. This is 
unusual as diuretics are known to activate the renin- 
angiotensin system in heart failure. A possible 
explanation for this is that the blood samples for plasma 
renin assay were taken before the drug had taken full 
effect.
Plasma noradrenaline levels significantly increased in the 
adriamycin/frusemide group. This could possibly have been 
secondary to diuretic-induced dehydration, as manifest by
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the significant increase in plasma urea which occured in 
this group of animals.
Diuretics are known to produce depletion of plasma 
potassium and magnesium although no change was seen in 
either of these indices.
In chapter 8, there was no significant correlation between 
certain indices which reflect the toxic effects of 
adriamycin, and the electrophysiological changes. These 
results do not support the hypothesis that the absence of 
a progressive shortening in ventricular repolarisation in 
the adriamycin/frusemide group, was related to a lack of 
adriamycin cytotoxicity.
The importance of the experiments presented in this thesis 
is that for the first time, chronic changes in ventricular 
repolarisation and refractoriness have been measured in an 
experimental model of heart failure.
The significant shortening in both of these parameters in 
the adriamycin and adriamycin/captopril groups, is 
proposed as a possible mechanism for sudden death in heart 
failure. The shortening in action potential duration and 
effective refractory period in the in vitro experiments 
lends further support to the hypothesis that the 
electrophysiological changes in the in vivo experiments 
are a consistent feature of this model of heart failure.
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Although these electrophsiological changes were present, 
the incidence of sudden death was low in the adriamycin 
group and subsequent comparison of the mortality rates 
with other groups is therefore difficult.
The absence of similar electrophysiological changes in the 
adriamycin/frusemide group questions the validity of the 
results in chapters 4 and 6. The variability in response 
of the rabbits to adriamycin is however a significant 
drawback with this model of heart failure.
Another weakness with this series of experiments is that 
no haemodynamic measurements were made to confirm the 
presence of heart failure, but the significant increase in 
heart and liver weight in the adriamycin group is indirect 
evidence that adriamycin did cause heart failure. As 
discussed in chapter 1.14, previous studies have shown 
that an identical injection protocol with adriamycin, 
induces heart failure in the rabbit as assessed by 
haemodynamic abnormalities.
Another further weakness with the study is the absence of 
activation of the renin-angiotensin and sympathetic 
nervous systems, both of which are known to occur in heart 
failure clinically. It has been previously described 
however, that untreated heart failure may be associated 
with normal levels of plasma renin, (Bayliss, J. et 
al(1987); Brown, J.J. et al(1970)).
190
Although there were significant electrophysiological 
changes in the animals treated with adriamycin as 
described in chapters 4 and 6, the incidence of sudden 
death was low. As this study was designed to attempt to 
elucidate the possible mechanisms predisposing to sudden 
death, further experiments would be required in which the 
incidence of sudden death was increased. One possibility 
may be that the use of digoxin or a higher dose of 
diuretics for a longer period of time may achieve this.
It is possible that the activation of neurohormonal 
mechanisms by a higher dose of diuretics may increase the 
incidence of sudden death.
It would also be interesting to apply the
electrophysiological techniques employed in this study to 
other experimental models of heart failure, both in the 
rabbit and other mammals. If similar electrophysiological 
changes were found in other models of heart failure, this 
would give more weight to the premise that the shortening 
in stim-T and ERP could be a potential mechanism for 
sudden death.
191
CHAPTER 10
CONCLUSIONS
1. Adriamycin induced heart failure in the rabbit is 
associated with significant shortening in ventricular 
repolarisation and refractoriness which could provide a 
mechanism for sudden death.
2. The electrophysiological changes in this study are 
independent of changes in plasma electrolytes and 
neurohormones.
3. Variation in response to adriamycin toxicity may occur 
in the rabbit, and the electrophysiological changes could 
be related to the severity of heart failure.
4. Captopril does not reverse the shortening in 
repolarisation and refractoriness induced by adriamycin, 
but reduces the frequency of ventricular arrhythmias 
possibly by preventing plasma electrolyte depletion. The 
animals treated with adriamycin and captopril did not show 
significant increases in heart and liver weights, which 
implies an improvement in heart failure.
5. The duration and dose of frusemide used to treat the 
animals in this study was not sufficient to cause 
activation of the renin-angiotensin system.
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6. The absence of a progressive and parallel shortening 
in stim-T and ERP in the animals treated with adriamycin 
and frusemide, may reflect the absence of heart failure in 
these animals as a result of variability in the response 
to adriamycin.
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